[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 100 of about 124
1. Yasuda T, Perry KD, Nelson M, Bui MM, Nasir A, Goldschmidt R, Gnepp DR, Bridge JA: Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature. Hum Pathol; 2009 Mar;40(3):341-8
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar rhabdomyosarcoma of the head and neck region in older adults: genetic characterization and a review of the literature.
  • Alveolar rhabdomyosarcoma is remarkably rare in adults older than 45 years.
  • A valuable diagnostic aid and important prognostic parameter in alveolar rhabdomyosarcoma is the identification of PAX3-FOXO1 [t(2;13)(q35;q14)] or PAX7-FOXO1 [t(1;13)(p36;q14)] rearrangements.
  • The purpose of this study was to document the clinicopathologic, immunophenotypic, and genetic features of head/neck alveolar rhabdomyosarcoma in older adults.
  • Definitive alveolar rhabdomyosarcoma diagnoses were confirmed genetically.
  • This study illustrates the diagnosis of head/neck alveolar rhabdomyosarcoma in older adults is complicated by its rarity, lack of an alveolar pattern, and a potentially misleading immunoprofile (CD56 and synaptophysin immunoreactivity) if myogenic markers are not used.
  • Both PAX3- and PAX7-FOXO1 alveolar rhabdomyosarcomas were identified in these patients.
  • In children, PAX7-FOXO1 alveolar rhabdomyosarcoma is associated with a significantly longer event-free survival.
  • In contrast, adult alveolar rhabdomyosarcoma behaves more aggressively with a worse overall survival than pediatric alveolar rhabdomyosarcoma.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Pathol. 1991 Aug;139(2):275-86 [1867319.001]
  • [Cites] Mod Pathol. 2008 Jul;21(7):795-806 [18487991.001]
  • [Cites] Hum Pathol. 1993 Jan;24(1):62-6 [7678094.001]
  • [Cites] J Laryngol Otol. 1993 Aug;107(8):716-20 [8409724.001]
  • [Cites] Laryngoscope. 1993 Dec;103(12):1362-6 [8246656.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Med Pediatr Oncol. 1997 Mar;28(3):165-70 [9024509.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1831-6 [9164192.001]
  • [Cites] Cancer Genet Cytogenet. 1998 Nov;107(1):43-7 [9809033.001]
  • [Cites] Am J Surg Pathol. 2005 Aug;29(8):1106-13 [16006807.001]
  • [Cites] J Laryngol Otol. 2005 Aug;119(8):639-42 [16102222.001]
  • [Cites] Lab Invest. 2006 Jun;86(6):547-56 [16607381.001]
  • [Cites] Am J Surg Pathol. 2000 Nov;24(11):1511-7 [11075852.001]
  • [Cites] Cancer. 2001 Feb 15;91(4):794-803 [11241248.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Oct;26(10):696-7 [15454847.001]
  • [Cites] Cancer. 1977 Oct;40(4):1562-70 [907970.001]
  • [Cites] Cancer. 1991 Feb 15;67(4):1019-24 [1991249.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):4031-2 [16921060.001]
  • [Cites] Int J Surg Pathol. 2006 Jul;14(3):238-42 [16959712.001]
  • [Cites] Diagn Cytopathol. 2006 Oct;34(10):704-6 [16955479.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1454-65 [17090187.001]
  • [Cites] Pathology. 2007 Apr;39(2):275-6 [17454764.001]
  • [Cites] Int J Surg Pathol. 2007 Apr;15(2):160-5 [17478770.001]
  • [Cites] Rinsho Ketsueki. 2007 Apr;48(4):315-20 [17515123.001]
  • [Cites] Fetal Pediatr Pathol. 2007 Jan-Feb;26(1):17-31 [17613043.001]
  • [Cites] Histopathology. 1991 Aug;19(2):182-4 [1822978.001]
  • (PMID = 18973919.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA036727-249009; United States / NCI NIH HHS / CA / P30 CA036727; United States / NCI NIH HHS / CA / P30 CA 36727; United States / NCI NIH HHS / CA / P30 CA036727-249009
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / Oncogene Proteins, Fusion; 0 / PAX3 protein, human; 0 / PAX7 Transcription Factor; 0 / PAX7 protein, human; 0 / Paired Box Transcription Factors
  • [Other-IDs] NLM/ NIHMS96749; NLM/ PMC2753286
  •  go-up   go-down


2. Cen L, Arnoczky KJ, Hsieh FC, Lin HJ, Qualman SJ, Yu S, Xiang H, Lin J: Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma. Mod Pathol; 2007 Sep;20(9):936-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phosphorylation profiles of protein kinases in alveolar and embryonal rhabdomyosarcoma.
  • Rhabdomyosarcoma is the most common pediatric soft-tissue sarcoma, which includes two major subtypes, alveolar and embryonal rhabdomyosarcoma.
  • However, the oncogenic process of rhabdomyosarcoma involves multi-stages of signaling protein dysregulation characterized by prolonged activation of tyrosine and serine/threonine kinases.
  • To better understand this protein dysregulation, we evaluated the phosphorylation profiles of multiple tyrosine and serine/threonine kinases to identify whether these protein kinases are activated in rhabdomyosarcoma.
  • We applied immunohistochemistry with phospho-specific antibodies to examine phosphorylation levels of selected receptor and non-receptor tyrosine kinases, mammalian target of rapamycin (mTOR), p70S6K, and protein kinase C (PKC) isozymes on alveolar and embryonal rhabdomyosarcoma tissue microarray slides.
  • Our results showed that the phosphorylation levels of these kinases are elevated in some rhabdomyosarcoma tissues compared to normal tissues.
  • Phosphorylation levels of receptor and non-receptor tyrosine kinases are elevated between 26 and 68% in alveolar rhabdomyosarcoma and between 24 and 71% in embryonal rhabdomyosarcoma, respectively, compared to normal tissues.
  • In addition, phosphorylation levels of mTOR and its downstream targets, p70S6K, S6, and 4EBP1, are increased between 50 and 72% in both subtypes of rhabdomyosarcoma.
  • Further, phosphorylation levels of PKCalpha, PKCdelta, PKCtheta, and PKCzeta/lambda are upregulated between 57 and 69% in alveolar rhabdomyosarcoma and between 43 and 72% in embryonal rhabdomyosarcoma.
  • This is the first report to create a phosphorylation profile of tyrosine and serine/threonine kinases involved in the mTOR and PKC pathways of alveolar and embryonal rhabdomyosarcoma.
  • [MeSH-major] Protein-Serine-Threonine Kinases / analysis. Protein-Tyrosine Kinases / analysis. Rhabdomyosarcoma, Alveolar / enzymology. Rhabdomyosarcoma, Embryonal / enzymology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17585318.001).
  • [ISSN] 0893-3952
  • [Journal-full-title] Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc
  • [ISO-abbreviation] Mod. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Adaptor Proteins, Signal Transducing; 0 / EIF4EBP1 protein, human; 0 / Isoenzymes; 0 / Phosphoproteins; 0 / Ribosomal Protein S6; EC 2.7.- / Protein Kinases; EC 2.7.1.1 / MTOR protein, human; EC 2.7.1.1 / TOR Serine-Threonine Kinases; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / Ribosomal Protein S6 Kinases, 70-kDa; EC 2.7.11.13 / Protein Kinase C
  •  go-up   go-down


3. Tan GC, Shiran MS, Hayati AR, Sharifah NA, Nuru AS, Rohaizak M: Alveolar rhabdomyosarcoma of the left hand with bilateral breast metastases in an adolescent female. J Chin Med Assoc; 2008 Dec;71(12):639-42
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar rhabdomyosarcoma of the left hand with bilateral breast metastases in an adolescent female.
  • Rhabdomyosarcoma is a common extramammary malignancy in pediatric age groups, but it rarely metastasizes to the breast.
  • We report a case of primary alveolar rhabdomyosarcoma of the upper extremities in a 17-year-old adolescent female who presented with bilateral lower limb weakness and bilateral breast lumps.
  • [MeSH-major] Breast Neoplasms / secondary. Hand / pathology. Rhabdomyosarcoma, Alveolar / pathology. Rhabdomyosarcoma, Alveolar / secondary

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19114329.001).
  • [ISSN] 1726-4901
  • [Journal-full-title] Journal of the Chinese Medical Association : JCMA
  • [ISO-abbreviation] J Chin Med Assoc
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China (Republic : 1949- )
  •  go-up   go-down


Advertisement
4. Blizniukov OP, Petrovichev NN, Perevoshchikov AG, Poliakov VG: [Diagnosis of micrometastases of alveolar rhabdomyosarcoma]. Arkh Patol; 2008 Mar-Apr;70(2):36-40
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Diagnosis of micrometastases of alveolar rhabdomyosarcoma].
  • Alveolar rhabgomyosarcoma is a highly malignant, small blue cell pediatric soft tissue tumor.
  • Identification of micrometastases in alveolar rhabdomyosarcoma is important because the poor prognosis associated with this subgroup necessitates a modified therapeutic regimen.
  • Since the obtained lymph node specimen can be very small; rhabdomyosarcoma cells are not easily detected using conventional histological methods.
  • To assess the value of myogenin staining in the diagnosis of micrometastases in alveolar rhabdomyosarcoma, the authors examined 36 lymph nodes from children bearing this tumor.
  • The PAX3/7-FKHR gene fusion that resulted from chromosomal translocation in alveolar rhabdomyosarcoma provided potential molecular diagnostic markers.
  • Thirty-six lymph nodes were examined and of them 17 lymph nodes had PAX3/7-FKHR fusion transcripts of alveolar rhadomyosarcoma cells.
  • The study demonstrates that molecular RT-PCR detection of micrometastases is the most sensitive method for diagnosing alveolar rhabdomyosarcoma.
  • [MeSH-major] Biomarkers, Tumor / biosynthesis. Eye Proteins / biosynthesis. Forkhead Transcription Factors / biosynthesis. Homeodomain Proteins / biosynthesis. Oncogene Proteins, Fusion / biosynthesis. Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / metabolism. Soft Tissue Neoplasms / diagnosis. Soft Tissue Neoplasms / metabolism. Transcription Factors / biosynthesis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18540440.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Russia (Federation)
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Eye Proteins; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / Homeodomain Proteins; 0 / Oncogene Proteins, Fusion; 0 / RAX protein, human; 0 / RNA, Neoplasm; 0 / Transcription Factors
  •  go-up   go-down


5. Martin LT, Glass M, Dosunmu E, Martin PT: Altered expression of natively glycosylated alpha dystroglycan in pediatric solid tumors. Hum Pathol; 2007 Nov;38(11):1657-68
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Altered expression of natively glycosylated alpha dystroglycan in pediatric solid tumors.
  • To date, however, there has been no study of the expression of dystroglycan in pediatric solid tumors.
  • Using a combination of immunostaining on tissue microarrays and immunoblotting of snap-frozen unfixed tissues, we demonstrate a significant reduction in native alpha dystroglycan expression in pediatric alveolar rhabdomyosarcoma (RMS), embryonal RMS, neuroblastoma (NBL), and medulloblastoma, whereas expression of beta dystroglycan, which is cotranslated with alpha dystroglycan, is largely unchanged.
  • Expression of natively glycosylated alpha dystroglycan was not altered in several other pediatric tumor types when compared with appropriate normal tissue controls.
  • These data provide the first evidence that alpha dystroglycan glycosylation and laminin binding to alpha dystroglycan are altered in certain pediatric solid tumors and suggest that aberrant dystroglycan glycosylation may contribute to tumor cell biology in patients with RMS, medulloblastoma, and NBL.

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Biol Ther. 2004 Oct;3(10):976 [15662132.001]
  • [Cites] J Biol Chem. 1998 Sep 11;273(37):23698-703 [9726975.001]
  • [Cites] Biochem Soc Trans. 2005 Dec;33(Pt 6):1254-5 [16246091.001]
  • [Cites] J Cell Sci. 2006 Jan 15;119(Pt 2):199-207 [16410545.001]
  • [Cites] Biochemistry. 2006 Feb 21;45(7):2042-52 [16475793.001]
  • [Cites] J Cell Physiol. 2006 May;207(2):520-9 [16447256.001]
  • [Cites] Brain Res. 2006 Feb 23;1075(1):223-8 [16466646.001]
  • [Cites] FEBS Lett. 2000 Feb 18;468(1):79-83 [10683445.001]
  • [Cites] Curr Opin Cell Biol. 1998 Oct;10(5):594-601 [9818169.001]
  • [Cites] Biochim Biophys Acta. 1998 Nov 27;1425(3):599-606 [9838223.001]
  • [Cites] Cell. 1998 Dec 11;95(6):859-70 [9865703.001]
  • [Cites] EMBO J. 1999 Feb 15;18(4):863-70 [10022829.001]
  • [Cites] Curr Opin Cell Biol. 1999 Oct;11(5):602-7 [10508656.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Feb;288(2):C377-88 [15385269.001]
  • [Cites] Mol Cell Neurosci. 2000 Apr;15(4):380-97 [10845774.001]
  • [Cites] Biochem Biophys Res Commun. 2000 Jul 21;274(1):93-8 [10903901.001]
  • [Cites] Mol Cell Biol Res Commun. 1999 Sep-Dec;2(3):162-71 [10662592.001]
  • [Cites] Hum Mol Genet. 2000 Sep 22;9(15):2335-40 [11001938.001]
  • [Cites] FEBS Lett. 2000 Nov 10;484(3):194-8 [11078877.001]
  • [Cites] Neuroscience. 2001;104(2):311-24 [11377836.001]
  • [Cites] Hum Pathol. 2001 Aug;32(8):791-5 [11521221.001]
  • [Cites] J Neurochem. 2001 Aug;78(4):824-34 [11520903.001]
  • [Cites] Dev Biol. 2002 Feb 1;242(1):58-73 [11795940.001]
  • [Cites] Physiol Rev. 2002 Apr;82(2):291-329 [11917091.001]
  • [Cites] Mol Cell Neurosci. 2002 Apr;19(4):539-51 [11988021.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Aug;283(2):C500-11 [12107060.001]
  • [Cites] Nature. 2002 Jul 25;418(6896):417-22 [12140558.001]
  • [Cites] Muscle Nerve. 2002 Nov;26(5):644-53 [12402286.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):7102-9 [12460932.001]
  • [Cites] Br J Cancer. 2003 Feb 24;88(4):579-85 [12592373.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):849-60 [12598319.001]
  • [Cites] Brain Res Mol Brain Res. 2003 Apr 10;112(1-2):177-81 [12670716.001]
  • [Cites] J Bone Joint Surg Am. 2003 Apr;85-A(4):667-74 [12672843.001]
  • [Cites] Neuromuscul Disord. 2003 Jun;13(5):365-75 [12798792.001]
  • [Cites] Glycobiology. 2003 Aug;13(8):55R-66R [12736199.001]
  • [Cites] Glycobiology. 2003 Aug;13(8):67R-75R [12736200.001]
  • [Cites] EMBO Rep. 2004 May;5(5):484-9 [15071496.001]
  • [Cites] Eur J Surg Oncol. 2004 Aug;30(6):589-92 [15256230.001]
  • [Cites] Eur J Cancer. 2004 Sep;40(14):2143-51 [15341990.001]
  • [Cites] Dev Biol. 1984 Jun;103(2):456-67 [6373447.001]
  • [Cites] J Cell Biol. 1990 Oct;111(4):1685-99 [2211832.001]
  • [Cites] Cell Regul. 1990 Sep;1(10):731-40 [2099832.001]
  • [Cites] Cell. 1991 Sep 20;66(6):1121-31 [1913804.001]
  • [Cites] Nature. 1992 Feb 20;355(6362):696-702 [1741056.001]
  • [Cites] J Cell Biol. 1993 Aug;122(4):809-23 [8349731.001]
  • [Cites] Hum Mol Genet. 1994 Sep;3(9):1589-97 [7833916.001]
  • [Cites] J Biol Chem. 1995 May 19;270(20):11711-4 [7744812.001]
  • [Cites] J Biol Chem. 1997 Jan 24;272(4):2156-62 [8999917.001]
  • [Cites] J Histochem Cytochem. 1998 Apr;46(4):449-57 [9524190.001]
  • [Cites] J Cell Physiol. 2005 Nov;205(2):163-9 [15920757.001]
  • (PMID = 17640712.001).
  • [ISSN] 0046-8177
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] ENG
  • [Grant] United States / NIAMS NIH HHS / AR / AR050202-02; United States / NIAMS NIH HHS / AR / R01 AR050202; United States / NIAMS NIH HHS / AR / R01 AR049722-01A2; United States / NIAMS NIH HHS / AR / AR 050202; United States / NIAMS NIH HHS / AR / AR049722-01A2; United States / NIAMS NIH HHS / AR / R01 AR050202-02; United States / NIAMS NIH HHS / AR / R01 AR049722
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Laminin; 146888-27-9 / Dystroglycans
  • [Other-IDs] NLM/ NIHMS190362; NLM/ PMC2850815
  •  go-up   go-down


6. Sullivan LM, Atkins KA, LeGallo RD: PAX immunoreactivity identifies alveolar rhabdomyosarcoma. Am J Surg Pathol; 2009 May;33(5):775-80
Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PAX immunoreactivity identifies alveolar rhabdomyosarcoma.
  • As such, we sought to assess it as a diagnostic marker in the evaluation of pediatric small round blue cell tumors.
  • Tumors selected for evaluation included embryonal rhabdomyosarcoma (55 cases), alveolar rhabdomyosarcoma (ARMS) (51 cases), neuroblastoma (22 cases), Wilms tumor (18 cases), Ewing Family of Tumors (11 cases), lymphoblastic lymphoma (8 cases), hepatoblastoma (6 cases), and granulocytic sarcoma (3 cases) as either cores in a tissue microarray or whole mount sections.
  • Of the rhabdomyosarcoma cases, 34 of 51 (67%) ARMS were immunoreactive whereas none of the 55 embryonal rhabdomyosarcoma cases stained.
  • [MeSH-major] B-Cell-Specific Activator Protein / analysis. Rhabdomyosarcoma, Alveolar / chemistry
  • [MeSH-minor] Adolescent. Bone Neoplasms / chemistry. Child. Child, Preschool. Gene Expression Regulation, Neoplastic. Hepatoblastoma / chemistry. Humans. Immunohistochemistry. Infant. Infant, Newborn. Kidney Neoplasms / chemistry. Liver Neoplasms / chemistry. Neuroblastoma / chemistry. Precursor Cell Lymphoblastic Leukemia-Lymphoma / metabolism. Predictive Value of Tests. Retrospective Studies. Rhabdomyosarcoma, Embryonal / chemistry. Sarcoma, Ewing / chemistry. Sarcoma, Myeloid / metabolism. Tissue Array Analysis. Translocation, Genetic. Wilms Tumor / chemistry

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19145202.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / B-Cell-Specific Activator Protein; 0 / PAX5 protein, human
  •  go-up   go-down


7. Nishijo K, Chen QR, Zhang L, McCleish AT, Rodriguez A, Cho MJ, Prajapati SI, Gelfond JA, Chisholm GB, Michalek JE, Aronow BJ, Barr FG, Randall RL, Ladanyi M, Qualman SJ, Rubin BP, LeGallo RD, Wang C, Khan J, Keller C: Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma. Cancer Res; 2009 Apr 1;69(7):2902-11
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Credentialing a preclinical mouse model of alveolar rhabdomyosarcoma.
  • The highly aggressive muscle cancer alveolar rhabdomyosarcoma (ARMS) is one of the most common soft tissue sarcoma of childhood, yet the outcome for the unresectable and metastatic disease is dismal and unchanged for nearly three decades.
  • At a whole-genome level, a cross-species gene set enrichment analysis and metagene projection study showed that our mouse model is most similar to human ARMS when compared with other pediatric cancers.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Oncogene. 2007 Nov 8;26(51):7267-81 [17525748.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] Pediatr Blood Cancer. 2008 Jul;51(1):34-41 [18260120.001]
  • [Cites] Nat Rev Cancer. 2008 Jun;8(6):438-49 [18500245.001]
  • [Cites] Genes Dev. 2008 Jun 15;22(12):1662-76 [18559481.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4572-83 [18628472.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6587-97 [18701482.001]
  • [Cites] Oncogene. 2008 Nov 20;27(51):6550-60 [18679424.001]
  • [Cites] Proc Natl Acad Sci U S A. 1999 Nov 9;96(23):13264-9 [10557309.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):831-5 [11556833.001]
  • [Cites] Genomics. 2002 Mar;79(3):278-84 [11863357.001]
  • [Cites] Neuromuscul Disord. 2002 Oct;12 Suppl 1:S125-41 [12206807.001]
  • [Cites] J Biol Chem. 2002 Nov 22;277(47):45276-84 [12228231.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3646-57 [12473573.001]
  • [Cites] J Biol Chem. 2003 Jan 3;278(1):27-36 [12401804.001]
  • [Cites] Nat Genet. 2004 Jul;36(7):687-93 [15220918.001]
  • [Cites] Lab Invest. 2004 Aug;84(8):1060-70 [15184910.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5539-45 [15313887.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2869-72 [8187070.001]
  • [Cites] Oncogene. 1995 Jul 6;11(1):119-30 [7624119.001]
  • [Cites] Mol Cell Biol. 1998 Jul;18(7):4118-30 [9632796.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2614-26 [15489287.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2608-13 [15520281.001]
  • [Cites] Lancet Oncol. 2005 Feb;6(2):77-84 [15683816.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Feb 1;102(5):1649-54 [15668399.001]
  • [Cites] Oncogene. 2005 Mar 10;24(11):1860-72 [15688035.001]
  • [Cites] Cancer Res. 2005 Sep 1;65(17):7530-2 [16140913.001]
  • [Cites] Genome Biol. 2005;6(9):R76 [16168083.001]
  • [Cites] Muscle Nerve. 2005 Oct;32(4):483-91 [15962335.001]
  • [Cites] Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50 [16199517.001]
  • [Cites] Mol Imaging. 2005 Oct-Dec;4(4):417-24 [16285903.001]
  • [Cites] J Cell Biol. 2006 Jan 2;172(1):91-102 [16380438.001]
  • [Cites] Mol Cell Biol. 2006 Apr;26(7):2531-9 [16537899.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2772-81 [16381018.001]
  • [Cites] Oncogene. 2006 Apr 27;25(18):2615-27 [16331253.001]
  • [Cites] Mol Cell Biol. 2006 Jul;26(13):4782-93 [16782868.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Sep 5;103(36):13439-44 [16938866.001]
  • [Cites] Cancer Res. 2006 Oct 15;66(20):10171-8 [17047082.001]
  • [Cites] Development. 2007 Mar;134(6):1171-80 [17301086.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5959-64 [17389406.001]
  • [Cites] J Pathol. 2007 Jun;212(2):143-51 [17471488.001]
  • [Cites] Genes Dev. 2007 Jun 1;21(11):1382-95 [17510286.001]
  • [Cites] Biochemistry. 2007 Aug 21;46(33):9551-63 [17655330.001]
  • [Cites] Cell Cycle. 2007 Nov 15;6(22):2846-54 [18032922.001]
  • (PMID = 19339268.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA074907-06; United States / NCI NIH HHS / CA / CA090438-06; United States / NCI NIH HHS / CA / CA064202-07; United States / NCI NIH HHS / CA / CA064202-13; United States / NCI NIH HHS / CA / R01 CA064202-08S1; United States / NCI NIH HHS / CA / P30CA54174; United States / NCI NIH HHS / CA / R01 CA064202-11; United States / NCI NIH HHS / CA / CA064202-08S1; United States / NCI NIH HHS / CA / R01 CA074907-09; United States / NCI NIH HHS / CA / K08 CA090438; United States / NCI NIH HHS / CA / CA074907-11; United States / NCI NIH HHS / CA / CA64202; United States / NCI NIH HHS / CA / R01 CA064202-06; United States / NCI NIH HHS / CA / R01 CA074907; United States / NCI NIH HHS / CA / CA064202-08; United States / NCI NIH HHS / CA / CA074907-07; United States / NCI NIH HHS / CA / R01 CA064202-14; United States / NCI NIH HHS / CA / R01 CA064202-13; United States / NCI NIH HHS / CA / R01 CA064202-07; United States / NCI NIH HHS / CA / R29 CA074907; United States / NCI NIH HHS / CA / CA074907-08; United States / NCI NIH HHS / CA / R01 CA064202-09; United States / NCI NIH HHS / CA / R01 CA064202; United States / NCI NIH HHS / CA / CA074907; United States / NCI NIH HHS / CA / CA074907-10A1; United States / NCI NIH HHS / CA / CA064202-11; United States / NCI NIH HHS / CA / CA074907-09; United States / NCI NIH HHS / CA / CA074907-06; United States / NCI NIH HHS / CA / R01 CA064202-08; United States / NCI NIH HHS / CA / R01 CA074907-11; United States / NCI NIH HHS / CA / CA064202-14; United States / NCI NIH HHS / CA / CA064202-10A1; United States / NCI NIH HHS / CA / R01 CA074907-07; United States / NCI NIH HHS / CA / P30 CA054174; United States / NCI NIH HHS / CA / CA064202-12; United States / NCI NIH HHS / CA / R01 CA074907-08; United States / NCI NIH HHS / CA / CA064202-06; United States / NCI NIH HHS / CA / R01 CA064202-12; United States / NCI NIH HHS / CA / K08 CA090438-06; United States / NCI NIH HHS / CA / R01 CA064202-10A1; United States / NCI NIH HHS / CA / CA064202-09; United States / NCI NIH HHS / CA / R01 CA074907-10A1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cdkn2a protein, mouse; 0 / Cyclin-Dependent Kinase Inhibitor p16; 0 / Forkhead Transcription Factors; 0 / Foxo1 protein, mouse; 0 / Oncogene Proteins, Fusion; 0 / PAX3-FKHR fusion protein, human; 0 / Paired Box Transcription Factors; 0 / Tumor Suppressor Protein p53; 138016-91-8 / Pax3 protein, mouse
  • [Other-IDs] NLM/ NIHMS96027; NLM/ PMC2789740
  •  go-up   go-down


8. Jones AE, Albano EA, Lovell MA, Hunger SP: Metastatic alveolar rhabdomyosarcoma in multiple endocrine neoplasia type 2A. Pediatr Blood Cancer; 2010 Dec 1;55(6):1213-6
Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic alveolar rhabdomyosarcoma in multiple endocrine neoplasia type 2A.
  • Rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma, accounts for 3% of childhood malignancies.
  • We describe a previously unreported association of MEN-2A with metastatic alveolar RMS and review the literature on associated hereditary cancer predisposition syndromes and current therapeutic options.
  • [MeSH-major] Multiple Endocrine Neoplasia Type 2a / pathology. Rhabdomyosarcoma, Alveolar / secondary

  • Genetic Alliance. consumer health - Multiple Endocrine Neoplasia.
  • Genetic Alliance. consumer health - Multiple endocrine neoplasia type 2A.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20533522.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / T32 CA082086
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Ben Arush MW, Bar Shalom R, Postovsky S, Militianu D, Haimi M, Zaidman I, Israel O: Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities. J Pediatr Hematol Oncol; 2006 Jul;28(7):440-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Assessing the use of FDG-PET in the detection of regional and metastatic nodes in alveolar rhabdomyosarcoma of extremities.
  • Alveolar rhabdomyosarcoma (ARS) accounts for 20% to 30% of childhood rhabdomyosarcoma and is known to have a worse prognosis than embryonal rhabdomyosarcoma.
  • Metastatic disease is more frequent in patients with alveolar tumors and these children with metastatic disease fare poorly, with a 5-year survival between 20% and 30%.
  • [MeSH-major] Extremities / pathology. Fluorodeoxyglucose F18. Lymphoma, Non-Hodgkin / diagnosis. Positron-Emission Tomography / methods. Rhabdomyosarcoma, Alveolar / diagnosis. Soft Tissue Neoplasms / diagnosis

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16825990.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


10. Paulino AC, Pappo A: Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk? Pediatr Blood Cancer; 2009 Dec 15;53(7):1332-3
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar rhabdomyosarcoma of the extremity and nodal metastasis: Is the in-transit lymphatic system at risk?
  • Alveolar rhabdomyosarcoma (RMS) of the extremity is not infrequently associated with regional node metastasis.
  • In this report we describe two patients with alveolar RMS of the lower extremity with inguinal metastasis at presentation.
  • The in-transit lymphatics can be a site of failure in children with alveolar RMS of the extremity and nodal involvement.
  • [MeSH-major] Lymphatic Metastasis / physiopathology. Rhabdomyosarcoma, Alveolar / secondary. Soft Tissue Neoplasms / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. DACARBAZINE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19711439.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Pyridines; 1CC1JFE158 / Dactinomycin; 24R60NVC41 / cositecan; 25X51I8RD4 / Niacinamide; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 7673326042 / irinotecan; 7GR28W0FJI / Dacarbazine; 85622-93-1 / temozolomide; 8N3DW7272P / Cyclophosphamide; 9ZOQ3TZI87 / sorafenib; UM20QQM95Y / Ifosfamide; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


11. Ehlers JP, Penne RB, Eagle RC Jr, Carrasco JR: Alveolar rhabdomyosarcoma presenting as an acute orbital mass in the medial rectus muscle. Ophthal Plast Reconstr Surg; 2007 Mar-Apr;23(2):149-51
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar rhabdomyosarcoma presenting as an acute orbital mass in the medial rectus muscle.
  • Rhabdomyosarcoma is the most common pediatric primary neoplasm in the orbit, often presenting with rapid proptosis and orbital symptoms.
  • We describe a 15-year-old girl who presented with an acute mass in her medial rectus muscle that was subsequently diagnosed as widely disseminated alveolar rhabdomyosarcoma.
  • To our knowledge, this represents the first reported case in which an enlarged extraocular muscle was the initial manifestation of disseminated alveolar rhabdomyosarcoma.
  • [MeSH-major] Oculomotor Muscles / pathology. Orbital Neoplasms / pathology. Rhabdomyosarcoma, Alveolar / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17413634.001).
  • [ISSN] 0740-9303
  • [Journal-full-title] Ophthalmic plastic and reconstructive surgery
  • [ISO-abbreviation] Ophthal Plast Reconstr Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / Neoplasm Proteins; 0 / PAX3 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


12. Mercado GE, Barr FG: Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances. Curr Mol Med; 2007 Feb;7(1):47-61
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fusions involving PAX and FOX genes in the molecular pathogenesis of alveolar rhabdomyosarcoma: recent advances.
  • Rhabdomyosarcoma is the most frequent soft tissue sarcoma in the pediatric population.
  • Two main histopathologic variants have been described, embryonal (ERMS) and alveolar (ARMS), which demonstrate clinical and genetic differences.
  • [MeSH-major] Oncogene Proteins, Fusion / genetics. Paired Box Transcription Factors / genetics. Rhabdomyosarcoma, Alveolar / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17311532.001).
  • [ISSN] 1566-5240
  • [Journal-full-title] Current molecular medicine
  • [ISO-abbreviation] Curr. Mol. Med.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA64202; United States / NCI NIH HHS / CA / CA87812; United States / NCI NIH HHS / CA / CA89461
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX3-FOXO1A fusion protein, human; 0 / Paired Box Transcription Factors
  • [Number-of-references] 101
  •  go-up   go-down


13. Ganesan P, Thulkar S, Rajan A, Bakhshi S: Solid variant of alveolar rhabdomyosarcoma mimicking non-Hodgkin lymphoma: case report and review of literature. J Pediatr Hematol Oncol; 2008 Oct;30(10):772-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Solid variant of alveolar rhabdomyosarcoma mimicking non-Hodgkin lymphoma: case report and review of literature.
  • Alveolar rhabdomyosarcoma is a high-grade neoplasm, which forms about 30% of rhabdomyosarcomas.
  • A histopathologic diagnosis of solid variant of alveolar rhabdomyosarcoma was made.
  • The pediatric and adolescent cases of this rare tumor reported in English language literature are reviewed.
  • [MeSH-major] Lymphoma, Non-Hodgkin / diagnosis. Rhabdomyosarcoma, Alveolar / diagnosis


14. Verkarre V, Galmiche-Rolland L, Sarnacki S, Jaubert F: Rhabdomyosarcoma an ubiquitous pediatric tumour. Arkh Patol; 2008 May-Jun;70(3):50-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma an ubiquitous pediatric tumour.
  • Rhabdomyosarcoma is the most common soft tissue tumor in children.
  • It occurs everywhere and its prognosis depends on the location and its histological type--embryonic or alveolar.
  • The new immunohistochemical markers desmin and myogenin in combination with molecular biological detection of specific translocations in alveolar rhabdomyosarcoma improved diagnostic capacities.
  • [MeSH-major] Rhabdomyosarcoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18727437.001).
  • [ISSN] 0004-1955
  • [Journal-full-title] Arkhiv patologii
  • [ISO-abbreviation] Arkh. Patol.
  • [Language] eng
  • [Publication-type] Lectures
  • [Publication-country] Russia (Federation)
  •  go-up   go-down


15. Arush MW, Kollender Y, Issakov J, Shalom RB, Arieh YB, Malkin L, Postovsky S: Unusual leptomeningeal dissemination in a child with extracranial metastatic alveolar rhabdomyosarcoma. Pediatr Hematol Oncol; 2009 Sep;26(6):473-8
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual leptomeningeal dissemination in a child with extracranial metastatic alveolar rhabdomyosarcoma.
  • The authors describe a 6-year-old boy diagnosed with alveolar rhabdomyosarcoma located in the thigh, with distal metastases to lungs, bones, and bone marrow.
  • This case demonstrates the rapidity with which leptomeningeal spread of extracranial metastatic alveolar rhabdomyosarcoma can occur and underscores the importance of diagnostic lumbar puncture and brain radiological investigations at diagnosis, even when the tumors are not in the parameningeal location.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Brain Neoplasms / secondary. Lung Neoplasms / secondary. Meningeal Neoplasms / secondary. Rhabdomyosarcoma, Alveolar / secondary. Soft Tissue Neoplasms / pathology


16. Kohashi K, Oda Y, Yamamoto H, Tamiya S, Takahira T, Takahashi Y, Tajiri T, Taguchi T, Suita S, Tsuneyoshi M: Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype. J Cancer Res Clin Oncol; 2008 Oct;134(10):1097-103
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alterations of RB1 gene in embryonal and alveolar rhabdomyosarcoma: special reference to utility of pRB immunoreactivity in differential diagnosis of rhabdomyosarcoma subtype.
  • PURPOSE: Rhabdomyosarcoma (RMS), which is the most common pediatric soft tissue sarcoma, is classified into two major histologic subtypes, embryonal RMS (ERMS) and alveolar RMS (ARMS).
  • [MeSH-major] Retinoblastoma Protein / biosynthesis. Retinoblastoma Protein / genetics. Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Embryonal / diagnosis. Rhabdomyosarcoma, Embryonal / genetics

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2005 Nov;18(11):1461-70 [15933756.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):3042-8 [8187094.001]
  • [Cites] Nature. 1987 Oct 15-21;329(6140):645-7 [3657988.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1755-9 [1347425.001]
  • [Cites] J Mol Diagn. 2004 Nov;6(4):356-65 [15507675.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):259-67 [11452933.001]
  • [Cites] AJR Am J Roentgenol. 2003 Sep;181(3):879-84 [12933497.001]
  • [Cites] Cancer. 2004 Dec 15;101(12 ):2817-24 [15536621.001]
  • [Cites] Am J Med Genet. 1998 Oct 2;79(4):253-9 [9781904.001]
  • [Cites] Cancer Genet Cytogenet. 2006 Jan 1;164(1):1-9 [16364756.001]
  • [Cites] Clin Cancer Res. 2003 Jan;9(1):235-42 [12538475.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):310-21 [11807989.001]
  • [Cites] Cancer Biol Ther. 2002 Mar-Apr;1(2):97-104 [12170781.001]
  • [Cites] Cancer Genet Cytogenet. 2006 May;167(1):57-65 [16682288.001]
  • [Cites] Cancer Genet Cytogenet. 1999 Mar;109(2):161-5 [10087953.001]
  • [Cites] Nat Rev Cancer. 2003 Sep;3(9):685-94 [12951587.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):421-2 [14706332.001]
  • [Cites] Eur J Cancer. 2004 Jul;40(10):1522-9 [15196536.001]
  • [Cites] Science. 1993 Apr 16;260(5106):361-4 [8469989.001]
  • [Cites] Oncogene. 2001 Mar 1;20(9):1103-9 [11314047.001]
  • [Cites] Diagn Mol Pathol. 2003 Dec;12(4):224-30 [14639108.001]
  • (PMID = 18386058.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Retinoblastoma Protein
  •  go-up   go-down


17. Charytonowicz E, Cordon-Cardo C, Matushansky I, Ziman M: Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell? Cancer Lett; 2009 Jul 8;279(2):126-36
SciCrunch. KEGG: Data: Disease Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar rhabdomyosarcoma: is the cell of origin a mesenchymal stem cell?
  • Alveolar rhabdomyosarcoma (ARMS) is a pediatric sarcoma that typically occurs in older children predominantly arising in the trunk and extremities, and exhibits a worse prognosis than other types of rhabdomyosarcomas.
  • [MeSH-major] Mesenchymal Stromal Cells / pathology. Rhabdomyosarcoma, Alveolar / metabolism. Rhabdomyosarcoma, Alveolar / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19008039.001).
  • [ISSN] 1872-7980
  • [Journal-full-title] Cancer letters
  • [ISO-abbreviation] Cancer Lett.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / Paired Box Transcription Factors
  • [Number-of-references] 100
  •  go-up   go-down


18. Leventhal DD, Spiegel J, Keane W: Laryngeal alveolar rhabdomyosarcoma involving the true vocal fold in an adult: Case report. Ear Nose Throat J; 2010 Dec;89(12):E8
Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Laryngeal alveolar rhabdomyosarcoma involving the true vocal fold in an adult: Case report.
  • Rhabdomyosarcoma of the larynx is extremely rare in adults, as only 17 well-documented cases have been previously reported in the English-language literature.
  • Of these, only 2 cases (both male) involved the alveolar subtype of rhabdomyosarcoma, and neither involved the true vocal folds.
  • We report a case of alveolar rhabdomyosarcoma of the true vocal fold in 54-year-old woman.
  • Management of head and neck rhabdomyosarcoma has evolved from radical surgery to less morbid procedures supplemented with radiation and chemotherapy.
  • Nevertheless, the success of treatment in the pediatric population supports its use in adults.
  • [MeSH-major] Laryngeal Neoplasms / pathology. Laryngeal Neoplasms / therapy. Rhabdomyosarcoma, Alveolar / pathology. Rhabdomyosarcoma, Alveolar / therapy. Vocal Cords / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21174270.001).
  • [ISSN] 1942-7522
  • [Journal-full-title] Ear, nose, & throat journal
  • [ISO-abbreviation] Ear Nose Throat J
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  •  go-up   go-down


19. Ragsdale BD, Lee JP, Mines J: Alveolar rhabdomyosarcoma on the external ear: a case report. J Cutan Pathol; 2009 Feb;36(2):267-9
MedlinePlus Health Information. consumer health - Skin Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Alveolar rhabdomyosarcoma on the external ear: a case report.
  • Alveolar rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma of childhood.
  • In fact, 'middle ear' is what is meant by 'ear' location in the many reports of pediatric RMS.
  • [MeSH-major] Ear Neoplasms / pathology. Rhabdomyosarcoma, Alveolar / pathology. Skin Neoplasms / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19208077.001).
  • [ISSN] 1600-0560
  • [Journal-full-title] Journal of cutaneous pathology
  • [ISO-abbreviation] J. Cutan. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Denmark
  •  go-up   go-down


20. Kazanowska B, Reich A, Stegmaier S, Békássy AN, Leuschner I, Chybicka A, Koscielniak E: Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children. Fetal Pediatr Pathol; 2007 Jan-Feb;26(1):17-31
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pax3-fkhr and pax7-fkhr fusion genes impact outcome of alveolar rhabdomyosarcoma in children.
  • Rhabdomyosarcoma is a highly malignant embryonic tumor of childhood.
  • [MeSH-major] Forkhead Transcription Factors / genetics. PAX7 Transcription Factor / genetics. Paired Box Transcription Factors / genetics. Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / genetics

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17613043.001).
  • [ISSN] 1551-3815
  • [Journal-full-title] Fetal and pediatric pathology
  • [ISO-abbreviation] Fetal Pediatr Pathol
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / PAX3 protein, human; 0 / PAX7 Transcription Factor; 0 / PAX7 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


21. De Pasquale MD, De Ioris MA, Serra A, Pessolano R, Donfrancesco A, De Sio L: Pancreatitis as an unusual presentation of rhabdomyosarcoma. Pediatr Blood Cancer; 2009 Jul;52(7):879-80
MedlinePlus Health Information. consumer health - Pancreatitis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatitis as an unusual presentation of rhabdomyosarcoma.
  • Acute pancreatitis is rarely associated with underlying childhood malignancies.
  • We report a 12-year-old male with acute pancreatitis as the presenting symptom of an alveolar metastatic rhabdomyosarcoma.
  • [MeSH-major] Pancreatitis / diagnosis. Rhabdomyosarcoma, Alveolar / diagnosis

  • Genetic Alliance. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2009 Wiley-Liss, Inc.
  • (PMID = 19213073.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kuroiwa M, Sakamoto J, Shimada A, Suzuki N, Hirato J, Park MJ, Sotomatsu M, Hayashi Y: Manifestation of alveolar rhabdomyosarcoma as primary cutaneous lesions in a neonate with Beckwith-Wiedemann syndrome. J Pediatr Surg; 2009 Mar;44(3):e31-5
SciCrunch. Clinical Genomic Database: Data: Gene Annotation .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Manifestation of alveolar rhabdomyosarcoma as primary cutaneous lesions in a neonate with Beckwith-Wiedemann syndrome.
  • We report a rare case of neonatal Beckwith-Wiedemann syndrome (BWS) associated with alveolar rhabdomyosarcoma (RMS).
  • Alveolar RMS was diagnosed on the basis of excisional biopsy.
  • Thus, neonatal alveolar RMS with BWS may result from an alternate molecular pathway.
  • [MeSH-major] Beckwith-Wiedemann Syndrome / complications. Rhabdomyosarcoma, Alveolar / complications. Rhabdomyosarcoma, Alveolar / diagnosis. Skin Neoplasms / complications

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Beckwith-Wiedemann Syndrome.
  • MedlinePlus Health Information. consumer health - Skin Cancer.
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19302842.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 0 / KCNQ1OT1 protein, human; 0 / Potassium Channels, Voltage-Gated; 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 7673326042 / irinotecan; 8N3DW7272P / Cyclophosphamide; XT3Z54Z28A / Camptothecin; VAC protocol
  •  go-up   go-down


23. McDonald MW, Esiashvili N, George BA, Katzenstein HM, Olson TA, Rapkin LB, Marcus RB Jr: Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys; 2008 Nov 1;72(3):884-91
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiotherapy with use of cone-down boost for pediatric head-and-neck rhabdomyosarcoma.
  • PURPOSE: To report our initial experience using intensity-modulated radiotherapy (IMRT) with a cone-down boost for pediatric head-and-neck rhabdomyosarcoma (RMS).
  • CONCLUSIONS: Our preliminary follow-up of pediatric head-and-neck RMS patients treated with IMRT revealed excellent local control.
  • [MeSH-major] Head and Neck Neoplasms / radiotherapy. Radiotherapy, Intensity-Modulated / methods. Rhabdomyosarcoma, Alveolar / radiotherapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18455321.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


24. Cribbs RK, Shehata BM, Ricketts RR: Primary ovarian rhabdomyosarcoma in children. Pediatr Surg Int; 2008 May;24(5):593-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary ovarian rhabdomyosarcoma in children.
  • Although rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children, primary rhabdomyosarcomas of the ovary are extremely rare, with only eight well-documented pediatric cases previously reported in the literature.
  • We present two additional cases: an alveolar RMS originating in the right ovary with metastatic spread to the splenic flexure of the colon and to both lungs in a 13-year-old African American girl, and an embryonal RMS arising in the right ovary of a 6-year-old Caucasian girl with pre-operative intra-abdominal rupture and a malignant right pleural effusion.
  • [MeSH-major] Ovarian Neoplasms / diagnosis. Rhabdomyosarcoma / diagnosis

  • MedlinePlus Health Information. consumer health - Ovarian Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1997 Sep 15;80(6):1165-70 [9305719.001]
  • [Cites] AMA Arch Pathol. 1959 Jul;68(1):74-82 [13660587.001]
  • [Cites] Int J Gynecol Pathol. 1998 Apr;17(2):113-9 [9553806.001]
  • [Cites] J Pathol Bacteriol. 1955 Oct;70(2):433-8 [13295919.001]
  • [Cites] Histopathology. 1989 Sep;15(3):309-11 [2807189.001]
  • [Cites] Cancer. 1983 Jul 15;52(2):297-300 [6574802.001]
  • [Cites] Cancer. 1989 Aug 15;64(4):899-904 [2545329.001]
  • [Cites] Gynecol Oncol. 1983 Jun;15(3):325-39 [6345285.001]
  • (PMID = 18004572.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


25. Herrmann D, Seitz G, Warmann SW, Bonin M, Fuchs J, Armeanu-Ebinger S: Cetuximab promotes immunotoxicity against rhabdomyosarcoma in vitro. J Immunother; 2010 Apr;33(3):279-86
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cetuximab promotes immunotoxicity against rhabdomyosarcoma in vitro.
  • Multidrug resistance is a common problem in the treatment of childhood rhabdomyosarcoma (RMS).
  • Expression of EGFR and binding of its specific antibody Cetuximab to embryonal RMS cell lines RD and A-204 and alveolar RMS Rh30 were monitored by flow cytometry.
  • Gene expression analysis revealed a high expression of EGFR in all embryonal RMS compared with alveolar RMS.
  • [MeSH-major] Antibodies, Monoclonal / pharmacology. Antibody-Dependent Cell Cytotoxicity / drug effects. Rhabdomyosarcoma, Alveolar / immunology. Rhabdomyosarcoma, Embryonal / immunology

  • Hazardous Substances Data Bank. CETUXIMAB .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20445348.001).
  • [ISSN] 1537-4513
  • [Journal-full-title] Journal of immunotherapy (Hagerstown, Md. : 1997)
  • [ISO-abbreviation] J. Immunother.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antineoplastic Agents; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; PQX0D8J21J / Cetuximab
  •  go-up   go-down


26. Treetipsatit J, Kittikowit W, Zielenska M, Chaipipat M, Thorner PS, Shuangshoti S: Mixed embryonal/alveolar rhabdomyosarcoma of the prostate: report of a case with molecular genetic studies and literature review. Pediatr Dev Pathol; 2009 Sep-Oct;12(5):383-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mixed embryonal/alveolar rhabdomyosarcoma of the prostate: report of a case with molecular genetic studies and literature review.
  • Alveolar rhabdomyosarcoma (RMS) is 1 of 2 main subtypes of RMS in the pediatric age group and tends to occur in the extremities.
  • We report a 28-year-old male with a prostatic tumor that was excised en bloc and showed a RMS with separate areas of embryonal and solid alveolar morphologies at the light microscopic level.
  • Both areas showed diffuse nuclear expression for myogenin, and both areas expressed the PAX3-FKHR fusion gene, a genetic change associated with alveolar but not embryonal RMS.
  • A review of the literature documented only 5 cases of RMS primary to the prostate showing alveolar or mixed histology.
  • Although the diagnostic category of mixed embryonal/alveolar RMS remains in use, the nature of this type of RMS is incompletely understood.
  • In our case, although the morphology was mixed embryonal/alveolar, at the genetic level this tumor was alveolar in nature.
  • [MeSH-major] Neoplasms, Complex and Mixed / pathology. Prostatic Neoplasms / pathology. Rhabdomyosarcoma, Alveolar / pathology. Rhabdomyosarcoma, Embryonal / pathology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • MedlinePlus Health Information. consumer health - Prostate Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19175284.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins, Fusion; 0 / PAX3-FKHR fusion protein, human
  •  go-up   go-down


27. Doelken R, Weigel S, Schueler F, Doelken G, Beck JF: Poor outcome of two children with relapsed state stage IV alveolar rhabdomyosarcoma after allogeneic stem cell transplantation. Pediatr Hematol Oncol; 2005 Dec;22(8):699-703
Genetic Alliance. consumer health - Transplantation.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Poor outcome of two children with relapsed state stage IV alveolar rhabdomyosarcoma after allogeneic stem cell transplantation.
  • The authors report on 2 boys, 11(1/2) and 13 years old, who received allogeneic stem cell transplantation (alloSCT) from their HLA-identical sibling after relapse of stage IV alveolar rhabdomyosarcoma.
  • The authors conclude that an alloSCT derived graft versus tumor effect might not be effective enough to overcome alveolar rhabdomyosarcoma when transplantation is carried out in a nonremission status.
  • [MeSH-major] Hematopoietic Stem Cell Transplantation / adverse effects. Rhabdomyosarcoma, Alveolar / therapy

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16251176.001).
  • [ISSN] 0888-0018
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


28. Goldstein M, Meller I, Issakov J, Orr-Urtreger A: Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors. Neoplasia; 2006 May;8(5):332-43
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Novel genes implicated in embryonal, alveolar, and pleomorphic rhabdomyosarcoma: a cytogenetic and molecular analysis of primary tumors.
  • Rhabdomyosarcoma, the most common pediatric soft tissue sarcoma, likely results from deregulation of the skeletal myogenesis program.
  • Using a combined approach of spectral karyotyping, array-based comparative genomic hybridization (CGH), and expression analysis, we examined 10 primary RMS tumors, including embryonal, alveolar, and the rare adult pleomorphic variant, to explore the involvement of different genes and genetic pathways in RMS tumorigenesis.
  • [MeSH-major] Biomarkers, Tumor / metabolism. Genetic Predisposition to Disease. Neoplasms / genetics. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Alveolar / metabolism. Rhabdomyosarcoma, Embryonal / embryology. Rhabdomyosarcoma, Embryonal / genetics

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Biol Chem. 2001 Oct 5;276(40):37307-16 [11489882.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2772-81 [16381018.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] Am J Physiol Cell Physiol. 2002 Feb;282(2):C383-94 [11788350.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):310-21 [11807989.001]
  • [Cites] EMBO J. 2002 Feb 15;21(4):483-92 [11847097.001]
  • [Cites] J Pathol. 2002 Apr;196(4):450-8 [11920742.001]
  • [Cites] Oncogene. 2002 Apr 25;21(18):2901-7 [11973651.001]
  • [Cites] Cytogenet Cell Genet. 2001;95(3-4):134-42 [12063389.001]
  • [Cites] Jpn J Cancer Res. 2002 Jun;93(6):652-9 [12079513.001]
  • [Cites] Oncogene. 2002 Sep 9;21(40):6175-83 [12214247.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(20):7204-16 [12242297.001]
  • [Cites] Cancer Res. 2002 Dec 1;62(23):6803-7 [12460888.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):73-7 [12550764.001]
  • [Cites] Biol Cell. 2002 Nov;94(7-8):535-43 [12566226.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Mar;141(2):120-7 [12606129.001]
  • [Cites] Biochem J. 2003 Apr 1;371(Pt 1):211-21 [12519076.001]
  • [Cites] J Cell Biol. 2003 Apr 14;161(1):197-209 [12695504.001]
  • [Cites] Matrix Biol. 2003 Mar;22(1):49-54 [12714041.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):327-32 [12865925.001]
  • [Cites] Annu Rev Biochem. 2003;72:743-81 [12676796.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5271-81 [14614009.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Jan 1;148(1):35-43 [14697639.001]
  • [Cites] Physiol Rev. 2004 Jan;84(1):209-38 [14715915.001]
  • [Cites] Cancer Res. 1989 Oct 1;49(19):5407-13 [2766305.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5100-6 [1717137.001]
  • [Cites] Cancer. 1994 Apr 15;73(8):2231-7 [8156531.001]
  • [Cites] Am J Clin Pathol. 1995 Dec;104(6):627-33 [8526204.001]
  • [Cites] Cytogenet Cell Genet. 1996;73(4):325-30 [8751388.001]
  • [Cites] Hum Mol Genet. 1996 Jan;5(1):15-21 [8789435.001]
  • [Cites] Med Pediatr Oncol. 1998 Mar;30(3):156-9 [9434823.001]
  • [Cites] Genes Chromosomes Cancer. 1998 May;22(1):16-25 [9591630.001]
  • [Cites] EMBO J. 1998 Jun 1;17(11):3052-65 [9606188.001]
  • [Cites] Nat Genet. 1998 Oct;20(2):189-93 [9771714.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5340-8 [10498887.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):42-50 [15630414.001]
  • [Cites] Cancer Res. 2005 Apr 1;65(7):2899-905 [15805292.001]
  • [Cites] Gene. 2005 Mar 28;348:65-71 [15777710.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Dec;26(4):275-85 [10534762.001]
  • [Cites] Neoplasia. 1999 Aug;1(3):262-75 [10935481.001]
  • [Cites] Cancer Genet Cytogenet. 2000 Sep;121(2):139-45 [11063797.001]
  • [Cites] J Biol Chem. 2000 Nov 17;275(46):36238-44 [10945974.001]
  • [Cites] Med Pediatr Oncol. 2001 Feb;36(2):259-67 [11452933.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):831-5 [11556833.001]
  • [Cites] Am J Clin Pathol. 2004 Mar;121(3):358-65 [15023040.001]
  • [Cites] Cancer Genet Cytogenet. 2004 May;151(1):73-7 [15120913.001]
  • [Cites] Cancer Res. 2004 Jul 1;64(13):4428-33 [15231651.001]
  • [Cites] Nat Genet. 2004 Nov;36(11):1159-61 [15475955.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1417-23 [4357758.001]
  • [Cites] Hum Pathol. 1985 Aug;16(8):838-43 [4018780.001]
  • [Cites] Nature. 1985 Nov 7-13;318(6041):69-73 [2997622.001]
  • [Cites] Cancer Res. 1987 Aug 15;47(16):4501-7 [3607778.001]
  • [Cites] Cytogenet Cell Genet. 1987;45(3-4):148-55 [3691179.001]
  • [Cites] Cancer Res. 1988 Feb 15;48(4):983-7 [3338090.001]
  • [Cites] Cancer Genet Cytogenet. 2005 May;159(1):10-7 [15860351.001]
  • [Cites] Cancer Genet Cytogenet. 2005 Dec;163(2):138-43 [16337856.001]
  • [Cites] Clin Exp Metastasis. 2000;18(6):439-43 [11592300.001]
  • (PMID = 16790082.001).
  • [ISSN] 1476-5586
  • [Journal-full-title] Neoplasia (New York, N.Y.)
  • [ISO-abbreviation] Neoplasia
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Canada
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Other-IDs] NLM/ PMC1592451
  •  go-up   go-down


29. Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveld GC: FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma. J Cell Biol; 2005 Sep 12;170(6):903-12
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FOXO1a acts as a selective tumor suppressor in alveolar rhabdomyosarcoma.
  • Rhabdomyosarcoma (RMS), the most common pediatric soft-tissue sarcoma, has two major histological subtypes: embryonal RMS (ERMS), which has a favorable prognosis, and alveolar RMS (ARMS), which has a poor outcome.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Trends Biochem Sci. 2002 Jul;27(7):352-60 [12114024.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(20):7204-16 [12242297.001]
  • [Cites] Biochem Soc Trans. 2003 Feb;31(Pt 1):292-7 [12546704.001]
  • [Cites] EMBO J. 2003 Mar 3;22(5):1147-57 [12606579.001]
  • [Cites] Sci STKE. 2003 Mar 4;2003(172):RE5 [12621150.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Sep 30;100(20):11285-90 [13679577.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8205-11 [14603261.001]
  • [Cites] Cell. 2004 May 14;117(4):421-6 [15137936.001]
  • [Cites] Gene. 1988 Jun 15;66(1):1-10 [3417148.001]
  • [Cites] J Cell Biol. 1994 Jun;125(6):1275-87 [8207057.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1522-35 [7862145.001]
  • [Cites] J Biol Chem. 1995 May 19;270(20):11719-22 [7744814.001]
  • [Cites] Proc Natl Acad Sci U S A. 1995 May 9;92(10):4206-10 [7753783.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(5):393-403 [7634381.001]
  • [Cites] J Cell Biochem. 1997 Dec 15;67(4):514-27 [9383710.001]
  • [Cites] Cardiovasc Res. 1997 Nov;36(2):163-73 [9463628.001]
  • [Cites] Mol Cell Biol. 2002 Apr;22(7):2025-36 [11884591.001]
  • [Cites] Dev Biol. 2002 Apr 15;244(2):305-18 [11944939.001]
  • [Cites] Cell Death Differ. 2002 May;9(5):493-504 [11973608.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Aug 20;99(17):11025-30 [12177420.001]
  • [Cites] Br J Cancer. 2001 Sep 14;85(6):831-5 [11556833.001]
  • [Cites] Mol Cell Biol. 1999 Jan;19(1):594-601 [9858583.001]
  • [Cites] Cell. 1999 Mar 19;96(6):857-68 [10102273.001]
  • [Cites] Mol Biol Cell. 1999 Oct;10(10):3137-50 [10512856.001]
  • [Cites] J Biol Chem. 2004 Nov 5;279(45):47311-9 [15322110.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2608-13 [15520281.001]
  • [Cites] Mol Cell Biol. 2005 Sep;25(17):7645-56 [16107711.001]
  • [Cites] Am J Pathol. 2000 Feb;156(2):399-408 [10666368.001]
  • [Cites] Clin Genet. 2000 Jan;57(1):16-25 [10733231.001]
  • [Cites] Nature. 2000 Apr 13;404(6779):782-7 [10783894.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):96-103 [10918230.001]
  • [Cites] Cell. 2000 Sep 15;102(6):777-86 [11030621.001]
  • [Cites] Mol Cell Biol. 2000 Dec;20(24):9138-48 [11094066.001]
  • [Cites] Philos Trans R Soc Lond B Biol Sci. 2000 Jul 29;355(1399):965-70 [11128990.001]
  • [Cites] Biochem J. 2000 Jul 15;349(Pt 2):629-34 [10880363.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1589-94 [11171995.001]
  • [CommentIn] NIH Guide Grants Contracts. 2011 Jun 17;:NOT-OD-11-084 [21714172.001]
  • [RetractionIn] Bois PR, Izeradjene K, Houghton PJ, Cleveland JL, Houghton JA, Grosveldz GC. J Cell Biol. 2007 May 7;177(3):563 [17485494.001]
  • [CommentIn] Fed Regist. 2011 Jun 9;76(111):33763-33764 [27737203.001]
  • (PMID = 16157701.001).
  • [ISSN] 0021-9525
  • [Journal-full-title] The Journal of cell biology
  • [ISO-abbreviation] J. Cell Biol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA071907; United States / NCI NIH HHS / CA / R01 CA087952; United States / NCI NIH HHS / CA / CA 71907; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CA / CA 96696; United States / NCI NIH HHS / CA / CA 87952; United States / NCI NIH HHS / CA / CA 23099; United States / NCI NIH HHS / CA / R01 CA096696; United States / NCI NIH HHS / CA / CA 21765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.; Retracted Publication
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXO1 protein, human; 0 / Fluorescent Dyes; 0 / Forkhead Transcription Factors; 0 / Indoles; 0 / Recombinant Fusion Proteins; 47165-04-8 / DAPI; EC 1.13.12.- / Luciferases; EC 3.4.22.- / CASP3 protein, human; EC 3.4.22.- / Casp3 protein, mouse; EC 3.4.22.- / Caspase 3; EC 3.4.22.- / Caspases
  • [Other-IDs] NLM/ PMC2171446
  •  go-up   go-down


30. Lisboa S, Cerveira N, Vieira J, Torres L, Ferreira AM, Afonso M, Norton L, Henrique R, Teixeira MR: Genetic diagnosis of alveolar rhabdomyosarcoma in the bone marrow of a patient without evidence of primary tumor. Pediatr Blood Cancer; 2008 Oct;51(4):554-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genetic diagnosis of alveolar rhabdomyosarcoma in the bone marrow of a patient without evidence of primary tumor.
  • Alveolar rhabdomyosarcoma (ARMS) is characterized by two pathognomonic translocations, both involving the FOXO1 gene.
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / genetics. Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / genetics

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18561177.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


31. van den Broeke LT, Pendleton CD, Mackall C, Helman LJ, Berzofsky JA: Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors. Cancer Res; 2006 Feb 1;66(3):1818-23
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Identification and epitope enhancement of a PAX-FKHR fusion protein breakpoint epitope in alveolar rhabdomyosarcoma cells created by a tumorigenic chromosomal translocation inducing CTL capable of lysing human tumors.
  • Here, we identify such a fusion protein breakpoint epitope in the PAX-FKHR fusion protein created by the t(2;13) translocation present in 80% of cases of alveolar rhabdomyosarcoma, a highly aggressive pediatric soft-tissue sarcoma.
  • These human peptide-specific CTL lyse human HLA-B7+ rhabdomyosarcoma tumor cells.
  • This epitope-enhanced peptide may serve as a candidate cancer vaccine for HLA-B7+ patients with alveolar rhabdomyosarcoma.
  • [MeSH-major] Epitopes / immunology. Forkhead Transcription Factors / immunology. Immunotherapy, Adoptive / methods. Oncogene Proteins, Fusion / immunology. Paired Box Transcription Factors / immunology. Rhabdomyosarcoma, Alveolar / immunology. T-Lymphocytes, Cytotoxic / immunology

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16452243.001).
  • [ISSN] 0008-5472
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Epitopes; 0 / Forkhead Transcription Factors; 0 / HLA-B7 Antigen; 0 / Oncogene Proteins, Fusion; 0 / Paired Box Transcription Factors
  •  go-up   go-down


32. Ferguson SE, Gerald W, Barakat RR, Chi DS, Soslow RA: Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults. Am J Surg Pathol; 2007 Mar;31(3):382-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathologic features of rhabdomyosarcoma of gynecologic origin in adults.
  • Rhabdomyosarcoma (RMS) is the most common soft tissue tumor found in children.
  • Of the remaining 4 tumors, 2 were of alveolar (vulva) and 2 of pleomorphic (uterus, 1; fallopian tube, 1) histologic subtype.
  • Adult RMS of gynecologic origin presents with locoregional disease and most are morphologically similar to pediatric RMS; however, adult RMS behaves more aggressively, with worse overall survival.
  • [MeSH-major] Genital Neoplasms, Female / pathology. Rhabdomyosarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Am J Surg Pathol. 2008 Jan;32(1):174 [18162788.001]
  • (PMID = 17325479.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


33. Machleder DJ, Banik R, Rosenberg RB, Parikh SR: An unusual case of rhabdomyosarcoma presenting as orbital apex syndrome. Int J Pediatr Otorhinolaryngol; 2005 Feb;69(2):249-54
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An unusual case of rhabdomyosarcoma presenting as orbital apex syndrome.
  • PRECIS: A 12-year-old female presented with symptoms and signs of orbital apex syndrome (OAS), secondary to stage IV alveolar rhabdomyosarcoma (RMS) originating in the sphenoid and ethmoid sinuses.
  • OBJECTIVE: To present a case of alveolar rhabdomyosarcoma, unusual in its presentation as orbital apex syndrome and also its origin from the sphenoid and ethmoid sinuses.
  • Emergent biopsy was interpreted as alveolar rhabdomyosarcoma; subsequent metastatic work-up revealed bone marrow metastases.
  • The patient was diagnosed with stage IV alveolar rhabdomyosarcoma and immediately started on combination orbital radiation therapy (RT) and systemic chemotherapy.
  • CONCLUSION: Alveolar rhabdomyosarcoma of paranasal origin, specifically from the sphenoid and ethmoid sinuses, should be included in the differential diagnosis for orbital apex syndrome in children.
  • [MeSH-major] Orbital Neoplasms / diagnosis. Orbital Neoplasms / secondary. Paranasal Sinus Neoplasms / diagnosis. Rhabdomyosarcoma, Alveolar / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15656960.001).
  • [ISSN] 0165-5876
  • [Journal-full-title] International journal of pediatric otorhinolaryngology
  • [ISO-abbreviation] Int. J. Pediatr. Otorhinolaryngol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 22
  •  go-up   go-down


34. Lazaridou MN, Nabili S, Lavy T: Orbital rhabdomyosarcoma masquerading as a mucocele. J Pediatr Ophthalmol Strabismus; 2008 Sep-Oct;45(5):306-8
MedlinePlus Health Information. consumer health - Tears.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital rhabdomyosarcoma masquerading as a mucocele.
  • The authors describe a case of orbital rhabdomyosarcoma masquerading as a lacrimal mucocele in a newborn infant.
  • Rhabdomyosarcoma is one of the few life-threatening diseases that an ophthalmologist may be the first to diagnose.
  • [MeSH-major] Lacrimal Apparatus Diseases / diagnosis. Mucocele / diagnosis. Orbital Neoplasms / diagnosis. Rhabdomyosarcoma, Alveolar / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18825904.001).
  • [ISSN] 0191-3913
  • [Journal-full-title] Journal of pediatric ophthalmology and strabismus
  • [ISO-abbreviation] J Pediatr Ophthalmol Strabismus
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  •  go-up   go-down


35. Jha P, Frölich AM, McCarville B, Navarro OM, Babyn P, Goldsby R, Daldrup-Link H: Unusual association of alveolar rhabdomyosarcoma with pancreatic metastasis: emerging role of PET-CT in tumor staging. Pediatr Radiol; 2010 Aug;40(8):1380-6
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Unusual association of alveolar rhabdomyosarcoma with pancreatic metastasis: emerging role of PET-CT in tumor staging.
  • BACKGROUND: Pancreatic metastases in childhood cancer have been rarely reported in the radiology literature although ample evidence exists in pathology reports for its occurrence in patients with alveolar rhabdomyosarcomas (RMS).
  • OBJECTIVE: Assess the occurrence of pancreatic metastases in alveolar rhabdomyosarcomas, increase awareness of this association and reassess current staging protocols.
  • RESULTS: Pancreatic metastases occurred in eight patients with alveolar RMS.
  • Pancreatic metastases were not associated with certain primary tumor locations or presence of other metastases, mandating an evaluation of the pancreas in all cases of alveolar rhabdomyosarcomas.
  • CONCLUSION: Radiologists should be sensitized and actively evaluate the pancreas in patients with alveolar RMS.
  • [MeSH-major] Pancreatic Neoplasms / complications. Pancreatic Neoplasms / radiography. Positron-Emission Tomography. Rhabdomyosarcoma, Alveolar / complications. Rhabdomyosarcoma, Alveolar / radiography

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Oncol. 2000 Jul;12(4):337-44 [10888419.001]
  • [Cites] J Clin Oncol. 2009 Jul 10;27(20):3391-7 [19398574.001]
  • [Cites] Growth Horm IGF Res. 2001 Oct;11(5):289-97 [11735247.001]
  • [Cites] Arch Dis Child. 2003 Apr;88(4):354-7 [12651771.001]
  • [Cites] Pediatr Dev Pathol. 2004 Jul-Aug;7(4):361-9 [15383931.001]
  • [Cites] Cancer. 1969 Jul;24(1):18-31 [5790286.001]
  • [Cites] Cell Growth Differ. 1990 Jul;1(7):325-31 [2177632.001]
  • [Cites] Pediatr Clin North Am. 1997 Aug;44(4):953-72 [9286294.001]
  • [Cites] Oncologist. 1999;4(1):34-44 [10337369.001]
  • [Cites] Acta Cytol. 1999 May-Jun;43(3):447-51 [10349379.001]
  • [Cites] Pediatr Hematol Oncol. 1999 Sep-Oct;16(5):463-7 [10505324.001]
  • [Cites] AJR Am J Roentgenol. 2005 Apr;184(4):1293-304 [15788613.001]
  • [Cites] Gastrointest Endosc. 2005 May;61(6):689-96 [15855973.001]
  • [Cites] Cancer Res. 2006 Jul 1;66(13):6570-8 [16818629.001]
  • [Cites] J Clin Oncol. 2007 Dec 1;25(34):5435-41 [18048826.001]
  • [Cites] Surg Clin North Am. 2008 Jun;88(3):615-27, vii [18514702.001]
  • [Cites] Eur J Nucl Med Mol Imaging. 2009 Jan;36(1):23-36 [18719909.001]
  • [Cites] Ann Nucl Med. 2009 Feb;23(2):155-61 [19225939.001]
  • [Cites] AJR Am J Roentgenol. 2001 Jun;176(6):1563-9 [11373233.001]
  • (PMID = 20180103.001).
  • [ISSN] 1432-1998
  • [Journal-full-title] Pediatric radiology
  • [ISO-abbreviation] Pediatr Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  • [Other-IDs] NLM/ PMC2895865
  •  go-up   go-down


36. Huh WW, Beverly Raney R: Orbital metastasis in patients with rhabdomyosarcoma: case series and review of the literature. J Pediatr Hematol Oncol; 2006 Oct;28(10):684-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Orbital metastasis in patients with rhabdomyosarcoma: case series and review of the literature.
  • We present 3 cases of children who developed recurrent rhabdomyosarcoma with metastases to the orbit and review the medical literature.
  • Alveolar rhabdomyosarcoma was diagnosed in 7 cases.
  • [MeSH-major] Orbital Neoplasms / secondary. Pelvic Neoplasms / secondary. Rhabdomyosarcoma / secondary

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17023831.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 18
  •  go-up   go-down


37. Barr FG, Duan F, Smith LM, Gustafson D, Pitts M, Hammond S, Gastier-Foster JM: Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. Genes Chromosomes Cancer; 2009 Aug;48(8):661-72
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.
  • Alveolar rhabdomyosarcoma (ARMS) is an aggressive pediatric cancer that is related to the skeletal muscle lineage and characterized by recurrent chromosomal translocations.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 1998 Dec;11(12):1222-7 [9872655.001]
  • [Cites] Am J Pathol. 1998 May;152(5):1107-23 [9588877.001]
  • [Cites] Pediatr Dev Pathol. 1998 Nov-Dec;1(6):550-61 [9724344.001]
  • [Cites] Biometrika. 1951 Jun;38(1-2):141-9 [14848119.001]
  • [Cites] J Clin Oncol. 2005 Feb 1;23(4):880-8 [15681534.001]
  • [Cites] Br J Cancer. 2005 Jul 11;93(1):124-30 [15970925.001]
  • [Cites] J Mol Diagn. 2006 May;8(2):202-8 [16645206.001]
  • [Cites] Cancer. 2006 May 15;106(10):2218-23 [16568472.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] Hum Pathol. 2006 Sep;37(9):1123-9 [16938516.001]
  • [Cites] Mol Cancer. 2006;5:39 [17002787.001]
  • [Cites] Oncogene. 2006 Nov 9;25(53):7106-16 [16732325.001]
  • [Cites] Semin Cancer Biol. 2007 Feb;17(1):42-55 [17161620.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Jun;28(2):220-6 [10825007.001]
  • [Cites] Neoplasia. 1999 Aug;1(3):262-75 [10935481.001]
  • [Cites] Clin Cancer Res. 2000 Aug;6(8):3199-204 [10955804.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):310-21 [11807989.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Cancer Lett. 2004 Feb 20;204(2):179-87 [15013217.001]
  • [Cites] Am J Clin Pathol. 1995 Dec;104(6):627-33 [8526204.001]
  • [Cites] Oncogene. 1996 Sep 5;13(5):1065-72 [8806696.001]
  • [Cites] Cancer Res. 1996 Nov 15;56(22):5141-5 [8912848.001]
  • [Cites] Genes Chromosomes Cancer. 1996 Dec;17(4):254-9 [8946207.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):93-101 [9149737.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1831-6 [9164192.001]
  • [Cites] Blood. 1999 Jun 15;93(12):4365-74 [10361135.001]
  • (PMID = 19422036.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA81659; United States / NCI NIH HHS / CA / CA24507; United States / NCI NIH HHS / CA / R01 CA104896; United States / NCI NIH HHS / CA / CA104896; United States / NCI NIH HHS / CA / U01 CA054021; United States / NCI NIH HHS / CA / CA081659-02; United States / NCI NIH HHS / CA / U10 CA081659-02; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / R01 CA104896-04; United States / NCI NIH HHS / CA / U10 CA024507; United States / NCI NIH HHS / CA / U10 CA98543; United States / NCI NIH HHS / CA / CA054021
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / MYCN protein, human; 0 / Nuclear Proteins; 0 / Oncogene Proteins; 0 / PAX3 protein, human; 0 / PAX7 Transcription Factor; 0 / PAX7 protein, human; 0 / Paired Box Transcription Factors; EC 2.7.11.22 / CDK4 protein, human; EC 2.7.11.22 / Cyclin-Dependent Kinase 4; EC 3.6.1.- / DDX1 protein, human; EC 3.6.4.13 / DEAD-box RNA Helicases
  • [Other-IDs] NLM/ NIHMS138256; NLM/ PMC2739400
  •  go-up   go-down


38. Seitz G, Warmann SW, Fuchs J, Heitmann H, Mahrt J, Busse AC, Ruck P, Hoffman RM, Wessels JT: Imaging of cell trafficking and metastases of paediatric rhabdomyosarcoma. Cell Prolif; 2008 Apr;41(2):365-74

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of cell trafficking and metastases of paediatric rhabdomyosarcoma.
  • OBJECTIVE: The aim of this study was to establish a preclinical mouse model to study metastases of paediatric rhabdomyosarcoma at the macroscopic and cellular levels, with different imaging methods.
  • EXPERIMENTAL DESIGN: The alveolar rhabdomyosarcoma cell line Rh30 was stably transfected with the red fluorescent protein (DsRed2) then was xenotransplanted (intravenous injection [n = 8], and footpad injection [n = 8]) into nude mice (NMRI nu/nu).
  • In a further series of animals (n = 8), in vivo cell trafficking of rhabdomyosarcoma cells using cellular imaging with an Olympus OV100 variable-magnification small-animal imaging system was used.
  • CONCLUSION: We established a model for visualization of experimental metastatic invasion and describe relevant tools for imaging childhood rhabdomyosarcoma metastases at the macroscopic and cellular levels.
  • Imaging of cell trafficking visualized the behaviour of tumour cells and development of metastases by accumulation and extravasation of rhabdomyosarcoma cells.
  • [MeSH-major] Image Interpretation, Computer-Assisted / methods. Imaging, Three-Dimensional / methods. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / secondary. X-Ray Intensifying Screens

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18336479.001).
  • [ISSN] 1365-2184
  • [Journal-full-title] Cell proliferation
  • [ISO-abbreviation] Cell Prolif.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Luminescent Proteins; 0 / red fluorescent protein
  •  go-up   go-down


39. Raney RB, Anderson JR, Brown KL, Huh WW, Maurer HM, Meyer WH, Parham DM, Rodeberg DA, Wolden SL, Donaldson SS, Soft-Tissue Sarcoma Committee of the Children's Oncology Group Arcadia California USA: Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group. Pediatr Blood Cancer; 2010 Oct;55(4):612-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment results for patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma on Intergroup Rhabdomyosarcoma Study Group (IRSG) protocols III and IV, 1984-1997: a report from the Children's Oncology Group.
  • PURPOSE: To assess local control, event-free survival (EFS), and overall survival (OS) rates in 71 patients with localized, completely resected (Group I) alveolar rhabdomyosarcoma (ALV RMS) and their relation to radiation therapy (RT) on IRSG Protocols III and IV, 1984-1997.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Wiley-Liss, Inc.
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3468-75 [10550144.001]
  • [Cites] J Clin Oncol. 1999 Dec;17(12):3706-19 [10577842.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] J Clin Oncol. 2009 Nov 1;27(31):5182-8 [19770373.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Eur J Cancer. 1998 Jun;34(7):1050-62 [9849454.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2618-28 [15728225.001]
  • [Cites] J Clin Oncol. 2009 Mar 20;27(9):1446-55 [19224858.001]
  • [CommentIn] Pediatr Blood Cancer. 2010 Oct;55(4):597-8 [20589627.001]
  • (PMID = 20806360.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA-98543; United States / NCI NIH HHS / CA / U10 CA072989; United States / NCI NIH HHS / CA / U10 CA029511; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-72989; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / CA-29511; United States / NCI NIH HHS / CA / U10 CA024507
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS263511; NLM/ PMC3128801
  •  go-up   go-down


40. Rodeberg DA, Erskine C, Celis E: In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma. J Pediatr Surg; 2007 Aug;42(8):1396-402
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] In vitro induction of immune responses to shared tumor-associated antigens in rhabdomyosarcoma.
  • PURPOSE: Currently, novel therapies to improve survival of patients with rhabdomyosarcoma (RMS) are being investigated.
  • METHODS: Rhabdomyosarcoma tumor lysate-pulsed human dendritic cells were used to stimulate HTL precursors (naive CD4+ T-cells) in vitro.
  • The HTLs were induced using lysate from a single alveolar RMS tumor cell line (RMS13).
  • The clones generated recognized all of the alveolar RMS cell lines (RMS13, Rh18, Rh28, Rh30, and Rh41), prostate cancer cell lines (LNCAP and LAPC4), melanoma cell lines (Mel 624 and G361), and breast cancer cell line (SKBR3).
  • [MeSH-major] Antigens, Neoplasm / immunology. CD4-Positive T-Lymphocytes / immunology. Cancer Vaccines / immunology. Dendritic Cells / immunology. Rhabdomyosarcoma / immunology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17706503.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50CA91956; United States / NCI NIH HHS / CA / R01CA80782
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Cancer Vaccines
  •  go-up   go-down


41. Suita S, Noguchi S, Takamatsu H, Mizote H, Nagasaki A, Inomata Y, Hara T, Okamura J, Miyazaki S, Kawakami K, Eguchi H, Tsuneyoshi M, Committee for Pediatric Solid Malignant Tumors in the Kyushu Area: Clinical characteristics and the prognosis of rhabdomyosarcoma - a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan. Eur J Pediatr Surg; 2005 Dec;15(6):409-13
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and the prognosis of rhabdomyosarcoma - a report from the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area, Japan.
  • AIM: There have been no nationwide group studies for patients with rhabdomyosarcoma in Japan.
  • PATIENTS AND METHODS: From 1982 to 1996, 79 rhabdomyosarcomas were registered by the Study Group for Pediatric Solid Malignant Tumors in the Kyushu Area.
  • The staging was done according to the Intergroup Rhabdomyosarcoma Study (IRS) Clinical Grouping Classification.
  • 3) histology: 35.8 % for the embryonal type, 36.8 % for the alveolar type.
  • To improve outcomes, a new nationwide group study for rhabdomyosarcoma, which we belong to, has just started in Japan.
  • [MeSH-major] Head and Neck Neoplasms / mortality. Rhabdomyosarcoma / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16418958.001).
  • [ISSN] 0939-7248
  • [Journal-full-title] European journal of pediatric surgery : official journal of Austrian Association of Pediatric Surgery ... [et al] = Zeitschrift für Kinderchirurgie
  • [ISO-abbreviation] Eur J Pediatr Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


42. Abd El-Aal HH, Habib EE, Mishrif MM: Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001). J Egypt Natl Canc Inst; 2006 Mar;18(1):51-60

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma: the experience of the pediatric unit of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) (from January 1992 to January 2001).
  • Our present study is a retrospective analysis of the treatment results of new rhabdomyosarcoma pediatric patients who had attended the pediatric unit clinic of Kasr El-Aini Center of Radiation Oncology and Nuclear Medicine (NEMROCK) from January 1992 to January 2001).
  • PATIENTS AND METHODS: Fifty-five new cases of pediatric rhabdomyosarcoma attended the pediatric unit outpatient clinic of (NEMROCK) from the period of January 1992 until January 2001.
  • RESULTS: Fifty-five new cases of pediatric rhabdomyosarcoma attended the pediatric unit outpatient clinic of (NEMROCK) and were evaluated.
  • 87.3%) compared to the alveolar type (7/55, i.e. 12.7%).
  • CONCLUSION: Despite the advances in the therapy of rhabdomyosarcoma.
  • Nearly 30% of the pediatric cases with rhabdomyosarcoma experience progressive or relapsing disease, which has a fatal end.
  • These findings will form the basis of a multi-institutional risk adapted relapse protocol for childhood rhabdomyosarcoma patients.
  • [MeSH-major] Rhabdomyosarcoma / mortality. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17237856.001).
  • [ISSN] 1110-0362
  • [Journal-full-title] Journal of the Egyptian National Cancer Institute
  • [ISO-abbreviation] J Egypt Natl Canc Inst
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Egypt
  •  go-up   go-down


43. Tanyous GH: Rhabdomyosarcoma of the nasal vestibule in a child. Sultan Qaboos Univ Med J; 2006 Dec;6(2):87-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma of the nasal vestibule in a child.
  • A case of rhabdomyosarcoma in a 2 year old girl without a pre-existing predisposing factor visited the ENT Department of Sultan Qaboos University Hospital (SQUH).
  • The histopathology report was alveolar rhabdomyosarcoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Otolaryngol. 2003 May-Jun;24(3):174-80 [12761705.001]
  • [Cites] Med Pediatr Oncol. 1991;19(2):110-4 [2011095.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • (PMID = 21748141.001).
  • [ISSN] 2075-051X
  • [Journal-full-title] Sultan Qaboos University medical journal
  • [ISO-abbreviation] Sultan Qaboos Univ Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC3074915
  • [Keywords] NOTNLM ; Case Report / Nasal rhabdomyosarcoma / Oman / pediatric age
  •  go-up   go-down


44. Barlow JW, Wiley JC, Mous M, Narendran A, Gee MF, Goldberg M, Sexsmith E, Malkin D: Differentiation of rhabdomyosarcoma cell lines using retinoic acid. Pediatr Blood Cancer; 2006 Nov;47(6):773-84
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Differentiation of rhabdomyosarcoma cell lines using retinoic acid.
  • BACKGROUND: Rhabdomyosarcoma (RMS) is the most frequent sporadic soft tissue sarcoma of childhood and adolescence.
  • Novel therapeutic approaches are necessary to improve on these outcomes particularly among the more aggressive alveolar RMS (ARMS) and late stages of disease, where 5-year survival is less than 20%.
  • [MeSH-major] Cell Differentiation / drug effects. Rhabdomyosarcoma / drug therapy. Tretinoin / pharmacology. Tumor Suppressor Protein p53 / genetics

  • Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .
  • Hazardous Substances Data Bank. ALITRETINOIN .
  • Hazardous Substances Data Bank. ETHANOL .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 Wiley-Liss, Inc.
  • (PMID = 16283617.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / TP53 protein, human; 0 / Troponin T; 0 / Tumor Suppressor Protein p53; 3K9958V90M / Ethanol; 5300-03-8 / alitretinoin; 5688UTC01R / Tretinoin
  •  go-up   go-down


45. Ognjanovic S, Linabery AM, Charbonneau B, Ross JA: Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005. Cancer; 2009 Sep 15;115(18):4218-26
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Trends in childhood rhabdomyosarcoma incidence and survival in the United States, 1975-2005.
  • BACKGROUND: Rhabdomyosarcoma (RMS) is the most common soft tissue sarcoma in children and adolescents aged<20 years; its etiology remains largely unknown.
  • It is believed that embryonal (ERMS) and alveolar rhabdomyosarcoma (ARMS), the most common subtypes, arise through distinct biologic mechanisms.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • [Cites] Pediatr Dev Pathol. 2001 Nov-Dec;4(6):550-8 [11826361.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] Biometrics. 1983 Dec;39(4):941-8 [6671129.001]
  • [Cites] Med Pediatr Oncol. 1988;16(1):33-9 [3277029.001]
  • [Cites] Br J Cancer. 1988 Dec;58(6):838-42 [3224086.001]
  • [Cites] Science. 1990 Nov 30;250(4985):1233-8 [1978757.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):365-8 [1735603.001]
  • [Cites] Cancer Causes Control. 1993 May;4(3):217-24 [8318638.001]
  • [Cites] Genet Epidemiol. 1995;12(5):467-74 [8557179.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Cancer. 1995 Dec 1;76(11):2343-50 [8635041.001]
  • [Cites] Cancer. 1996 Oct 1;78(7):1483-91 [8839555.001]
  • [Cites] Diagn Mol Pathol. 1997 Apr;6(2):91-7 [9098647.001]
  • [Cites] Cancer Res. 1999 Apr 1;59(7 Suppl):1743s-1746s [10197590.001]
  • [Cites] Oncologist. 1999;4(1):34-44 [10337369.001]
  • [Cites] Pediatr Dev Pathol. 1998 Nov-Dec;1(6):550-61 [9724344.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1457-67 [15712273.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] J Pathol. 2007 Jun;212(2):143-51 [17471488.001]
  • [Cites] Med Sci Monit. 2008 Jan;14(1):RA8-15 [18160950.001]
  • [Cites] Cancer. 2008 Jan 15;112(2):416-32 [18074355.001]
  • [Cites] Bone. 2008 May;42(5):982-9 [18337201.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2003 Feb 15;117C(1):42-8 [12561057.001]
  • [Cites] Cancer Res. 2003 Oct 15;63(20):6643-50 [14583457.001]
  • [Cites] J Pediatr. 2004 May;144(5):666-8 [15127010.001]
  • [Cites] Curr Probl Cancer. 1978 Mar;2(9):1-36 [109248.001]
  • [Cites] Eur J Cancer. 2008 Oct;44(15):2226-32 [18691878.001]
  • [Cites] Med Pediatr Oncol. 2002 Dec;39(6):554-7; discussion 552-3 [12376977.001]
  • [Cites] J Natl Cancer Inst. 1982 Jan;68(1):107-13 [6948120.001]
  • (PMID = 19536876.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / T32 CA099936-07; United States / NCI NIH HHS / CA / T32 CA099936-06S1; United States / NCI NIH HHS / CA / CA099936-07; United States / NCI NIH HHS / CA / T32 CA099936; United States / NCI NIH HHS / CA / CA099936-06S1
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS218300; NLM/ PMC2953716
  •  go-up   go-down


46. Ognjanovic S, Carozza SE, Chow EJ, Fox EE, Horel S, McLaughlin CC, Mueller BA, Puumala S, Reynolds P, Von Behren J, Spector L: Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype. Br J Cancer; 2010 Jan 5;102(1):227-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Birth characteristics and the risk of childhood rhabdomyosarcoma based on histological subtype.
  • BACKGROUND: Little is known about risk factors for childhood rhabdomyosarcoma (RMS) and the histology-specific details are rare.
  • METHODS: Case-control studies formed by linking cancer and birth registries of California, Minnesota, New York, Texas and Washington, which included 583 RMS cases (363 embryonal and 85 alveolar RMS) and 57 966 randomly selected control subjects, were analysed using logistic regression.
  • The associations of RMS (overall, and based on embryonal or alveolar histology) with birth weight across five 500 g categories (from 2000 to 4500 g) were examined using normal birth weight (2500-3999 g) as a reference.
  • CONCLUSIONS: These data suggest a positive association between accelerated in utero growth and embryonal RMS, but not alveolar RMS.
  • These results warrant cautious interpretation owing to the small number of alveolar RMS cases.
  • [MeSH-major] Rhabdomyosarcoma / epidemiology. Soft Tissue Neoplasms / epidemiology
  • [MeSH-minor] Adolescent. Adult. Age of Onset. Birth Order. Birth Weight. Child. Child, Preschool. Diseases in Twins / epidemiology. Embryonic Development. Female. Gestational Age. Humans. Infant. Infant, Newborn. Male. Maternal Age. Paternal Age. Rhabdomyosarcoma, Alveolar / embryology. Rhabdomyosarcoma, Alveolar / epidemiology. Rhabdomyosarcoma, Embryonal / embryology. Rhabdomyosarcoma, Embryonal / epidemiology. Risk Factors. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eur J Pediatr. 2001 Jun;160(6):333-8 [11421411.001]
  • [Cites] Br J Cancer. 2008 Jul 8;99(1):179-81 [18560404.001]
  • [Cites] Clin Genet. 2002 Jul;62(1):84-8 [12123493.001]
  • [Cites] J Pediatr. 2002 Oct;141(4):538-42 [12378194.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jan;89(1):384-91 [14715876.001]
  • [Cites] Pediatr Clin North Am. 2004 Jun;51(3):639-54, viii [15157589.001]
  • [Cites] Eur J Obstet Gynecol Reprod Biol. 2004 Sep 10;116(1):3-15 [15294360.001]
  • [Cites] Cancer Genet Cytogenet. 2004 Oct 15;154(2):169-74 [15474156.001]
  • [Cites] Ann Intern Med. 1969 Oct;71(4):747-52 [5360287.001]
  • [Cites] J Natl Cancer Inst. 1969 Dec;43(6):1365-73 [5396222.001]
  • [Cites] J Natl Cancer Inst. 1982 Jan;68(1):107-13 [6948120.001]
  • [Cites] Med Pediatr Oncol. 1988;16(1):33-9 [3277029.001]
  • [Cites] Br J Cancer. 1988 Dec;58(6):838-42 [3224086.001]
  • [Cites] Genes Chromosomes Cancer. 1989 Sep;1(1):23-35 [2487144.001]
  • [Cites] Int J Cancer. 1992 Feb 1;50(3):365-8 [1735603.001]
  • [Cites] Nature. 1993 Apr 22;362(6422):747-9 [8385745.001]
  • [Cites] Cancer Causes Control. 1993 May;4(3):217-24 [8318638.001]
  • [Cites] J Clin Invest. 1995 Apr;95(4):1606-11 [7706467.001]
  • [Cites] J Pediatr. 1998 Mar;132(3 Pt 1):398-400 [9544889.001]
  • [Cites] Med Pediatr Oncol. 1999 Jan;32(1):38-43 [9917751.001]
  • [Cites] Oncologist. 1999;4(1):34-44 [10337369.001]
  • [Cites] Am J Clin Nutr. 2005 Mar;81(3):678-85 [15755839.001]
  • [Cites] Cancer. 2005 Apr 1;103(7):1457-67 [15712273.001]
  • [Cites] Am J Med Genet C Semin Med Genet. 2005 Aug 15;137C(1):72-7 [16010679.001]
  • [Cites] Nat Genet. 2005 Oct;37(10):1038-40 [16170316.001]
  • [Cites] J Obstet Gynecol Neonatal Nurs. 2006 Jan-Feb;35(1):3-12 [16466348.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):816-22 [16391296.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):345-8 [16534790.001]
  • [Cites] Cancer. 2007 Apr 1;109(7):1406-12 [17330850.001]
  • [Cites] J Pediatr Hematol Oncol. 2007 May;29(5):341-4 [17483716.001]
  • [Cites] J Pathol. 2007 Jun;212(2):143-51 [17471488.001]
  • [Cites] Am J Epidemiol. 2008 Aug 15;168(4):366-73 [18579539.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Jan;18(1):162-8 [19124494.001]
  • [Cites] Int J Cancer. 2009 Jun 1;124(11):2658-70 [19173295.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2009 Apr;18(4):1271-6 [19293315.001]
  • [Cites] Pediatrics. 2009 Jul;124(1):96-104 [19564288.001]
  • [Cites] Cancer. 2009 Sep 15;115(18):4218-26 [19536876.001]
  • [Cites] BMJ. 2002 Feb 2;324(7332):283-7 [11823363.001]
  • (PMID = 19997102.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2813761
  •  go-up   go-down


47. Seitz G, Warmann SW, Fuchs J, Mau-Holzmann UA, Ruck P, Heitmann H, Hoffman RM, Mahrt J, Müller GA, Wessels JT: Visualization of xenotransplanted human rhabdomyosarcoma after transfection with red fluorescent protein. J Pediatr Surg; 2006 Aug;41(8):1369-76

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Visualization of xenotransplanted human rhabdomyosarcoma after transfection with red fluorescent protein.
  • The aims of this study were to establish a DsRed2-transfected human rhabdomyosarcoma (RMS) cell line and to perform a xenotransplantation on nude mice to use imaging as a tool for further basic research studies on this neoplasm.
  • PROCEDURE: The human alveolar RMS cell line Rh30 was transfected with the pDsRed2-N1 vector by lipofection.
  • [MeSH-major] Luminescent Agents. Luminescent Proteins. Neoplasm Transplantation. Rhabdomyosarcoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16863839.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Luminescent Agents; 0 / Luminescent Proteins; 0 / red fluorescent protein
  •  go-up   go-down


48. Galindo RL, Allport JA, Olson EN: A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR. Proc Natl Acad Sci U S A; 2006 Sep 5;103(36):13439-44
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A Drosophila model of the rhabdomyosarcoma initiator PAX7-FKHR.
  • Alveolar rhabdomyosarcoma (ARMS) is an aggressive myogenic-type tumor and a gain-of-function disease, caused by misexpression of the PAX3-FKHR or PAX7-FKHR fusion oncoprotein from structurally rearranged chromosomes.
  • PAX3-FKHR misexpressed in terminally differentiating mouse myofibers can cause rhabdomyosarcoma at a low frequency, suggesting that skeletal muscle is an ARMS tissue of origin.
  • [MeSH-major] Drosophila / genetics. Forkhead Transcription Factors / genetics. Oncogene Proteins, Fusion. PAX7 Transcription Factor / genetics. Rhabdomyosarcoma, Alveolar / genetics

  • FlyBase. FlyBase .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genes Dev. 2003 Dec 1;17(23):2950-65 [14665670.001]
  • [Cites] Nature. 2005 Feb 24;433(7028):884-7 [15729346.001]
  • [Cites] Science. 1982 Oct 22;218(4570):348-53 [6289436.001]
  • [Cites] Mol Cell Biol. 1987 Jun;7(6):2104-11 [3600660.001]
  • [Cites] Nat Biotechnol. 2000 Mar;18(3):304-8 [10700146.001]
  • [Cites] Cell. 2000 Sep 29;103(1):63-74 [11051548.001]
  • [Cites] Development. 2001 Feb;128(3):395-405 [11152638.001]
  • [Cites] Cell. 2000 Dec 22;103(7):1099-109 [11163185.001]
  • [Cites] Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):1589-94 [11171995.001]
  • [Cites] Oncogene. 2001 Sep 10;20(40):5736-46 [11607823.001]
  • [Cites] Trends Genet. 2002 Jan;18(1):41-7 [11750700.001]
  • [Cites] Dev Biol. 2002 Apr 15;244(2):226-42 [11944933.001]
  • [Cites] Mol Cell Biol. 2002 Oct;22(20):7204-16 [12242297.001]
  • [Cites] Genesis. 2002 Sep-Oct;34(1-2):135-8 [12324968.001]
  • [Cites] Immunol Rev. 2003 Aug;194:19-28 [12846804.001]
  • [Cites] Nature. 2003 Oct 2;425(6957):507-12 [14523446.001]
  • [Cites] Science. 2003 Nov 14;302(5648):1227-31 [14551319.001]
  • [Cites] Development. 2003 Dec;130(25):6257-72 [14602676.001]
  • [Cites] J Cell Biol. 1988 Jun;106(6):2127-37 [3133379.001]
  • [Cites] Oncogene. 1989 Apr;4(4):473-81 [2654809.001]
  • [Cites] Cell. 1991 Nov 15;67(4):701-16 [1934068.001]
  • [Cites] Development. 1991 Sep;113(1):79-89 [1765010.001]
  • [Cites] Development. 1991 Sep;113(1):91-102 [1765011.001]
  • [Cites] Development. 1993 May;118(1):21-31 [8375335.001]
  • [Cites] Development. 1993 Jun;118(2):401-15 [8223268.001]
  • [Cites] Science. 1995 Feb 3;267(5198):688-93 [7839146.001]
  • [Cites] Science. 1995 Mar 24;267(5205):1788-92 [7892602.001]
  • [Cites] Methods Cell Biol. 1994;44:445-87 [7707967.001]
  • [Cites] Development. 1996 Feb;122(2):409-18 [8625792.001]
  • [Cites] EMBO J. 1996 Jul 15;15(14):3722-31 [8670876.001]
  • [Cites] Neuron. 1996 Oct;17(4):641-54 [8893022.001]
  • [Cites] Oncogene. 1997 Feb 13;14(6):697-704 [9038377.001]
  • [Cites] J Cell Sci. 1998 Apr;111 ( Pt 8):1081-93 [9512504.001]
  • [Cites] Genes Dev. 1998 Dec 15;12(24):3910-22 [9869644.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] Genetics. 1999 Sep;153(1):135-77 [10471706.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2614-26 [15489287.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2608-13 [15520281.001]
  • [Cites] Dev Biol. 2004 Nov 15;275(2):375-88 [15501225.001]
  • (PMID = 16938866.001).
  • [ISSN] 0027-8424
  • [Journal-full-title] Proceedings of the National Academy of Sciences of the United States of America
  • [ISO-abbreviation] Proc. Natl. Acad. Sci. U.S.A.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / Oncogene Proteins, Fusion; 0 / PAX7 Transcription Factor; 0 / PAX7 protein, human
  • [Other-IDs] NLM/ PMC1569182
  •  go-up   go-down


49. Seitz G, Warmann SW, Vokuhl CO, Heitmann H, Treuner C, Leuschner I, Fuchs J: Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma. Pediatr Surg Int; 2007 May;23(5):431-9
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effects of standard chemotherapy on tumor growth and regulation of multidrug resistance genes and proteins in childhood rhabdomyosarcoma.
  • The prognosis of rhabdomyosarcoma (RMS) in advanced stages is still sobering.
  • The aim of this study was to investigate the development of multidrug resistance in cell lines and in xenografts of alveolar and embryonal RMS treated according to the German Soft Tissue Sarcoma Study (CWS).
  • Alveolar and embryonal RMS cell lines were treated with Vincristine, Topotecan, Carboplatin, Actinomycin D, or Ifosfamide.
  • Nude mice (NMRI nu/nu, n = 10 per group) underwent xenotransplantation of human embryonal or alveolar RMS.
  • In the cell lines, an up-regulation of MDR-1 gene was found in alveolar rhabdomyosarcoma.
  • In embryonal rhabdomyosarcoma, an up-regulation of LRP and MRP was found.
  • Standard chemotherapy of alveolar rhabdomyosarcoma resulted in a significant reduction of tumor growth (P < 0.05) in all groups.
  • In embryonal rhabdomyosarcoma strongest effects were found after treatment with Ifosfamide, Vincristine and Carboplatin (P < 0.05).
  • RT-PCR revealed a MDR1-dependent mechanism in alveolar rhabdomyosarcoma.
  • In embryonal rhabdomyosarcoma, MDR1 occurred to a lower degree.
  • [MeSH-major] Drug Resistance, Neoplasm / drug effects. Gene Expression Regulation, Neoplastic / drug effects. Genes, MDR / genetics. Multidrug Resistance-Associated Proteins / drug effects. Rhabdomyosarcoma, Alveolar / drug therapy. Rhabdomyosarcoma, Embryonal / drug therapy. Soft Tissue Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):96-103 [10918230.001]
  • [Cites] Cancer. 2002 Oct 15;95(8):1795-801 [12365029.001]
  • [Cites] Hum Pathol. 2003 Feb;34(2):150-5 [12612883.001]
  • [Cites] Pediatr Dev Pathol. 2002 May-Jun;5(3):276-82 [12007020.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] Cancer. 1997 Sep 15;80(6):1165-70 [9305719.001]
  • [Cites] Cell Mol Biol (Noisy-le-grand). 1994 Mar;40(2):137-45 [7911694.001]
  • [Cites] Pediatr Blood Cancer. 2007 Mar;48(3):311-7 [16609945.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Paediatr Drugs. 2002;4(1):21-8 [11817983.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Clin Cancer Res. 1999 Nov;5(11):3617-31 [10589779.001]
  • [Cites] Cancer. 1998 Dec 1;83(11):2400-7 [9840541.001]
  • [Cites] Clin Cancer Res. 1999 Aug;5(8):2198-204 [10473106.001]
  • [Cites] Cancer Chemother Pharmacol. 2003 Aug;52(2):131-8 [12783202.001]
  • [Cites] Int J Oncol. 1998 May;12(5):1143-9 [9538141.001]
  • [Cites] Pediatr Hematol Oncol. 2005 Jul-Aug;22(5):373-86 [16020127.001]
  • [Cites] Anticancer Res. 2000 Sep-Oct;20(5C):3759-65 [11268451.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):791-8 [16077930.001]
  • [Cites] Cancer Res. 2003 Apr 1;63(7):1515-9 [12670898.001]
  • [Cites] J Clin Oncol. 1990 Apr;8(4):689-704 [1968964.001]
  • [Cites] J Natl Cancer Inst. 1973 Nov;51(5):1417-23 [4357758.001]
  • [Cites] J Pathol. 1996 Sep;180(1):85-9 [8943821.001]
  • [Cites] Cancer. 2003 May 15;97(10):2597-604 [12733159.001]
  • [Cites] Cancer Gene Ther. 2005 Apr;12 (4):397-406 [15618970.001]
  • [Cites] Br J Cancer. 2000 Aug;83(3):338-45 [10917549.001]
  • [Cites] Br J Cancer. 2001 Nov 30;85(11):1746-52 [11742497.001]
  • [Cites] Curr Drug Targets. 2006 Jul;7(7):813-21 [16842213.001]
  • [Cites] Cancer Res. 1993 Apr 1;53(7):1475-9 [7680954.001]
  • [Cites] J Clin Oncol. 1990 Mar;8(3):443-52 [2407808.001]
  • [Cites] J Biol Chem. 2001 Mar 2;276(9):6874-8 [11152666.001]
  • [Cites] Clin Cancer Res. 2001 Oct;7(10 ):3193-8 [11595714.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3844-51 [16921036.001]
  • [Cites] Lancet Oncol. 2000 Oct;1:75-85 [11905672.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Anticancer Drugs. 1997 Feb;8(2):125-40 [9073309.001]
  • [Cites] Cancer Chemother Rep. 1966 May;50(4):219-44 [4957125.001]
  • [Cites] Cancer. 2003 Apr 15;97(8):1999-2005 [12673730.001]
  • [Cites] Cancer Invest. 2000;18(3):223-41 [10754991.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2618-28 [15728225.001]
  • [Cites] Cancer Res. 2006 May 1;66(9):4742-9 [16651427.001]
  • [Cites] Anticancer Res. 2003 Nov-Dec;23 (6C):4607-11 [14981903.001]
  • (PMID = 17211591.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Multidrug Resistance-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


50. Bouron-Dal Soglio D, Rougemont AL, Absi R, Barrette S, Montpetit A, Fetni R, Fournet JC: SNP genotyping of a sclerosing rhabdomyosarcoma: reveals highly aneuploid profile and a specific MDM2/HMGA2 amplification. Hum Pathol; 2009 Sep;40(9):1347-52

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] SNP genotyping of a sclerosing rhabdomyosarcoma: reveals highly aneuploid profile and a specific MDM2/HMGA2 amplification.
  • Since the first description of sclerosing rhabdomyosarcoma in 2000, 19 pediatric cases have been reported in the literature.
  • However, it is debated whether sclerosing rhabdomyosarcoma represents a specific rhabdomyosarcoma entity or a variant of embryonal or alveolar rhabdomyosarcoma.
  • To date, 6 sclerosing rhabdomyosarcoma karyotypes and 1 sclerosing rhabdomyosarcoma comparative genomic hybridization profile have been reported.
  • We present the first whole-genome tumoral genotyping of a sclerosing rhabdomyosarcoma by high-density single nucleotide polymorphism array.
  • Amplification of the 12q13-q15 region containing SAS, GLI, CDK4, and MDM2 has been observed in rhabdomyosarcoma.
  • Further studies are needed to assess if this anomaly is a specific marker of sclerosing rhabdomyosarcoma.
  • [MeSH-major] Aneuploidy. HMGA2 Protein / genetics. Polymorphism, Single Nucleotide. Proto-Oncogene Proteins c-mdm2 / genetics. Rhabdomyosarcoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19454362.001).
  • [ISSN] 1532-8392
  • [Journal-full-title] Human pathology
  • [ISO-abbreviation] Hum. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / HMGA2 Protein; EC 6.3.2.19 / MDM2 protein, human; EC 6.3.2.19 / Proto-Oncogene Proteins c-mdm2
  •  go-up   go-down


51. Seitz G, Pfeiffer M, Fuchs J, Warmann SW, Leuschner I, Vokuhl C, Lang P, Handgretinger R, Armeanu-Ebinger S: Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice. Oncol Rep; 2010 Oct;24(4):1067-72

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Establishment of a rhabdomyosarcoma xenograft model in human-adapted mice.
  • The outcome of patients with advanced stage rhabdomyosarcoma (RMS) is still sobering.
  • The aim of this study was to develop a humanized mouse model of childhood RMS as a basis for the study of immunotherapeutic approaches.
  • Eight weeks after transplantation, the subcutaneous xenotransplantation of human alveolar and embryonal RMS cell lines was carried out.
  • The xenotransplantation of alveolar RMS resulting in subcutaneous tumor growth was feasible in 7 animals.
  • A histological work up showed either alveolar or embryonal RMS cells with central necrosis.
  • The establishment of subcutaneous tumor xenografts was more effective in the alveolar subtype.
  • This model offers a basic tool for further analyzing novel immunotherapeutic approaches in RMS, and could possibly be used in other solid pediatric tumors.
  • [MeSH-major] Disease Models, Animal. Rhabdomyosarcoma. Soft Tissue Neoplasms. Transplantation, Heterologous / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20811690.001).
  • [ISSN] 1791-2431
  • [Journal-full-title] Oncology reports
  • [ISO-abbreviation] Oncol. Rep.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


52. Sultan I, Qaddoumi I, Yaser S, Rodriguez-Galindo C, Ferrari A: Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients. J Clin Oncol; 2009 Jul 10;27(20):3391-7
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparing adult and pediatric rhabdomyosarcoma in the surveillance, epidemiology and end results program, 1973 to 2005: an analysis of 2,600 patients.
  • PURPOSE: To compare clinical features and outcomes of adults and children reported to have rhabdomyosarcoma.
  • PATIENTS AND METHODS: We analyzed data from 1,071 adults (age > 19 years) and 1,529 children (age < or = 19 years) reported in the public-access Surveillance, Epidemiology and End Results database as having rhabdomyosarcoma, diagnosed from 1973 to 2005.
  • RESULTS: Adults with rhabdomyosarcoma had significantly worse outcome than children (5-year overall survival rates, 27% +/- 1.4% and 61% +/- 1.4%, respectively; P < .0001).
  • Tumors in adults were more likely to be at an unfavorable site (65% v 55%; P < .0001) and to have histologies that are unusual during childhood, particularly the pleomorphic subtype (19%) and not otherwise specified (43%).
  • However, alveolar subtype and unfavorable primary site lost significance when analysis was restricted to adults.
  • CONCLUSION: Adults reported to have rhabdomyosarcoma had worse survival than children with similar tumors.
  • Predictors of poor outcome in children were valid in adults except for alveolar histology and unfavorable tumor site.
  • [MeSH-major] Rhabdomyosarcoma / epidemiology. SEER Program / statistics & numerical data

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19398574.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


53. D'Angelo P, Carli M, Ferrari A, Manzitti C, Mura R, Miglionico L, Di Cataldo A, Grigoli A, Cecchetto G, Bisogno G, AIEOP Soft Tissue Sarcoma Committee: Breast metastases in children and adolescents with rhabdomyosarcoma: Experience of the Italian Soft Tissue Sarcoma Committee. Pediatr Blood Cancer; 2010 Dec 15;55(7):1306-9
MedlinePlus Health Information. consumer health - Breast Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Breast metastases in children and adolescents with rhabdomyosarcoma: Experience of the Italian Soft Tissue Sarcoma Committee.
  • BACKGROUND: Breast metastasis from rhabdomyosarcoma (RMS) is an uncommon event but may be problematic in treatment decision-making.
  • All patients were females, aged 13-17 years with alveolar histology and multiple metastasis sites (2-5).
  • CONCLUSIONS: Our data suggest that investigations of the mammary region should be part of the usual diagnostic workup in adolescent girls with alveolar RMS, especially if the primary tumor arises in the extremities.
  • [MeSH-major] Breast Neoplasms / secondary. Muscle Neoplasms / pathology. Rhabdomyosarcoma / secondary

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Wiley-Liss, Inc.
  • (PMID = 20730885.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


54. Myers AL, Williams RF, Ng CY, Hartwich JE, Davidoff AM: Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation. J Pediatr Surg; 2010 Jun;45(6):1080-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Bevacizumab-induced tumor vessel remodeling in rhabdomyosarcoma xenografts increases the effectiveness of adjuvant ionizing radiation.
  • We tested this hypothesis using bevacizumab, an anti-VEGF antibody, in rhabdomyosarcoma (RMS) xenografts.
  • METHODS: Mice bearing orthotopic alveolar RMS xenografts were treated with a single dose of bevacizumab, IR, or a combination of the two on different schedules.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • [Cites] Nature. 1993 Apr 29;362(6423):841-4 [7683111.001]
  • [Cites] Surg Clin North Am. 2008 Jun;88(3):615-27, vii [18514702.001]
  • [Cites] Oncogene. 2005 Dec 1;24(54):8025-37 [16116481.001]
  • [Cites] Clin Cancer Res. 2007 Jul 1;13(13):3942-50 [17606728.001]
  • [Cites] Trends Mol Med. 2007 Jun;13(6):223-30 [17462954.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3844-51 [16921036.001]
  • [Cites] J Neurooncol. 1987;4(4):403-15 [3572471.001]
  • [Cites] Science. 1983 Feb 25;219(4587):983-5 [6823562.001]
  • [Cites] Blood. 2002 Nov 1;100(9):3361-8 [12384438.001]
  • [Cites] Nat Med. 2001 Sep;7(9):987-9 [11533692.001]
  • (PMID = 20620299.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / 21766; United States / NCI NIH HHS / CA / CA23099; United States / NCI NIH HHS / CA / P30 CA021765-29; United States / NCI NIH HHS / CA / P01 CA023099-290014; None / None / / P30 CA021765-29; United States / NCI NIH HHS / CA / CA023099-290014; United States / NCI NIH HHS / CA / P01 CA023099; United States / NCI NIH HHS / CA / P30 CA021765
  • [Publication-type] Comparative Study; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Actins; 0 / Antibodies, Monoclonal; 0 / Antibodies, Monoclonal, Humanized; 0 / Antigens, CD34; 0 / Vascular Endothelial Growth Factor A; 2S9ZZM9Q9V / Bevacizumab
  • [Other-IDs] NLM/ NIHMS182905; NLM/ PMC2904306
  •  go-up   go-down


55. Cecchetto G, Carretto E, Bisogno G, Dall'Igna P, Ferrari A, Scarzello G, Donfrancesco A, Alaggio R, Indolfi P, Carli M: Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee. Pediatr Blood Cancer; 2008 Nov;51(5):593-7
Genetic Alliance. consumer health - Soft tissue sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Complete second look operation and radiotherapy in locally advanced non-alveolar rhabdomyosarcoma in children: A report from the AIEOP soft tissue sarcoma committee.
  • BACKGROUND: To evaluate the effect of radiotherapy (RT) in association with complete second look operation, histologically confirmed, on outcome of patients with IRS Gr.III non-alveolar RMS.
  • Although the limited number of patients does not allow statistically significant conclusions, our experience suggests that RT may have a positive influence on local control for completely resected non-alveolar RMS.
  • [MeSH-major] Rhabdomyosarcoma / radiotherapy. Rhabdomyosarcoma / surgery. Second-Look Surgery

  • Genetic Alliance. consumer health - Rhabdomyosarcoma alveolar.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18668515.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


56. Durbin AD, Somers GR, Forrester M, Pienkowska M, Hannigan GE, Malkin D: JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma. J Clin Invest; 2009 Jun;119(6):1558-70
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] JNK1 determines the oncogenic or tumor-suppressive activity of the integrin-linked kinase in human rhabdomyosarcoma.
  • Here, we demonstrated that ILK functions as an oncogene in the highly aggressive pediatric sarcoma alveolar rhabdomyosarcoma (ARMS) and as a tumor suppressor in the related embryonal rhabdomyosarcoma (ERMS).
  • Ectopic expression of the fusion gene characteristic of ARMS (paired box 3-forkhead homolog in rhabdomyosarcoma [PAX3-FKHR]) in ERMS cells was sufficient to convert them to an ARMS signaling phenotype and render ILK activity oncogenic.
  • These findings indicate what we believe to be a novel effector pathway regulated by ILK, provide a mechanism for interconversion of oncogenic and tumor-suppressor functions of a single regulatory protein based on the genetic background of the tumor cells, and suggest a rationale for tailored therapy of rhabdomyosarcoma based on the different activities of ILK.
  • [MeSH-major] Mitogen-Activated Protein Kinase 8 / metabolism. Oncogene Proteins / metabolism. Protein-Serine-Threonine Kinases / metabolism. Rhabdomyosarcoma / enzymology. Tumor Suppressor Proteins / metabolism

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Virchows Arch. 1998 Aug;433(2):113-7 [9737788.001]
  • [Cites] EMBO J. 1996 Jun 3;15(11):2760-70 [8654373.001]
  • [Cites] Oncogene. 2004 Nov 25;23(55):8959-70 [15467740.001]
  • [Cites] Nat Rev Cancer. 2005 Jan;5(1):51-63 [15630415.001]
  • [Cites] Cancer Res. 2005 Feb 15;65(4):1497-504 [15735038.001]
  • [Cites] Mol Cell Biol. 2005 May;25(9):3648-57 [15831470.001]
  • [Cites] Biochem Biophys Res Commun. 2005 Jun 17;331(4):1061-8 [15882985.001]
  • [Cites] Pediatr Dev Pathol. 2006 Mar-Apr;9(2):132-42 [16822084.001]
  • [Cites] Cancer Sci. 2006 Jul;97(7):563-7 [16827794.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] Hepatology. 2006 Sep;44(3):612-22 [16941698.001]
  • [Cites] Oncogene. 2007 Mar 1;26(10):1372-84 [16936772.001]
  • [Cites] J Cell Biol. 2007 May 7;177(3):501-13 [17485490.001]
  • [Cites] Cell Cycle. 2007 Jun 1;6(11):1298-303 [17534150.001]
  • [Cites] Genes Dev. 2007 Jul 15;21(14):1731-46 [17626791.001]
  • [Cites] Int J Radiat Biol. 2007 Nov-Dec;83(11-12):793-802 [18058367.001]
  • [Cites] Mol Cancer Ther. 2008 Jan;7(1):59-70 [18202010.001]
  • [Cites] Genes Dev. 2008 Feb 15;22(4):449-62 [18258752.001]
  • [Cites] Cancer Res. 2008 May 1;68(9):3476-85 [18451176.001]
  • [Cites] Biochem Biophys Res Commun. 1996 Dec 4;229(1):36-43 [8954080.001]
  • [Cites] Hum Mol Genet. 1998 May;7(5):895-903 [9536095.001]
  • [Cites] Cancer Cell. 2008 Jul 8;14(1):36-46 [18598942.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6587-97 [18701482.001]
  • [Cites] J Histochem Cytochem. 2008 Sep;56(9):819-29 [18505933.001]
  • [Cites] Proc Natl Acad Sci U S A. 1998 Sep 15;95(19):11211-6 [9736715.001]
  • [Cites] Nat Protoc. 2008;3(6):1101-8 [18546601.001]
  • [Cites] Proc Natl Acad Sci U S A. 2000 Mar 28;97(7):3207-12 [10716737.001]
  • [Cites] J Biol Chem. 2001 Jul 20;276(29):27462-9 [11313365.001]
  • [Cites] Oncogene. 2001 Oct 25;20(48):7064-72 [11704830.001]
  • [Cites] Nat Cell Biol. 2002 May;4(5):E131-6 [11988758.001]
  • [Cites] J Cell Sci. 2002 Sep 15;115(Pt 18):3587-99 [12186945.001]
  • [Cites] J Biol Chem. 2002 Oct 18;277(42):40043-54 [12171923.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):78-84 [12506174.001]
  • [Cites] Mol Cell. 2003 Jun;11(6):1491-501 [12820963.001]
  • [Cites] Biochem Biophys Res Commun. 2003 Oct 24;310(3):796-803 [14550274.001]
  • [Cites] Oncogene. 2003 Nov 6;22(50):8205-11 [14603261.001]
  • [Cites] Cancer Cell. 2004 Jan;5(1):79-90 [14749128.001]
  • [Cites] Int J Cancer. 2004 Oct 10;111(6):881-91 [15300800.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5683-92 [15313908.001]
  • [Cites] J Biol Chem. 2004 Aug 27;279(35):36490-6 [15218033.001]
  • [Cites] J Biol Chem. 2004 Oct 15;279(42):43893-9 [15299025.001]
  • [Cites] Science. 1989 Apr 14;244(4901):217-21 [2649981.001]
  • [Cites] Br J Cancer. 1993 Apr;67(4):674-9 [8471424.001]
  • [Cites] Nature. 1996 Jan 4;379(6560):91-6 [8538749.001]
  • [CommentIn] J Clin Invest. 2009 Jun;119(6):1452-5 [19504719.001]
  • (PMID = 19478459.001).
  • [ISSN] 1558-8238
  • [Journal-full-title] The Journal of clinical investigation
  • [ISO-abbreviation] J. Clin. Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Oncogene Proteins; 0 / Oncogene Proteins, Fusion; 0 / PAX3-FKHR fusion protein, human; 0 / RNA, Small Interfering; 0 / Tumor Suppressor Proteins; EC 2.7.1.- / integrin-linked kinase; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.24 / Mitogen-Activated Protein Kinase 8
  • [Other-IDs] NLM/ PMC2689127
  •  go-up   go-down


57. Sartori F, Alaggio R, Zanazzo G, Garaventa A, Di Cataldo A, Carli M, Rosolen A, AIEOP Comitato Strategico de Studio-Sarcomi: Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers. Cancer; 2006 Apr 15;106(8):1766-75
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of a prospective minimal disseminated disease study in human rhabdomyosarcoma using three different molecular markers.
  • BACKGROUND: Rhabdomyosarcoma (RMS) has 2 major histologic subtypes: alveolar (ARMS) and embryonal (ERMS).
  • METHODS: We determined the sensitivity and specificity of MyoD1, myogenin, and PAX-FKHR transcripts as RMS markers and used them to study prospectively by reverse-transcriptase polymerase chain reaction (RT-PCR) a series of consecutive unselected RMS patients enrolled in the Italian Association of Pediatric Hematology and Oncology national trial.
  • [MeSH-major] Rhabdomyosarcoma / diagnosis. Rhabdomyosarcoma / secondary
  • [MeSH-minor] Biomarkers, Tumor / analysis. Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / secondary. Child. Forkhead Transcription Factors / analysis. Humans. Immunohistochemistry. MyoD Protein / analysis. Myogenin / analysis. Paired Box Transcription Factors / analysis. Reverse Transcriptase Polymerase Chain Reaction. Rhabdomyosarcoma, Alveolar / chemistry. Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / secondary. Rhabdomyosarcoma, Embryonal / chemistry. Rhabdomyosarcoma, Embryonal / diagnosis. Rhabdomyosarcoma, Embryonal / secondary. Sensitivity and Specificity

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2006 American Cancer Society
  • (PMID = 16544315.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / MyoD Protein; 0 / MyoD1 myogenic differentiation protein; 0 / Myogenin; 0 / PAX3 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


58. Seitz G, Bonin M, Fuchs J, Poths S, Ruck P, Warmann SW, Armeanu-Ebinger S: Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma. Int J Oncol; 2010 Feb;36(2):491-500
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of glutathione-S-transferase as a treatment strategy for multidrug resistance in childhood rhabdomyosarcoma.
  • Multidrug resistance (MDR) is a common problem in the treatment of childhood rhabdomyosarcoma (RMS).
  • The aim of this study was to investigate the role of glutathione-S-transferase (GST) as mechanism of MDR in childhood RMS and to analyze possible reversal strategies.
  • Female athymic mice underwent xenotransplantation with embryonal or alveolar RMS cells and were treated with vincristine.
  • Gene expression analysis using Affymetrix HU-Gene 1.0 arrays revealed 2314 differentially expressed genes between the groups in alveolar RMS and 1387 in embryonal RMS.
  • In order to analyze possible GST activity after chemotherapy with other commonly used drugs (doxorubicin, topotecan), cell culture experiments with alveolar and embryonal RMS cells were carried out.
  • We detected a novel mechanism for MDR in childhood RMS mediated via genes and proteins of the GST family.
  • The GST family represents a promising target for further treatment strategies in childhood RMS.
  • [MeSH-major] Drug Resistance, Multiple / genetics. Drug Resistance, Neoplasm / genetics. Glutathione Transferase / antagonists & inhibitors. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Embryonal / genetics

  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20043085.001).
  • [ISSN] 1791-2423
  • [Journal-full-title] International journal of oncology
  • [ISO-abbreviation] Int. J. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Enzyme Inhibitors; 5J49Q6B70F / Vincristine; 7M7YKX2N15 / Topotecan; 80168379AG / Doxorubicin; EC 2.5.1.18 / Glutathione Transferase
  •  go-up   go-down


59. Williamson D, Lu YJ, Gordon T, Sciot R, Kelsey A, Fisher C, Poremba C, Anderson J, Pritchard-Jones K, Shipley J: Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype. J Clin Oncol; 2005 Feb 1;23(4):880-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Relationship between MYCN copy number and expression in rhabdomyosarcomas and correlation with adverse prognosis in the alveolar subtype.
  • Increased copy number and overexpression of MYCN in the pediatric cancer rhabdomyosarcoma has been described in a number of small studies with conflicting conclusions about its association with clinicopathologic characteristics.
  • PATIENTS AND METHODS: Using quantitative polymerase chain reaction, we measured MYCN copy number and expression levels in rhabdomyosarcoma samples from 113 and 92 individuals with a confirmed diagnosis of rhabdomyosarcoma, respectively.
  • RESULTS: Increased copy number of MYCN was found to be a feature of both the embryonal and alveolar subtypes.
  • The copy number and expression levels were significantly greater in the alveolar subtype, although the range of expression in both subtypes spanned several orders of magnitude.
  • MYCN copy number showed a significant correlation with expression in the alveolar subtype; this relationship between copy number and expression could be modeled as a logarithmic function.
  • It is notable that relatively high expression frequently occurred in embryonal rhabdomyosarcoma without high copy number and that low expression was found in some cases with high copy number.
  • In patients with alveolar rhabdomyosarcoma, overexpression (greater than median) or gain of genomic copies of MYCN were significantly associated with adverse outcome.
  • CONCLUSION: MYCN deregulation is a feature of rhabdomyosarcoma tumorigenesis, defines groups of patients with a poor prognosis, and is a potential target for novel therapies.
  • [MeSH-major] Gene Dosage. Genes, myc. Rhabdomyosarcoma / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15681534.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


60. Nikas I, Theofanopoulou M, Lampropoulou P, Pourtsidis A, Hadjigeorgi C, Kosmidis H: Optic pathway glioma associated with orbital rhabdomyosarcoma and bilateral optic nerve sheath dural ectasia in a child with neurofibromatosis-1. Pediatr Radiol; 2006 Nov;36(11):1200-3
MedlinePlus Health Information. consumer health - Neurofibromatosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Optic pathway glioma associated with orbital rhabdomyosarcoma and bilateral optic nerve sheath dural ectasia in a child with neurofibromatosis-1.
  • We present a 2(1/2)-year-old boy with NF-1 who demonstrated coexisting optic pathway glioma with involvement of the chiasm and optic nerve, orbital alveolar rhabdomyosarcoma and bilateral optic nerve sheath dural ectasia.
  • [MeSH-major] Dilatation, Pathologic / diagnostic imaging. Glioma / diagnostic imaging. Neurofibromatoses / diagnostic imaging. Optic Nerve Neoplasms / diagnostic imaging. Orbital Neoplasms / diagnostic imaging. Rhabdomyosarcoma / diagnostic imaging


61. Gallego S, Llort A, Roma J, Sabado C, Gros L, de Toledo JS: Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay. J Cancer Res Clin Oncol; 2006 Jun;132(6):356-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of bone marrow micrometastasis and microcirculating disease in rhabdomyosarcoma by a real-time RT-PCR assay.
  • PURPOSE: To assess if molecular detection of minimal disseminated disease by real-time reverse transcription and polymerase chain reaction (RT-PCR) could contribute to a better treatment stratification in patients with rhabdomyosarcoma (RMS).
  • METHODS: Relative quantification of the tumor-mRNA present in serial samples of bone marrow (BM) and peripheral blood (PB) from 16 patients with RMS (7 alveolar and 9 embryonal) was performed by a real-time RT-PCR assay.
  • Expression of MyoD1 and acetylcholine receptor (AChR) was analyzed in all samples, along with PAX3/7-FKHR in samples from alveolar tumors.
  • [MeSH-major] Bone Marrow Neoplasms / diagnosis. Bone Marrow Neoplasms / secondary. Neoplastic Cells, Circulating. Reverse Transcriptase Polymerase Chain Reaction / methods. Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Embryonal / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1999 Sep;24(5):527-33 [10482938.001]
  • [Cites] Cancer. 1996 Sep 15;78(6):1320-7 [8826957.001]
  • [Cites] J Mol Diagn. 1999 Nov;1(1):23-31 [11272905.001]
  • [Cites] Cancer. 2004 Mar 1;100(5):1053-8 [14983502.001]
  • [Cites] Am J Pathol. 1998 Feb;152(2):437-44 [9466570.001]
  • [Cites] Methods. 2001 Dec;25(4):402-8 [11846609.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1755-9 [1347425.001]
  • [Cites] Br J Cancer. 2003 Apr 7;88(7):1091-4 [12671691.001]
  • [Cites] Am J Pathol. 1998 Feb;152(2):577-83 [9466584.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 Feb;23(2):99-104 [11216714.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] J Exp Clin Cancer Res. 2000 Sep;19(3):375-81 [11144532.001]
  • [Cites] J Clin Oncol. 2001 Mar 15;19(6):1795-801 [11251011.001]
  • [Cites] Trends Mol Med. 2003 May;9(5):189-95 [12763523.001]
  • [Cites] Cancer Res. 1994 Jun 1;54(11):2869-72 [8187070.001]
  • [Cites] Nat Genet. 1993 Feb;3(2):113-7 [8098985.001]
  • [Cites] Genes Chromosomes Cancer. 2000 Apr;27(4):337-44 [10719362.001]
  • [Cites] Med Pediatr Oncol. 2003 Jan;40(1):1-8 [12426678.001]
  • (PMID = 16435141.001).
  • [ISSN] 0171-5216
  • [Journal-full-title] Journal of cancer research and clinical oncology
  • [ISO-abbreviation] J. Cancer Res. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / MyoD Protein; 0 / MyoD1 myogenic differentiation protein; 0 / Oncogene Proteins, Fusion; 0 / RNA, Messenger; 0 / Receptors, Nicotinic
  •  go-up   go-down


62. Eguía-Aguilar P, Ponce-Castañeda V, Nájera-García N, Nieto-Martínez K, Kofman-Alfaro S, Sadowinski-Pine S, Valencia-Mayoral P, Arenas-Huertero F, Perezpeña-Diazconti M: Detection of fusion genes in formalin-fixed paraffin-embedded tissue sections of rhabdomyosarcoma by RT-PCR and fluorescence in situ hybridization in Mexican patients. Arch Med Res; 2010 Feb;41(2):119-24
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Detection of fusion genes in formalin-fixed paraffin-embedded tissue sections of rhabdomyosarcoma by RT-PCR and fluorescence in situ hybridization in Mexican patients.
  • BACKGROUND AND AIMS: Rhabdomyosarcoma (RMS) is a pediatric tumor whose classification is based on histological criteria according to two main subgroups, embryonal RMS (ERMS) and alveolar RMS (ARMS).
  • [MeSH-major] In Situ Hybridization, Fluorescence / methods. Recombinant Fusion Proteins / genetics. Reverse Transcriptase Polymerase Chain Reaction / methods. Rhabdomyosarcoma / genetics

  • Hazardous Substances Data Bank. FORMALDEHYDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 IMSS. Published by Elsevier Inc. All rights reserved.
  • (PMID = 20470941.001).
  • [ISSN] 1873-5487
  • [Journal-full-title] Archives of medical research
  • [ISO-abbreviation] Arch. Med. Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Recombinant Fusion Proteins; 1HG84L3525 / Formaldehyde
  •  go-up   go-down


63. Heerema-McKenney A, Wijnaendts LC, Pulliam JF, Lopez-Terrada D, McKenney JK, Zhu S, Montgomery K, Mitchell J, Marinelli RJ, Hart AA, van de Rijn M, Linn SC: Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype. Am J Surg Pathol; 2008 Oct;32(10):1513-22
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Diffuse myogenin expression by immunohistochemistry is an independent marker of poor survival in pediatric rhabdomyosarcoma: a tissue microarray study of 71 primary tumors including correlation with molecular phenotype.
  • The pathologic classification of rhabdomyosarcoma (RMS) into embryonal or alveolar subtype is an important prognostic factor guiding the therapeutic protocol chosen for an individual patient.
  • The aim of this study is to identify immunohistochemical markers of potential prognostic significance in pediatric RMS and to correlate their expression with PAX-3/FKHR and PAX-7/FKHR fusion status.
  • A single tissue microarray containing 71 paraffin-embedded pediatric RMSs was immunostained with antibodies against p53, bcl-2, Ki-67, CD44, myogenin, and MyoD1.
  • After adjustment for Intergroup Rhabdomyosarcoma Study-TNM stage, tumor site, age, tumor histology, and translocation status by multivariable analysis, only myogenin retained an independent association with RFI (P=0.034) and OS (P=0.0069).
  • [MeSH-major] Biomarkers, Tumor / analysis. Immunohistochemistry. Myogenin / analysis. Rhabdomyosarcoma, Alveolar / chemistry. Rhabdomyosarcoma, Embryonal / chemistry. Tissue Array Analysis

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18708938.001).
  • [ISSN] 1532-0979
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, CD44; 0 / Biomarkers, Tumor; 0 / CD44 protein, human; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / Ki-67 Antigen; 0 / MYOG protein, human; 0 / MyoD Protein; 0 / MyoD1 myogenic differentiation protein; 0 / Myogenin; 0 / Oncogene Proteins, Fusion; 0 / PAX3-FKHR fusion protein, human; 0 / PAX7 Transcription Factor; 0 / PAX7 protein, human; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / TP53 protein, human; 0 / Tumor Suppressor Protein p53
  •  go-up   go-down


64. Ferrari A, Miceli R, Meazza C, Casanova M, Favini F, Morosi C, Trecate G, Marchianò A, Luksch R, Cefalo G, Terenziani M, Spreafico F, Polastri D, Podda M, Catania S, Schiavello E, Giannatempo P, Gandola L, Massimino M, Mariani L: Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma. J Clin Oncol; 2010 Mar 10;28(8):1322-8
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Comparison of the prognostic value of assessing tumor diameter versus tumor volume at diagnosis or in response to initial chemotherapy in rhabdomyosarcoma.
  • PURPOSE: In this study on a series of 205 patients with rhabdomyosarcoma, we investigated whether the prognostic effect of tumor size, at diagnosis or in terms of tumor response after induction chemotherapy, differed when tumor diameter or tumor volume were considered.
  • RESULTS: Initial tumor size was significantly larger in male or older patients and in T2 or alveolar tumors, but was not associated with the achievement of complete surgical resection.
  • CONCLUSION: In our analysis, initial tumor size and tumor response were significant prognostic factors in rhabdomyosarcoma, regardless of whether tumor diameter or volume was considered.
  • [MeSH-major] Decision Support Techniques. Imaging, Three-Dimensional. Rhabdomyosarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20124176.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


65. Ohta H, Hashii Y, Yoneda A, Takizawa S, Kusuki S, Tokimasa S, Fukuzawa M, Tsuboi A, Murao A, Oka Y, Oji Y, Aozasa K, Nakatsuka S, Sugiyama H, Ozono K: WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report. Pediatr Hematol Oncol; 2009 Jan;26(1):74-83
Genetic Alliance. consumer health - Rhabdomyosarcoma 1.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] WT1 (Wilms tumor 1) peptide immunotherapy for childhood rhabdomyosarcoma: a case report.
  • In this study, the authors used WT1 peptide vaccination to treat a 6-year-old girl with metastatic alveolar rhabdomyosarcoma.
  • WT1 peptide-based immunotherapy should be a promising option for high-risk rhabdomyosarcoma in childhood.
  • [MeSH-major] Immunotherapy / methods. Peptide Fragments / therapeutic use. Rhabdomyosarcoma, Alveolar / drug therapy. WT1 Proteins / therapeutic use

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19206012.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Peptide Fragments; 0 / WT1 Proteins
  •  go-up   go-down


66. Rao PK, Missiaglia E, Shields L, Hyde G, Yuan B, Shepherd CJ, Shipley J, Lodish HF: Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells. FASEB J; 2010 Sep;24(9):3427-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Distinct roles for miR-1 and miR-133a in the proliferation and differentiation of rhabdomyosarcoma cells.
  • Rhabdomyosarcoma is the most common soft tissue sarcoma in the pediatric population.
  • Levels of miR-1 and miR-133a are drastically reduced in representative cell lines from each major rhabdomyosarcoma subtype (embryonal and alveolar).
  • Introduction of miR-1 and miR-133a into an embryonal rhabdomyosarcoma-derived cell line is cytostatic, thereby suggesting a tumor suppressor-like role for these myogenic miRNAs.
  • More important, these results point to the promise of enhancing rhabdomyosarcoma therapy using miRNAs as agents that mediate cytostasis and promote muscle differentiation.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma 1.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Genome Biol. 2004;5(3):R13 [15003116.001]
  • [Cites] Genes Chromosomes Cancer. 2009 Jun;48(6):455-67 [19235922.001]
  • [Cites] J Clin Invest. 2009 Aug;119(8):2366-78 [19620785.001]
  • [Cites] J Biol Chem. 2009 Oct 23;284(43):29596-604 [19710019.001]
  • [Cites] Genes Chromosomes Cancer. 1999 Dec;26(4):275-85 [10534762.001]
  • [Cites] J Biol Chem. 2000 Jan 7;275(1):41-6 [10617583.001]
  • [Cites] Mol Cell. 2000 Aug;6(2):233-44 [10983972.001]
  • [Cites] Nat Genet. 2001 Feb;27(2):187-90 [11175787.001]
  • [Cites] J Biol Chem. 2001 Nov 2;276(44):41486-91 [11522799.001]
  • [Cites] Development. 2001 Nov;128(22):4623-33 [11714687.001]
  • [Cites] Exp Cell Res. 1993 Sep;208(1):209-17 [8395398.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1522-35 [7862145.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5340-8 [10498887.001]
  • [Cites] Cancer. 1958 Jan-Feb;11(1):181-99 [13500314.001]
  • [Cites] Cell. 2005 Jan 14;120(1):15-20 [15652477.001]
  • [Cites] RNA. 2005 Mar;11(3):241-7 [15701730.001]
  • [Cites] Genes Dev. 2005 Mar 1;19(5):553-69 [15706034.001]
  • [Cites] Science. 2005 Jul 8;309(5732):310-1 [15919954.001]
  • [Cites] Nature. 2005 Jul 14;436(7048):214-20 [15951802.001]
  • [Cites] Cell. 2005 Dec 16;123(6):1133-46 [16337999.001]
  • [Cites] Nat Genet. 2006 Feb;38(2):228-33 [16380711.001]
  • [Cites] Pathol Int. 2006 May;56(5):246-55 [16669873.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Jun 6;103(23):8721-6 [16731620.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] Am J Surg Pathol. 2006 Aug;30(8):962-8 [16861966.001]
  • [Cites] Dev Biol. 2007 Nov 15;311(2):359-68 [17936265.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20844-9 [18093911.001]
  • [Cites] Blood. 2008 Mar 1;111(5):2505-15 [18299451.001]
  • [Cites] Oncogene. 2008 Mar 27;27(14):2015-26 [17922033.001]
  • [Cites] Oncogene. 2008 Nov 20;27(51):6550-60 [18679424.001]
  • [Cites] Cancer Cell. 2008 Nov 4;14(5):369-81 [18977326.001]
  • [Cites] Nat Protoc. 2009;4(1):44-57 [19131956.001]
  • [Cites] Cell. 2009 Jan 23;136(2):215-33 [19167326.001]
  • [Cites] Mol Biol Cell. 2009 Feb;20(4):1120-31 [19109424.001]
  • [Cites] Genes Dev. 2009 Mar 1;23(5):619-32 [19240126.001]
  • [Cites] Curr Biol. 2002 Apr 30;12(9):735-9 [12007417.001]
  • [Cites] Genome Biol. 2003;4(5):P3 [12734009.001]
  • [Cites] Cell. 2003 Dec 26;115(7):787-98 [14697198.001]
  • [Cites] Cell. 2004 Jan 23;116(2):281-97 [14744438.001]
  • (PMID = 20466878.001).
  • [ISSN] 1530-6860
  • [Journal-full-title] FASEB journal : official publication of the Federation of American Societies for Experimental Biology
  • [ISO-abbreviation] FASEB J.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / R01 DK068348; United Kingdom / Cancer Research UK / / C5066/A9541
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / MicroRNAs
  • [Other-IDs] NLM/ PMC3231107
  •  go-up   go-down


67. Okamura K, Yamamoto H, Ishimaru Y, Takayasu H, Otani Y, Yamagishi J, Takahashi A, Kuwano H, Nagashima K, Ikeda H: Clinical characteristics and surgical treatment of perianal and perineal rhabdomyosarcoma: analysis of Japanese patients and comparison with IRSG reports. Pediatr Surg Int; 2006 Feb;22(2):129-34
MedlinePlus Health Information. consumer health - Anal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical characteristics and surgical treatment of perianal and perineal rhabdomyosarcoma: analysis of Japanese patients and comparison with IRSG reports.
  • Twenty-nine patients, 26 patients identified in the Japanese literature and three of our own, were analyzed and the results were compared with the data reported from the Intergroup Rhabdomyosarcoma Study Group (IRSG).
  • Alveolar histology was diagnosed in 18 patients.
  • In patients more than 10 years of age, the female predominance was more prominent and the incidences of advanced clinical groups/stages and alveolar histology were significantly higher than those in patients younger than 10 years of age.
  • [MeSH-major] Anus Neoplasms / surgery. Perineum. Rhabdomyosarcoma / surgery. Soft Tissue Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 1989 Jan;24(1):5-10 [2723995.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):104-9 [10918231.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] Cancer. 1990 Jun 15;65(12):2787-92 [2187589.001]
  • [Cites] J Pediatr Surg. 1995 Jul;30(7):942-4 [7472949.001]
  • [Cites] J Pediatr Surg. 2003 Mar;38(3):347-53 [12632347.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Cancer. 1994 Jan 1;73(1):109-17 [8275414.001]
  • [Cites] J Pediatr Surg. 2000 Feb;35(2):317-21 [10693687.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2427-34 [10856103.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Pediatr Surg. 1999 May;34(5):731-4; discussion 734-5 [10359173.001]
  • (PMID = 16308704.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Comparative Study; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 36
  •  go-up   go-down


68. Singh S, Vinson C, Gurley CM, Nolen GT, Beggs ML, Nagarajan R, Wagner EF, Parham DM, Peterson CA: Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice. Am J Pathol; 2010 Oct;177(4):2055-66
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Impaired Wnt signaling in embryonal rhabdomyosarcoma cells from p53/c-fos double mutant mice.
  • Rhabdomyosarcoma is a primitive neoplasm with a poorly understood etiology that exhibits features of fetal skeletal muscle.
  • It represents the most frequent malignant soft tissue sarcoma affecting the pediatric population and is often treated very aggressively.
  • Embryonal rhabdomyosarcoma (ERMS) and alveolar rhabdomyosarcoma constitute the two major subtypes and exhibit different molecular features.
  • Identification of the Wnt2 gene and its overexpression in ERMS cells was confirmed in human rhabdomyosarcoma cell lines and prompted further analysis of the Wnt signaling pathway.

  • Genetic Alliance. consumer health - Rhabdomyosarcoma embryonal.
  • COS Scholar Universe. author profiles.
  • KOMP Repository. gene/protein/disease-specific - KOMP Repository (subscription/membership/fee required).
  • Mouse Genome Informatics (MGI). Mouse Genome Informatics (MGI) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] FEBS Lett. 2004 Aug 27;573(1-3):83-92 [15327980.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5385-9 [15289346.001]
  • [Cites] Cell. 1989 Aug 25;58(4):659-67 [2548731.001]
  • [Cites] Proc Natl Acad Sci U S A. 1990 Aug;87(15):5863-7 [2143022.001]
  • [Cites] J Cell Biol. 1990 Sep;111(3):1149-59 [2167895.001]
  • [Cites] Cancer Res. 1991 Oct 1;51(19):5100-6 [1717137.001]
  • [Cites] Genomics. 1992 Aug;13(4):1322-4 [1505965.001]
  • [Cites] Proc Natl Acad Sci U S A. 1993 Apr 1;90(7):2910-4 [7681991.001]
  • [Cites] J Med Genet. 2006 Feb;43(2):119-28 [15908567.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7578-88 [16885357.001]
  • [Cites] Breast Cancer Res Treat. 2006 Nov;100(1):49-58 [16791480.001]
  • [Cites] Arch Pathol Lab Med. 2006 Oct;130(10):1454-65 [17090187.001]
  • [Cites] J Cell Sci. 2006 Dec 1;119(Pt 23):4850-6 [17090604.001]
  • [Cites] Oncogene. 2007 May 24;26(24):3492-502 [17146436.001]
  • [Cites] Cancer Res. 2007 Jul 15;67(14):6691-9 [17638879.001]
  • [Cites] Cytotherapy. 2007;9(7):667-81 [17917885.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):55-61 [18172252.001]
  • [Cites] Mol Cell Biol. 2008 May;28(9):2941-51 [18316399.001]
  • [Cites] J Gerontol A Biol Sci Med Sci. 2008 Jun;63(6):566-79 [18559630.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):550-64 [19147825.001]
  • [Cites] Pediatr Dev Pathol. 2009 Sep-Oct;12(5):371-3 [19222307.001]
  • [Cites] Biochem Cell Biol. 1993 Mar-Apr;71(3-4):197-204 [8398078.001]
  • [Cites] Nat Genet. 1993 Nov;5(3):225-9 [8275085.001]
  • [Cites] Clin Exp Metastasis. 1994 Jul;12(4):329-34 [7913670.001]
  • [Cites] J Clin Invest. 1994 Jul;94(1):445-8 [8040287.001]
  • [Cites] Cell. 1995 Sep 8;82(5):721-32 [7545543.001]
  • [Cites] Development. 1996 Feb;122(2):429-37 [8625794.001]
  • [Cites] Curr Biol. 1996 Dec 1;6(12):1664-8 [8994831.001]
  • [Cites] Proc Natl Acad Sci U S A. 1997 Jan 21;94(2):701-6 [9012848.001]
  • [Cites] Trends Genet. 1997 Apr;13(4):157-62 [9097727.001]
  • [Cites] J Biol Chem. 1997 Oct 3;272(40):24735-8 [9312064.001]
  • [Cites] Mol Cell Biol. 1997 Nov;17(11):6563-73 [9343420.001]
  • [Cites] Nat Med. 1998 May;4(5):619-22 [9585239.001]
  • [Cites] Oncologist. 1999;4(1):34-44 [10337369.001]
  • [Cites] Genes Dev. 2004 Nov 1;18(21):2614-26 [15489287.001]
  • [Cites] J Cell Sci. 2004 Dec 1;117(Pt 25):5965-73 [15564374.001]
  • [Cites] Mod Pathol. 2005 Jan;18(1):68-74 [15375433.001]
  • [Cites] Pediatr Dev Pathol. 2004 Nov-Dec;7(6):583-94 [15630526.001]
  • [Cites] Cell Res. 2005 Jan;15(1):28-32 [15686623.001]
  • [Cites] Mol Biol Cell. 2005 Apr;16(4):2039-48 [15673614.001]
  • [Cites] Cancer Res. 2005 Jun 1;65(11):4490-5 [15930263.001]
  • [Cites] Int J Oncol. 2005 Sep;27(3):791-8 [16077930.001]
  • [Cites] Oncogene. 2000 Aug 31;19(37):4210-20 [10980594.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2334-5 [11402330.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2390-400 [11402335.001]
  • [Cites] Oncogene. 2001 Apr 30;20(19):2453-64 [11402340.001]
  • [Cites] Genes Chromosomes Cancer. 2002 Mar;33(3):310-21 [11807989.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):409-16 [11809689.001]
  • [Cites] Cancer Biol Ther. 2002 Mar-Apr;1(2):97-104 [12170781.001]
  • [Cites] Bioessays. 2002 Oct;24(10):881-4 [12325120.001]
  • [Cites] J Cell Sci. 2003 Jul 1;116(Pt 13):2627-34 [12775774.001]
  • [Cites] Cancer Res. 2003 Jun 1;63(11):2728-32 [12782574.001]
  • [Cites] Development. 2003 Aug;130(15):3503-14 [12810597.001]
  • [Cites] Cell. 2003 Jun 27;113(7):841-52 [12837243.001]
  • [Cites] Br J Cancer. 2003 Jul 21;89(2):327-32 [12865925.001]
  • [Cites] Int J Mol Med. 2003 Nov;12(5):811-6 [14533014.001]
  • [Cites] Cancer Cell. 2003 Nov;4(5):349-60 [14667502.001]
  • [Cites] Nat Rev Cancer. 2003 Nov;3(11):859-68 [14668816.001]
  • [Cites] Cancer Cell. 2003 Dec;4(6):477-82 [14706339.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):269-80 [15059650.001]
  • [Cites] N Engl J Med. 2004 Apr 1;350(14):1464-6; author reply 1464-6 [15074001.001]
  • [Cites] Mod Pathol. 2004 Jun;17(6):660-9 [15098008.001]
  • [Cites] Cell. 2004 Jun 25;117(7):927-39 [15210113.001]
  • [Cites] Exp Cell Res. 1987 May;170(1):80-92 [3569436.001]
  • (PMID = 20829439.001).
  • [ISSN] 1525-2191
  • [Journal-full-title] The American journal of pathology
  • [ISO-abbreviation] Am. J. Pathol.
  • [Language] ENG
  • [Grant] United States / NIA NIH HHS / AG / R01 AG020941; United States / NIA NIH HHS / AG / AG20941
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Messenger; 0 / Transcription Factor AP-1; 0 / Tumor Suppressor Protein p53; 0 / Wnt Proteins; 0 / beta Catenin; EC 1.13.12.- / Luciferases
  • [Other-IDs] NLM/ PMC2947299
  •  go-up   go-down


69. Morris CL, Mukundan S Jr, Heimann A, Cummings TJ, Chesnutt DA: Stage IV primitive-appearing sinus and orbital rhabdomyosarcoma presenting in a 68-year-old female previously treated for breast cancer. Orbit; 2008;27(1):73-7
Hazardous Substances Data Bank. DACARBAZINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage IV primitive-appearing sinus and orbital rhabdomyosarcoma presenting in a 68-year-old female previously treated for breast cancer.
  • A 68-year-old female who had undergone treatment several years previously for breast cancer presented with diplopia and unilateral proptosis and exposure keratopathy related to biopsy-proven rhabdomyosarcoma of the sinus and orbit.
  • Histopathologic examination showed primitive-appearing rhabdomyosarcoma with some features suggestive of the alveolar subtype.
  • Orbital or sinus rhabdomyosarcoma is seen almost exclusively in the pediatric population, but may very rarely occur in adults.
  • There are several genetic mutations that appear to play a role in both rhabdomyosarcoma and certain breast tumors.
  • In our patient with atypical demographics for rhabdomyosarcoma, the previous neoplasm and treatment thereof may have predisposed to the development of this rare tumor.
  • [MeSH-major] Maxillary Sinus Neoplasms / pathology. Orbital Neoplasms / pathology. Rhabdomyosarcoma / pathology

  • Genetic Alliance. consumer health - Sinus cancer.
  • Genetic Alliance. consumer health - Breast Cancer.
  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18307153.001).
  • [ISSN] 1744-5108
  • [Journal-full-title] Orbit (Amsterdam, Netherlands)
  • [ISO-abbreviation] Orbit
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 7GR28W0FJI / Dacarbazine; 80168379AG / Doxorubicin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; MAID protocol
  •  go-up   go-down


70. Makawita S, Ho M, Durbin AD, Thorner PS, Malkin D, Somers GR: Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors. Pediatr Dev Pathol; 2009 Mar-Apr;12(2):127-35
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Expression of insulin-like growth factor pathway proteins in rhabdomyosarcoma: IGF-2 expression is associated with translocation-negative tumors.
  • Recent studies have shown a significant involvement of insulin-like growth factor (IGF) signaling components in the pathogenesis of rhabdomyosarcoma (RMS).
  • The present study utilized immunohistochemistry to determine the expression patterns of IGF1, IGF2, IGF binding protein 2 (IGFBP2), IGF receptor 1 (IGF1R), and IGF receptor 2 (IGF2R) in 24 embryonal RMS (ERMS) and 8 alveolar RMS (ARMS).
  • [MeSH-major] Insulin-Like Growth Factor II / metabolism. Rhabdomyosarcoma / metabolism. Soft Tissue Neoplasms / metabolism. Translocation, Genetic / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18788888.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Forkhead Transcription Factors; 0 / PAX3 protein, human; 0 / Paired Box Transcription Factors; 0 / RNA, Messenger; 0 / RNA, Neoplasm; 67763-97-7 / Insulin-Like Growth Factor II
  •  go-up   go-down


71. Arndt CA, Stoner JA, Hawkins DS, Rodeberg DA, Hayes-Jordan AA, Paidas CN, Parham DM, Teot LA, Wharam MD, Breneman JC, Donaldson SS, Anderson JR, Meyer WH: Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803. J Clin Oncol; 2009 Nov 01;27(31):5182-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Vincristine, actinomycin, and cyclophosphamide compared with vincristine, actinomycin, and cyclophosphamide alternating with vincristine, topotecan, and cyclophosphamide for intermediate-risk rhabdomyosarcoma: children's oncology group study D9803.
  • PURPOSE: The purpose of this study was to compare the outcome of patients with intermediate-risk rhabdomyosarcoma (RMS) treated with standard VAC (vincristine, dactinomycin, and cyclophosphamide) chemotherapy to that of patients treated with VAC alternating with vincristine, topotecan, and cyclophosphamide (VAC/VTC).
  • Treatment strata were embryonal RMS, stage 2/3, group III (33%); embryonal RMS, group IV, less than age 10 years (7%); alveolar RMS or undifferentiated sarcoma (UDS), stage 1 or group I (17%); alveolar RMS/UDS (27%); and PME (16%).
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Rhabdomyosarcoma / drug therapy

  • COS Scholar Universe. author profiles.
  • Hazardous Substances Data Bank. Topotecan .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. VINCRISTINE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Jun;17(6):1815-24 [10561220.001]
  • [Cites] J Clin Oncol. 2011 Apr 1;29(10):1312-8 [21357783.001]
  • [Cites] J Clin Oncol. 2001 Jan 1;19(1):213-9 [11134215.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3463-9 [11481351.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] J Clin Oncol. 2004 Apr 15;22(8):1398-403 [15007087.001]
  • [Cites] J Clin Oncol. 2004 May 15;22(10):1894-901 [15143082.001]
  • [Cites] Clin Cancer Res. 2004 Sep 15;10(18 Pt 1):6072-9 [15447992.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • [Cites] Cancer Res. 1993 Jun 15;53(12):2823-9 [8504425.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] Cancer Chemother Pharmacol. 1995;36(5):393-403 [7634381.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2123-39 [7636557.001]
  • [Cites] Cancer. 1997 Jun 15;79(12):2435-9 [9191535.001]
  • [Cites] J Pediatr Hematol Oncol. 1998 Jul-Aug;20(4):315-8 [9703003.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):362-9 [17264331.001]
  • [Cites] J Clin Oncol. 2000 Jun;18(12):2427-34 [10856103.001]
  • (PMID = 19770373.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / U10 CA098413; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U10 CA98413; United States / NCI NIH HHS / CA / U10 CA98543
  • [Publication-type] Journal Article; Randomized Controlled Trial; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 7M7YKX2N15 / Topotecan; 8N3DW7272P / Cyclophosphamide
  • [Other-IDs] NLM/ PMC2773476
  •  go-up   go-down


72. Raney RB, Chintagumpala M, Anderson J, Pappo A, Qualman S, Wharam M, Wiener E, Meyer W, Soft-Tissue Sarcoma Committee of the Children's Oncology Group, Arcadia, California: Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997. Pediatr Blood Cancer; 2008 May;50(5):958-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Results of treatment of patients with superficial facial rhabdomyosarcomas on protocols of the Intergroup Rhabdomyosarcoma Study Group (IRSG), 1984-1997.
  • PURPOSE: We analyzed the outcome of 47 patients with superficial facial rhabdomyosarcoma (RMS) treated on Intergroup Rhabdomyosarcoma Study Group (IRSG) Protocols-III, -IV-Pilot, and -IV.
  • Eight-year EFS rates were 72% for 22 patients with embryonal RMS and 53% for 23 patients with alveolar RMS (P = 0.28).

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • [Cites] Cancer. 1984 Feb 15;53(4):1016-9 [6692285.001]
  • [Cites] Med Pediatr Oncol. 1987;15(2):51-7 [3587117.001]
  • [Cites] J Clin Oncol. 1995 Mar;13(3):610-30 [7884423.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Mar-Apr;19(2):124-9 [9149741.001]
  • [Cites] Cancer. 1996 Jan 1;77(1):193-200 [8630930.001]
  • [Cites] J Pediatr Hematol Oncol. 1995 Nov;17(4):331-7 [7583389.001]
  • [Cites] Br J Cancer. 1977 Jan;35(1):1-39 [831755.001]
  • [Cites] J Clin Oncol. 2003 Feb 15;21(4):638-45 [12586800.001]
  • [Cites] Head Neck. 2002 May;24(5):468-73 [12001077.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1987 Nov;113(11):1225-7 [3663351.001]
  • [Cites] Ophthalmology. 1987 Mar;94(3):251-4 [3587902.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • [Cites] Cancer. 2001 Dec 15;92(12):3135-46 [11753993.001]
  • [Cites] Med Pediatr Oncol. 2002 Jan;38(1):22-32 [11835233.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] Am J Surg. 1989 Oct;158(4):373-7 [2802044.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1990 Apr;116(4):428-31 [2317324.001]
  • [Cites] Cancer. 1993 Mar 1;71(5):1904-22 [8448756.001]
  • (PMID = 18240175.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U10 CA072989; United States / NCI NIH HHS / CA / U10 CA029511; United States / NCI NIH HHS / CA / U10 CA072989-04; United States / NCI NIH HHS / CA / CA-24507; United States / NCI NIH HHS / CA / CA-72989; None / None / / U10 CA072989-04; United States / NCI NIH HHS / CA / U10 CA024507-26; None / None / / U10 CA024507-26; United States / NCI NIH HHS / CA / U10 CA029511-28; United States / NCI NIH HHS / CA / CA-29511; United States / NCI NIH HHS / CA / U10 CA024507
  • [Publication-type] Clinical Trial; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS319313; NLM/ PMC3357210
  •  go-up   go-down


73. Kayton ML: Pulmonary metastasectomy in pediatric patients. Thorac Surg Clin; 2006 May;16(2):167-83, vi
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pulmonary metastasectomy in pediatric patients.
  • This article describes the historical development of pediatric pulmonary metastasectomy but demonstrates that progress has been slow in understanding its proper applications.
  • Because many pediatric metastatic tumors are rare, surgeons have grouped together patients of different histologies for the generation and analysis of case series.
  • By examining tumor types individually, however, it is seen that certain histologies (adrenocortical carcinoma, alveolar soft part sarcoma, osteosarcoma) mandate surgical metastasectomy for patient survival.
  • Other pediatric tumors (Wilms tumor, Ewing's sarcoma) are radiation sensitive, and the application of metastasectomy is controversial.
  • In the case of still other types of tumor (neuroblastoma, differentiated thyroid cancer, rhabdomyosarcoma), metastasectomy is seldom performed except in highly unusual situations.
  • Techniques for minimally invasive biopsy and for muscle-sparing thoracotomy are described for pediatric patients.

  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16805206.001).
  • [ISSN] 1547-4127
  • [Journal-full-title] Thoracic surgery clinics
  • [ISO-abbreviation] Thorac Surg Clin
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 91
  •  go-up   go-down


74. Goldstein M, Meller I, Orr-Urtreger A: FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes. Genes Chromosomes Cancer; 2007 Nov;46(11):1028-38
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] FGFR1 over-expression in primary rhabdomyosarcoma tumors is associated with hypomethylation of a 5' CpG island and abnormal expression of the AKT1, NOG, and BMP4 genes.
  • Rhabdomyosarcoma (RMS), the most common pediatric soft tissue sarcoma likely results from abnormal proliferation and differentiation during skeletal myogenesis.
  • Multiple genetic alterations are associated with the three RMS histopathological subtypes, embryonal, alveolar, and pleomorphic adult variant.
  • [MeSH-major] Bone Morphogenetic Proteins / genetics. Carrier Proteins / genetics. CpG Islands. DNA Methylation. Proto-Oncogene Proteins c-akt / genetics. Receptor, Fibroblast Growth Factor, Type 1 / genetics. Rhabdomyosarcoma / genetics

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17696196.001).
  • [ISSN] 1045-2257
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / BMP4 protein, human; 0 / Bone Morphogenetic Protein 4; 0 / Bone Morphogenetic Proteins; 0 / Carrier Proteins; 0 / DNA Primers; 148294-77-3 / noggin protein; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1; EC 2.7.11.1 / AKT1 protein, human; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt
  •  go-up   go-down


75. Bouron-Dal Soglio D, Rougemont AL, Absi R, Giroux LM, Sanchez R, Barrette S, Fournet JC: Beta-catenin mutation does not seem to have an effect on the tumorigenesis of pediatric rhabdomyosarcomas. Pediatr Dev Pathol; 2009 Sep-Oct;12(5):371-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Beta-catenin mutation does not seem to have an effect on the tumorigenesis of pediatric rhabdomyosarcomas.
  • Involvement of the Wnt signal transduction pathway has been shown in different pediatric embryonal tumors, such as hepatoblastoma, nephroblastoma, pancreatoblastoma, and medulloblastoma.
  • There are few data available on the status of beta-catenin in rhabdomyosarcoma (RMS), another pediatric embryonal tumor.
  • The aims of this study were 1st to verify the status of the exon 3 of CTNNB1 and 2nd to assess the usefulness of beta-catenin immunostaining in a small series of 8 embryonal RMS, 3 alveolar RMS, and 1 sclerosing RMS (SRMS).
  • We conclude that there is no evidence of beta-catenin mutation in the genesis of rhabdomyosarcoma and that beta-catenin does not represent a useful immunomarker to help distinguish between embryonal RMS and alveolar RMS.
  • [MeSH-major] Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Alveolar / pathology. Rhabdomyosarcoma, Embryonal / genetics. Rhabdomyosarcoma, Embryonal / pathology. beta Catenin / genetics

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19222307.001).
  • [ISSN] 1093-5266
  • [Journal-full-title] Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society
  • [ISO-abbreviation] Pediatr. Dev. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / beta Catenin
  •  go-up   go-down


76. Oue T, Yoneda A, Uehara S, Yamanaka H, Fukuzawa M: Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg; 2010 Feb;45(2):387-92
Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Increased expression of the hedgehog signaling pathway in pediatric solid malignancies.
  • However, the correlation between the Hh signaling and tumorigenesis of pediatric malignancies has not been well documented.
  • The present study was undertaken to examine the expression of the Hh signaling pathway in various pediatric tumors to elucidate the role of Hh signaling in pediatric malignancies.
  • METHODS: Surgical specimens were obtained from 68 patients with pediatric malignancies (neuroblastoma, 25; rhabdomyosarcoma, 18; hepatic tumor, 12; and renal tumor, 13).
  • RESULTS: In neuroblastoma, 96%, 100%, and 68%; in rhabdomyosarcoma, 78%, 100%, and 78%; in Wilms' tumor, 71%, 100%, and 43%; and in hepatoblastoma, 100%, 100%, and 73% of the specimens stained positive for Shh, Ptch, and Gli1, respectively.
  • In rhabdomyosarcoma, the expression of Gli1 was higher in alveolar type than in embryonal type.
  • CONCLUSIONS: These findings suggest that the Shh-Ptch1-Gli1 signaling pathways are frequently activated in most pediatric malignant tumors.
  • The Hh signaling pathway may therefore play an important role in the differentiation and malignant potential of pediatric malignancies.
  • [MeSH-minor] Adolescent. Cell Line, Tumor. Child. Female. Gene Expression Regulation, Neoplastic. Hepatoblastoma / genetics. Hepatoblastoma / metabolism. Humans. Immunohistochemistry. Infant. Infant, Newborn. Male. Receptors, Cell Surface / genetics. Receptors, Cell Surface / metabolism. Rhabdomyosarcoma / genetics. Rhabdomyosarcoma / metabolism. Transcription Factors / genetics. Transcription Factors / metabolism. Wilms Tumor / genetics. Wilms Tumor / metabolism

  • MedlinePlus Health Information. consumer health - Cancer in Children.
  • National BioResource Project. culture/stock collections - NBRP resources .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 Elsevier Inc. All rights reserved.
  • (PMID = 20152358.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / GLI1 protein, human; 0 / Hedgehog Proteins; 0 / Receptors, Cell Surface; 0 / Transcription Factors; 0 / patched receptors
  •  go-up   go-down


77. Kayton ML, Meyers P, Wexler LH, Gerald WL, LaQuaglia MP: Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults. J Pediatr Surg; 2006 Jan;41(1):187-93
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinical presentation, treatment, and outcome of alveolar soft part sarcoma in children, adolescents, and young adults.
  • PURPOSE: Alveolar soft part sarcoma is a rare soft tissue neoplasm that can affect children and adolescents.
  • METHODS: After institutional review board approval, we examined the records of all patients younger than 25 years old who received treatment at our institution for alveolar soft part sarcoma in the past 30 years.
  • Younger patients tended to have Intergroup Rhabdomyosarcoma Study group I disease.
  • CONCLUSIONS: Achievement of complete microscopic resection is critical in localized alveolar soft part sarcoma, but incomplete excision and misdiagnosis are often encountered.


78. Kayton ML, Delgado R, Busam K, Cody HS 3rd, Athanasian EA, Coit D, La Quaglia MP: Experience with 31 sentinel lymph node biopsies for sarcomas and carcinomas in pediatric patients. Cancer; 2008 May 1;112(9):2052-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Experience with 31 sentinel lymph node biopsies for sarcomas and carcinomas in pediatric patients.
  • BACKGROUND: Few data exist regarding techniques, indications, and outcomes for sentinel lymph node biopsy in pediatric patients with sarcomas and carcinomas.
  • METHODS: A retrospective 10-year review was conducted, with Institutional Review Board waiver, of the pathology, lymphoscintigraphy, and clinical records for all pediatric patients selected to undergo sentinel lymph node biopsy at a major cancer center.
  • RESULTS: Thirty-one sentinel lymph node biopsies were performed in 30 pediatric patients (median age, 12 years; range, 2-21 years).
  • Positive sentinel lymph nodes occurred in 1 of 9 patients with rhabdomyosarcoma and in 2 of 5 patients with breast cancer, and in both of these diseases the sentinel lymph node results helped guide treatment decisions.
  • CONCLUSIONS: Sentinel lymph node biopsy for pediatric soft-tissue tumors can be performed safely, and the results can alter treatment decisions both for children with rhabdomyosarcoma and adolescents with breast cancer.
  • In patients with nonrhabdomyosarcoma soft-tissue sarcoma, we observed no positive sentinel lymph nodes and no lymph node basin recurrences; these data should prompt the prospective study of sentinel lymph node biopsy as a modality that might help guide the administration or withholding of regional therapy among pediatric patients with nonrhabdomyosarcoma soft-tissue sarcoma.
  • [MeSH-minor] Adolescent. Adult. Breast Neoplasms / pathology. Child. Child, Preschool. Female. Humans. Lymphography. Male. Middle Aged. Retrospective Studies. Rhabdomyosarcoma / pathology. Sarcoma, Alveolar Soft Part / pathology. Sarcoma, Clear Cell / pathology

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18338809.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


79. Wang Z, Velagaleti GV, Eltorky MA, Tang WW, Hawkins HK, Jones EA, Northup J, Panova N, Qiu S: Cytogenetic and molecular studies of an unusual case of multiple primary alveolar rhabdomyosarcomas: low-level chromosomal instability and reciprocal translocation t(6;11). Exp Mol Pathol; 2007 Feb;82(1):58-62
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cytogenetic and molecular studies of an unusual case of multiple primary alveolar rhabdomyosarcomas: low-level chromosomal instability and reciprocal translocation t(6;11).
  • Cytogenetic and molecular studies have shown that approximately 80% of cases of alveolar rhabdomyosarcoma (ARMS) have consistent chromosomal translocation of either t(2;13) or t(1;13), resulting in either PAX3-FKHR or PAX7-FKHR gene fusions.
  • The findings suggest that cytogenetic abnormalities of chromosome 6 may be associated with the development of early onset multiple ARMS in a subgroup of pediatric patients as seen in this case.
  • [MeSH-major] Chromosomes, Human, Pair 6 / genetics. Neoplasms, Multiple Primary / genetics. Neoplasms, Multiple Primary / pathology. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Alveolar / pathology

  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17097083.001).
  • [ISSN] 0014-4800
  • [Journal-full-title] Experimental and molecular pathology
  • [ISO-abbreviation] Exp. Mol. Pathol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


80. Casanova M, Meazza C, Favini F, Fiore M, Morosi C, Ferrari A: Rhabdomyosarcoma of the extremities: a focus on tumors arising in the hand and foot. Pediatr Hematol Oncol; 2009 Jul-Aug;26(5):321-31
MedlinePlus Health Information. consumer health - Foot Health.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Rhabdomyosarcoma of the extremities: a focus on tumors arising in the hand and foot.
  • METHODS: The authors reviewed the clinical data on 60 patients <21 years old with limb RMS treated at the Pediatric Oncology Unit of the Istituto Nazionale Tumori of Milan, in Italy, over a 30-year period.
  • The alveolar subtype was identified in 62% of cases.
  • [MeSH-major] Foot / pathology. Hand / pathology. Rhabdomyosarcoma / mortality. Rhabdomyosarcoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19579078.001).
  • [ISSN] 1521-0669
  • [Journal-full-title] Pediatric hematology and oncology
  • [ISO-abbreviation] Pediatr Hematol Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


81. Missiaglia E, Selfe J, Hamdi M, Williamson D, Schaaf G, Fang C, Koster J, Summersgill B, Messahel B, Versteeg R, Pritchard-Jones K, Kool M, Shipley J: Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development. Genes Chromosomes Cancer; 2009 Jun;48(6):455-67
SciCrunch. ArrayExpress: Data: Microarray .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Genomic imbalances in rhabdomyosarcoma cell lines affect expression of genes frequently altered in primary tumors: an approach to identify candidate genes involved in tumor development.
  • Rhabdomyosarcomas (RMS) are the most common pediatric soft tissue sarcomas.
  • They resemble developing skeletal muscle and are histologically divided into two main subtypes; alveolar and embryonal RMS.
  • Characteristic genomic aberrations, including the PAX3- and PAX7-FOXO1 fusion genes in alveolar cases, have led to increased understanding of their molecular biology.
  • Copy number and expression of FGFR1 was validated in additional primary material and found amplified in 6 out of 196 cases and overexpressed relative to skeletal muscle and myoblasts, with significantly higher expression levels in the embryonal compared with alveolar subtypes.
  • [MeSH-major] Allelic Imbalance. Gene Dosage. Gene Expression Regulation, Neoplastic. Neoplasm Proteins / genetics. Rhabdomyosarcoma / genetics

  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - Cell lines described in this publication .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19235922.001).
  • [ISSN] 1098-2264
  • [Journal-full-title] Genes, chromosomes & cancer
  • [ISO-abbreviation] Genes Chromosomes Cancer
  • [Language] eng
  • [Grant] United Kingdom / Cancer Research UK / /
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Neoplasm Proteins; EC 2.7.10.1 / FGFR1 protein, human; EC 2.7.10.1 / Receptor, Fibroblast Growth Factor, Type 1
  •  go-up   go-down


82. Kebudi R, Ayan I, Görgün O, Ağaoğlu FY, Vural S, Darendeliler E: Brain metastasis in pediatric extracranial solid tumors: survey and literature review. J Neurooncol; 2005 Jan;71(1):43-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Brain metastasis in pediatric extracranial solid tumors: survey and literature review.
  • OBJECTIVES: Brain is a rare site of metastasis in most extracranial pediatric solid tumors.
  • The aim of this study is to investigate the incidence, treatment, prognosis of brain metastasis in extracranial pediatric malignant tumors in a single institution and to review the literature.
  • METHODS: From September 1989 to December 2002, 1100 children <or=16 years of age with extracranial solid tumors including lymphomas were diagnosed and treated in the Division of Pediatric Oncology, Oncology Institute, Istanbul University.
  • The diagnosis was sarcomas in 12 patients: 5 osteosarcomas, 4 Ewing's sarcoma family tumors, 1 rhabdomyosarcoma, 1 clear cell sarcoma of the soft tissue, 1 alveolar soft part sarcoma.
  • Only one patient with alveolar soft part sarcoma is alive with disease 20 months from diagnosis of brain metastasis.
  • Although, the outcome for these patients is dismal in this series and in the literature; reports of long term survival in a few cases with Wilms' tumor, osteosarcoma and alveolar soft part sarcoma who had isolated brain metastasis, suggest that a subset of patients may benefit from therapy.

  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Childhood Brain Tumors.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15719274.001).
  • [ISSN] 0167-594X
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Netherlands
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 43
  •  go-up   go-down


83. Mattke AC, Bailey EJ, Schuck A, Dantonello T, Leuschner I, Klingebiel T, Treuner J, Koscielniak E: Does the time-point of relapse influence outcome in pediatric rhabdomyosarcomas? Pediatr Blood Cancer; 2009 Jul;52(7):772-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Does the time-point of relapse influence outcome in pediatric rhabdomyosarcomas?
  • BACKGROUND: Childhood rhabdomyosarcoma (RMS), a soft tissue malignant tumor of skeletal muscle origin, accounts for approximately 3.5% of the cases of cancer among children 0-14 years and 2% of the cases among adolescents and young adults 15-19 years of age.
  • PROCEDURE: We evaluated survival (SUR) after first relapse depending on the time to relapse (TTR) in RMSs of childhood and adolescence.
  • Embryonal RMS showed four year SUR of 16%, 30%, and 46% (P < 0.001) whereas alveolar histology showed four year SUR of 8%, 6%, and 23% (P < 0.01) for early, intermediate, and late relapse respectively.
  • [MeSH-major] Neoplasm Recurrence, Local / mortality. Neoplasms, Muscle Tissue / mortality. Rhabdomyosarcoma / mortality


84. Casanova M, Meazza C, Gronchi A, Fiore M, Zaffignani E, Podda M, Collini P, Gandola L, Ferrari A: Soft-tissue sarcomas of the extremities in patients of pediatric age. J Child Orthop; 2007 Sep;1(3):195-203

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft-tissue sarcomas of the extremities in patients of pediatric age.
  • Here we report the experience of the Pediatric Oncology Unit of the Istituto Nazionale Tumori of Milan, Italy, concerning 204 patients with STS of the limbs treated between 1977 and 2006.
  • METHODS: The study series included 52 patients with rhabdomyosarcoma (RMS)(65% of which were of the alveolar subtype), nine with extraosseous Ewing sarcoma and 143 with non-rhabdomyosarcoma soft-tissue sarcomas (NRSTS), 38% of which were synovial sarcoma.
  • DISCUSSION: While the limbs are the most common sites of NRSTS and are often characterized by a more favorable prognosis than for axial tumors, the clinical features of extremity RMS often differ from those of RMS of other sites, with a higher incidence of unfavorable prognostic factors (e.g., alveolar subtype) and consequently unsatisfactory treatment results.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Pediatr Surg. 2000 Jun;35(6):961-4 [10873044.001]
  • [Cites] J Pediatr Surg. 2000 Feb;35(2):317-21 [10693687.001]
  • [Cites] Cancer. 2006 Feb 1;106(3):708-17 [16353216.001]
  • [Cites] J Clin Oncol. 2005 Nov 20;23(33):8422-30 [16293873.001]
  • [Cites] Cancer. 2005 Nov 1;104(9):2006-12 [16161038.001]
  • [Cites] J Clin Oncol. 2005 Jun 20;23(18):4021-30 [15767645.001]
  • [Cites] Expert Rev Anticancer Ther. 2005 Apr;5(2):307-18 [15877527.001]
  • [Cites] J Pediatr Surg. 1997 Aug;32(8):1181-4 [9269966.001]
  • [Cites] J Pediatr Surg. 1997 May;32(5):698-702 [9165454.001]
  • [Cites] J Pediatr Surg. 1996 Jan;31(1):191-6 [8632278.001]
  • [Cites] Semin Surg Oncol. 1993 Nov-Dec;9(6):510-9 [8284570.001]
  • [Cites] Cancer. 1990 Dec 15;66(12):2482-91 [2249188.001]
  • [Cites] Med Pediatr Oncol. 1990;18(6):466-71 [2233517.001]
  • [Cites] World J Surg. 1988 Oct;12(5):676-84 [3072777.001]
  • [Cites] J Pediatr Surg. 1989 Jan;24(1):5-10 [2723995.001]
  • [Cites] Cancer. 1988 Jan 15;61(2):209-20 [3275486.001]
  • [Cites] J Pediatr Surg. 1990 Feb;25(2):238-43; discussion 243-4 [2303993.001]
  • [Cites] Int J Cancer. 1984 Jan 15;33(1):37-42 [6693192.001]
  • [Cites] Pediatr Dev Pathol. 2004 Jul-Aug;7(4):361-9 [15383931.001]
  • [Cites] Clin Orthop Relat Res. 2004 Sep;(426):129-34 [15346063.001]
  • [Cites] Pediatr Blood Cancer. 2004 Apr;42(4):295-310 [14966825.001]
  • [Cites] J Pediatr Hematol Oncol. 2003 Nov;25(11):905-9 [14608203.001]
  • [Cites] Med Pediatr Oncol. 2003 Dec;41(6):584-7 [14595726.001]
  • [Cites] Pediatr Surg Int. 2003 Aug;19(6):453-6 [12740706.001]
  • [Cites] J Pediatr Surg. 2002 Oct;37(10):1424-9 [12378447.001]
  • [Cites] Eur J Surg Oncol. 2000 Nov;26(7):669-78 [11078614.001]
  • (PMID = 19308495.001).
  • [ISSN] 1863-2521
  • [Journal-full-title] Journal of children's orthopaedics
  • [ISO-abbreviation] J Child Orthop
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2656726
  •  go-up   go-down


85. De Corti F, Dall'Igna P, Bisogno G, Casara D, Rossi CR, Foletto M, Alaggio R, Carli M, Cecchetto G: Sentinel node biopsy in pediatric soft tissue sarcomas of extremities. Pediatr Blood Cancer; 2009 Jan;52(1):51-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sentinel node biopsy in pediatric soft tissue sarcomas of extremities.
  • However, only few reports describe this procedure for the evaluation of regional lymph nodes in childhood and adolescents.
  • The diagnosis was rhabdomyosarcoma in 5 and other soft tissue sarcomas in 12: Ewing/PNET sarcoma 6, epithelioid sarcoma 1, malignant peripheral-nerve-sheath tumor 1, undifferentiated sarcoma 1, myxoid liposarcoma 2, adult-type fibrosarcoma 1.
  • Nodes were positive for metastasis in two patients with alveolar rhabdomyosarcoma and undifferentiated sarcoma.
  • It could be an alternative to aggressive or random biopsies for extremity rhabdomyosarcoma and it can contribute to define those non-rhabdomyosarcoma soft tissue sarcomas that spread to regional nodes.
  • [MeSH-major] Extremities. Rhabdomyosarcoma / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18819127.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


86. Cecchetto G, Alaggio R, Dall'Igna P, Bisogno G, Ferrari A, Gigante C, Casanova M, Sotti G, Zanetti I, Carli M: Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age: results from the Italian studies. Cancer; 2005 Nov 1;104(9):2006-12
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Localized unresectable non-rhabdo soft tissue sarcomas of the extremities in pediatric age: results from the Italian studies.
  • BACKGROUND: Treatment of initially unresectable nonrhabdo soft tissue sarcomas (NRSTS) in pediatric age is debated, due to their different chemosensitivity.
  • Clinical TNM and surgical Intergroup Rhabdomyosarcoma Staging systems were adopted.
  • Nonchemosensitive (CTns) sarcomas, 31: fibrosarcoma, 11; malignant peripheral nerve sheet tumors, 10; liposarcoma, 2; hemangiopericitoma adult type, 2; epithelioid sarcoma, 2; and alveolar soft part sarcoma, leiomyosarcoma, clear cell sarcoma, and sarcoma NOS, each 1.

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2005 American Cancer Society.
  • (PMID = 16161038.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


87. Barroca H: Fine needle biopsy and genetics, two allied weapons in the diagnosis, prognosis, and target therapeutics of solid pediatric tumors. Diagn Cytopathol; 2008 Sep;36(9):678-84
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Fine needle biopsy and genetics, two allied weapons in the diagnosis, prognosis, and target therapeutics of solid pediatric tumors.
  • The recognition that genetic defects identify some pediatric solid tumors and may represent prognostic markers has provided cytologists with an extra tool for dealing with such tumors.
  • Using some entities as archetypes, we discuss the importance of the association of fine needle biopsy and genetics, in the diagnosis, prognosis, and therapy selection of solid pediatric tumors.
  • Immunocytochemistry is important to differentiate neuroblastoma, PNET/Ewing sarcoma, alveolar rhabdomyosarcoma, lymphoma, and desmoplastic small round cell tumor.
  • Cytopathologists should be aware of the genetic alterations characterizing pediatric tumors in order to collect extra material to perform cytogenetics, FISH, PCR, and Southern blotting, to achieve the correct identification of such genetic changes.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18677757.001).
  • [ISSN] 1097-0339
  • [Journal-full-title] Diagnostic cytopathology
  • [ISO-abbreviation] Diagn. Cytopathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 29
  •  go-up   go-down


88. Hu K, Lee C, Qiu D, Fotovati A, Davies A, Abu-Ali S, Wai D, Lawlor ER, Triche TJ, Pallen CJ, Dunn SE: Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas. Mol Cancer Ther; 2009 Nov;8(11):3024-35
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small interfering RNA library screen of human kinases and phosphatases identifies polo-like kinase 1 as a promising new target for the treatment of pediatric rhabdomyosarcomas.
  • Rhabdomyosarcoma, consisting of alveolar (aRMS) and embryonal (eRMS) subtypes, is the most common type of sarcoma in children.
  • Currently, there are no targeted drug therapies available for rhabdomyosarcoma.
  • Inhibiting polo-like kinase 1 (PLK1) had the most remarkable impact on growth inhibition (approximately 80%) and apoptosis on all three rhabdomyosarcoma cell lines tested, namely, RH30, CW9019 (aRMS), and RD (eRMS), whereas there was no effect on normal muscle cells.
  • Pediatric Ewing's sarcoma (TC-32), neuroblastoma (IMR32 and KCNR), and glioblastoma (SF188) models were also highly sensitive to PLK1 inhibition.
  • Finally, based on cDNA microarray analyses, PLK1 mRNA was overexpressed (>1.5 fold) in 10 of 10 rhabdomyosarcoma cell lines and in 47% and 51% of primary aRMS (17 of 36 samples) and eRMS (21 of 41 samples) tumors, respectively, compared with normal muscles.
  • Similarly, pediatric Ewing's sarcoma, neuroblastoma, and osteosarcoma tumors expressed high PLK1.
  • We conclude that PLK1 could be a promising therapeutic target for the treatment of a wide range of pediatric solid tumors including rhabdomyosarcoma.

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - TTC-516 (CVCL_8004) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - TTC-1318 (CVCL_AQ33) .
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - TTC-442 (CVCL_B255) .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Chem Biol. 2008 May;15(5):459-66 [18482698.001]
  • [Cites] Cancer Res. 2008 May 15;68(10):3767-76 [18483260.001]
  • [Cites] Oncology. 2008;74(3-4):198-206 [18714168.001]
  • [Cites] Cancer Res. 2008 Oct 1;68(19):8039-48 [18829562.001]
  • [Cites] Curr Opin Pharmacol. 2008 Aug;8(4):375-83 [18644252.001]
  • [Cites] Neoplasia. 2008 Nov;10(11):1303-13 [18953440.001]
  • [Cites] Cancer Res. 2008 Nov 1;68(21):8661-6 [18974106.001]
  • [Cites] Oncogene. 2008 Nov 20;27(51):6550-60 [18679424.001]
  • [Cites] Int J Cancer. 2009 Feb 1;124(3):578-88 [19004025.001]
  • [Cites] J Clin Oncol. 2008 Dec 1;26(34):5497-9 [18955441.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):550-64 [19147825.001]
  • [Cites] Leukemia. 2009 Sep;23(9):1564-76 [19421227.001]
  • [Cites] Med Pediatr Oncol. 2000 Aug;35(2):96-103 [10918230.001]
  • [Cites] Nature. 2001 Mar 8;410(6825):215-20 [11242082.001]
  • [Cites] Nat Med. 2001 Jun;7(6):673-9 [11385503.001]
  • [Cites] EMBO Rep. 2002 Apr;3(4):341-8 [11897663.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 May 13;100(10):5789-94 [12732729.001]
  • [Cites] Int J Cancer. 2004 Jul 10;110(5):687-94 [15146558.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5539-45 [15313887.001]
  • [Cites] Nature. 1987 Oct 15-21;329(6140):645-7 [3657988.001]
  • [Cites] Mol Cell Biol. 1995 Mar;15(3):1522-35 [7862145.001]
  • [Cites] Oncogene. 1995 Jul 6;11(1):119-30 [7624119.001]
  • [Cites] J Clin Oncol. 1995 Aug;13(8):2123-39 [7636557.001]
  • [Cites] Cancer. 1995 Sep 15;76(6):1073-85 [8625211.001]
  • [Cites] J Pediatr Hematol Oncol. 1997 Nov-Dec;19(6):483-91 [9407933.001]
  • [Cites] Oncogene. 1999 Sep 20;18(38):5340-8 [10498887.001]
  • [Cites] FASEB J. 2005 Mar;19(3):404-6 [15629888.001]
  • [Cites] FASEB J. 2005 Apr;19(6):611-3 [15661849.001]
  • [Cites] Nat Cell Biol. 2005 Jun;7(6):591-600 [15864305.001]
  • [Cites] Pediatr Blood Cancer. 2006 Mar;46(3):329-38 [16261596.001]
  • [Cites] J Med Genet. 2006 Feb;43(2):119-28 [15908567.001]
  • [Cites] Mol Cell Biol. 2006 Mar;26(6):2093-108 [16507989.001]
  • [Cites] Int J Cancer. 2006 Jun 1;118(11):2772-81 [16381018.001]
  • [Cites] Nat Rev Cancer. 2006 Apr;6(4):321-30 [16557283.001]
  • [Cites] Mol Cancer Ther. 2006 May;5(5):1299-308 [16731763.001]
  • [Cites] Neoplasia. 2006 May;8(5):332-43 [16790082.001]
  • [Cites] Neoplasia. 2006 May;8(5):394-401 [16790088.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] BMC Genomics. 2006;7:287 [17090319.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3431-40 [17409454.001]
  • [Cites] Carcinogenesis. 2007 May;28(5):899-912 [17259655.001]
  • [Cites] Clin Transl Oncol. 2007 Jul;9(7):415-9 [17652054.001]
  • [Cites] Mod Pathol. 2007 Sep;20(9):936-46 [17585318.001]
  • [Cites] Mol Pharmacol. 2007 Sep;72(3):641-52 [17595327.001]
  • [Cites] Curr Opin Chem Biol. 2007 Aug;11(4):424-32 [17652007.001]
  • [Cites] BMC Cancer. 2007;7:111 [17598902.001]
  • [Cites] Oncogene. 2007 Nov 8;26(51):7267-81 [17525748.001]
  • [Cites] Curr Probl Cancer. 2008 Jan-Feb;32(1):7-34 [18206520.001]
  • [Cites] Cancer Res. 2008 Aug 15;68(16):6587-97 [18701482.001]
  • (PMID = 19887553.001).
  • [ISSN] 1538-8514
  • [Journal-full-title] Molecular cancer therapeutics
  • [ISO-abbreviation] Mol. Cancer Ther.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / CA088199-04; United States / NCI NIH HHS / CA / U01 CA088199; United States / NCI NIH HHS / CA / 1U01 CA11475-04; United States / NCI NIH HHS / CA / U01 CA088199-04
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Cell Cycle Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Small Interfering; EC 2.7.- / Protein Kinases; EC 2.7.11.1 / Protein-Serine-Threonine Kinases; EC 2.7.11.1 / polo-like kinase 1; EC 3.1.3.- / Phosphoric Monoester Hydrolases
  • [Other-IDs] NLM/ NIHMS150149; NLM/ PMC2783569
  •  go-up   go-down


89. Morton CL, Houghton PJ, Kolb EA, Gorlick R, Reynolds CP, Kang MH, Maris JM, Keir ST, Wu J, Smith MA: Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program. Pediatr Blood Cancer; 2010 Aug;55(2):295-303
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Initial testing of the replication competent Seneca Valley virus (NTX-010) by the pediatric preclinical testing program.
  • RESULTS: In vitro NTX-010 demonstrated a marked cytotoxic effect in a subset of the cell lines from the neuroblastoma, Ewing sarcoma, and rhabdomyosarcoma panels.
  • In vivo the most consistent activity was observed for the rhabdomyosarcoma and the neuroblastoma panels, with all four of the alveolar rhabdomyosarcoma xenografts and four of five neuroblastoma xenografts achieving CR or maintained CR.
  • [MeSH-minor] Animals. Cell Line, Tumor. Disease-Free Survival. Humans. Mice. Neuroblastoma / pathology. Neuroblastoma / therapy. RNA Viruses. Rhabdomyosarcoma / pathology. Rhabdomyosarcoma / therapy. Sarcoma, Ewing / pathology. Sarcoma, Ewing / therapy. Treatment Outcome. Tumor Burden. Xenograft Model Antitumor Assays

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2010 Wiley-Liss, Inc.
  • [Cites] J Clin Invest. 2000 May;105(9):1169-72 [10791988.001]
  • [Cites] Expert Opin Biol Ther. 2009 Jul;9(7):817-30 [19527106.001]
  • [Cites] Nat Biotechnol. 2000 Jul;18(7):723-7 [10888838.001]
  • [Cites] J Clin Oncol. 2001 Jan 15;19(2):289-98 [11208818.001]
  • [Cites] J Natl Cancer Inst. 2001 Jun 20;93(12):903-12 [11416111.001]
  • [Cites] Cancer Lett. 2001 Oct 22;172(1):27-36 [11595126.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1696-701 [11912142.001]
  • [Cites] Hum Gene Ther. 2002 Mar 20;13(5):641-52 [11916487.001]
  • [Cites] Cancer Gene Ther. 2002 Dec;9(12):961-6 [12522435.001]
  • [Cites] Cancer Res. 2003 Jan 15;63(2):348-53 [12543787.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):693-702 [12576437.001]
  • [Cites] Int J Oncol. 2004 Apr;24(4):919-23 [15010830.001]
  • [Cites] Cancer Res. 1988 Aug 1;48(15):4189-95 [3390813.001]
  • [Cites] J Natl Cancer Inst. 1994 Aug 17;86(16):1228-33 [8040891.001]
  • [Cites] EMBO J. 1998 Jun 15;17(12):3351-62 [9628872.001]
  • [Cites] Science. 1998 Nov 13;282(5392):1332-4 [9812900.001]
  • [Cites] Clin Cancer Res. 2005 Oct 1;11(19 Pt 1):6950-8 [16203787.001]
  • [Cites] Oncogene. 2005 Nov 21;24(52):7640-55 [16299526.001]
  • [Cites] Clin Cancer Res. 2006 Jan 1;12(1):223-34 [16397046.001]
  • [Cites] Mod Pathol. 2006 May;19(5):659-68 [16528378.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Aug 22;103(34):12873-8 [16908838.001]
  • [Cites] Mol Aspects Med. 2007 Feb;28(1):42-58 [17300834.001]
  • [Cites] Curr Cancer Drug Targets. 2007 Mar;7(2):157-67 [17346107.001]
  • [Cites] Mol Cancer Ther. 2007 Mar;6(3):886-97 [17363483.001]
  • [Cites] J Pathol. 2007 Jun;212(2):143-51 [17471488.001]
  • [Cites] Cancer Res. 2007 Aug 15;67(16):7850-5 [17699791.001]
  • [Cites] Pediatr Blood Cancer. 2007 Dec;49(7):928-40 [17066459.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1623-33 [17971529.001]
  • [Cites] J Gen Virol. 2008 May;89(Pt 5):1265-75 [18420805.001]
  • [Cites] Mod Pathol. 2008 Jul;21(7):795-806 [18487991.001]
  • [Cites] Clin Cancer Res. 2008 Jul 15;14(14):4572-83 [18628472.001]
  • [ErratumIn] Pediatr Blood Cancer. 2012 Apr;58(4):652
  • (PMID = 20582972.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P50 CA108786; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CM / N01 CM042216; United States / NCI NIH HHS / CA / P30 CA021765; United States / NCI NIH HHS / CM / N01-CM-42216; United States / NCI NIH HHS / CA / N01CM42216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS218652; NLM/ PMC3003870
  •  go-up   go-down


90. Antillon F, Castellanos M, Valverde P, Luna-Fineman S, Garrido C, Serrato T, Rodriguez-Galindo C, Casanova M, Ferrari A: Treating Pediatric soft tissue sarcomas in a country with limited resources: the experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala. Pediatr Blood Cancer; 2008 Dec;51(6):760-4
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treating Pediatric soft tissue sarcomas in a country with limited resources: the experience of the Unidad Nacional de Oncologia Pediatrica in Guatemala.
  • PATIENTS AND METHODS: We reviewed the clinical data, treatment and outcome of 80 patients, 47 cases of rhabdomyosarcoma (RMS) and 33 of non-rhabdomyosarcoma soft tissue sarcoma (NRSTS), treated between January 2000 and October 2007.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Developing Countries. Rhabdomyosarcoma, Alveolar / drug therapy. Rhabdomyosarcoma, Embryonal / drug therapy. Soft Tissue Neoplasms / drug therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18680154.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


91. Smith MA, Morton CL, Phelps DA, Kolb EA, Lock R, Carol H, Reynolds CP, Maris JM, Keir ST, Wu J, Houghton PJ: Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program. Pediatr Blood Cancer; 2008 Jul;51(1):34-41
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Stage 1 testing and pharmacodynamic evaluation of the HSP90 inhibitor alvespimycin (17-DMAG, KOS-1022) by the pediatric preclinical testing program.
  • PROCEDURES: Alvespimycin was tested against the in vitro panel of the Pediatric Preclinical Testing Program (PPTP) at concentrations from 1 nM to 10 microM and was tested against the PPTP's in vivo tumor panels by intraperitoneal administration using a 50 mg/kg BID twice weekly x 6 weeks dose and schedule.
  • RESULTS: Alvespimycin had a median IC(50) of 68 nM against the PPTP's in vitro panel, with a trend for lower IC(50) values for the rhabdomyosarcoma panel (median IC(50) 32 nM) and for higher IC(50) values for the neuroblastoma panel (median IC(50) 380 nM).
  • Using the time to event activity measure, alvespimycin had intermediate or high activity against 4 of 28 evaluable solid tumor xenografts, including 3 of 4 alveolar rhabdomyosarcoma xenografts (one with a partial response).
  • The greatest drug effect was observed for the alveolar rhabdomyosarcoma xenografts in the rhabdomyosarcoma panel.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2008 Wiley-Liss, Inc.
  • (PMID = 18260120.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CM / N01 CM042216; United States / NCI NIH HHS / CA / CA108786; United States / NCI NIH HHS / CA / CA21765; United States / NCI NIH HHS / CM / N01-CM-42216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzoquinones; 0 / HSP90 Heat-Shock Proteins; 0 / Lactams, Macrocyclic; 001L2FE0M3 / 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin
  •  go-up   go-down


92. Orbach D, Rey A, Oberlin O, Sanchez de Toledo J, Terrier-Lacombe MJ, van Unnik A, Quintana E, Stevens MC: Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee. J Clin Oncol; 2005 Jul 1;23(19):4363-71
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Soft tissue sarcoma or malignant mesenchymal tumors in the first year of life: experience of the International Society of Pediatric Oncology (SIOP) Malignant Mesenchymal Tumor Committee.
  • Sixty-four patients had rhabdomyosarcoma (RMS), 26 had undifferentiated sarcoma, and 12 had other histology.
  • Infants with alveolar subtype had a poorer survival than those with non-RMS MMT or nonalveolar RMS (5-year OS, 37% v 75% or 82%, respectively; P = .002).
  • CONCLUSION: OS was satisfactory even when local treatment was not aggressive, although the prognosis was poor for infants with alveolar RMS or metastatic tumors.
  • [MeSH-minor] Age Factors. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Child. Child, Preschool. Cyclophosphamide / therapeutic use. Dactinomycin / therapeutic use. Doxorubicin / administration & dosage. Epirubicin / therapeutic use. Etoposide / administration & dosage. Humans. Ifosfamide / therapeutic use. Infant. Infant, Newborn. Neoplasm Metastasis. Neoplasm Recurrence, Local. Rhabdomyosarcoma / drug therapy. Survival Analysis. Teniposide / administration & dosage. Vincristine / therapeutic use

  • Genetic Alliance. consumer health - Malignant mesenchymal tumor.
  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. TENIPOSIDE .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • Hazardous Substances Data Bank. EPIRUBICIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15994146.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Comparative Study; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 3Z8479ZZ5X / Epirubicin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; 957E6438QA / Teniposide; UM20QQM95Y / Ifosfamide; CEV protocol; IVA protocol
  •  go-up   go-down


93. Aitken L, Levin D, Blau A, Lewin MR: Acute hearing loss, dysarthria, dysphagia, and a rubbery intraoral mass in an 18-year-old woman. Pediatr Emerg Care; 2009 Aug;25(8):516-8
MedlinePlus Health Information. consumer health - Tinnitus.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Rhabdomyosarcoma is the most common soft tissue tumor of childhood, frequently presenting in the head and neck, genitourinary tract, or extremities.
  • We present a case of rhabdomyosarcoma in which an 18-year-old woman presented with abrupt onset unilateral hearing loss, tinnitus, dysarthria, dysphagia, and a new painless red bump on the palate.
  • With an alveolar subtype and older age, both predictors of poor prognosis, early recognition of disease of these symptoms is vital.
  • [MeSH-major] Deglutition Disorders / etiology. Dysarthria / etiology. Hearing Loss, Sensorineural / etiology. Palatal Neoplasms / diagnosis. Rhabdomyosarcoma, Alveolar / diagnosis. Tinnitus / etiology

  • Genetic Alliance. consumer health - Dysphagia.
  • MedlinePlus Health Information. consumer health - Swallowing Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19687710.001).
  • [ISSN] 1535-1815
  • [Journal-full-title] Pediatric emergency care
  • [ISO-abbreviation] Pediatr Emerg Care
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


94. Davicioni E, Anderson JR, Buckley JD, Meyer WH, Triche TJ: Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group. J Clin Oncol; 2010 Mar 1;28(7):1240-6
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Gene expression profiling for survival prediction in pediatric rhabdomyosarcomas: a report from the children's oncology group.
  • PURPOSE: We investigated whether tumors from diagnostic biopsies of primary rhabdomyosarcoma (RMS) contain relevant prognostic information in the form of gene expression signatures that can be used to model and predict outcome of patients.
  • However, it was correlated with a risk classification used by the Children's Oncology Group and the biologic subsets of alveolar histology tumors.

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1999 Nov;17(11):3487-93 [10550146.001]
  • [Cites] Am J Pathol. 2009 Feb;174(2):550-64 [19147825.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):215-20 [11846299.001]
  • [Cites] J Clin Oncol. 2002 Jun 1;20(11):2672-9 [12039929.001]
  • [Cites] Eur J Cancer. 2002 Sep;38(13):1708-16 [12175686.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):78-84 [12506174.001]
  • [Cites] J Natl Cancer Inst. 2003 Jan 1;95(1):14-8 [12509396.001]
  • [Cites] Nat Genet. 2003 Jan;33(1):49-54 [12469122.001]
  • [Cites] Arch Dis Child. 2003 Apr;88(4):354-7 [12651771.001]
  • [Cites] Arch Pathol Lab Med. 2003 Oct;127(10):1290-7 [14521467.001]
  • [Cites] J Clin Oncol. 2004 Jan 1;22(1):143-9 [14701776.001]
  • [Cites] Cancer Treat Rev. 2004 May;30(3):269-80 [15059650.001]
  • [Cites] PLoS Biol. 2004 Apr;2(4):E108 [15094809.001]
  • [Cites] Stat Med. 2004 Jun 15;23(11):1767-80 [15160407.001]
  • [Cites] Bioinformatics. 2004 Aug 4;20 Suppl 1:i208-15 [15262801.001]
  • [Cites] Cancer Res. 2004 Aug 15;64(16):5539-45 [15313887.001]
  • [Cites] Oncogene. 2004 Sep 9;23(41):6864-71 [15286710.001]
  • [Cites] Mol Cell Biol. 2004 Nov;24(22):9726-35 [15509777.001]
  • [Cites] J Clin Oncol. 1997 May;15(5):1831-6 [9164192.001]
  • [Cites] Mol Cell Biol. 1998 Jan;18(1):566-75 [9418903.001]
  • [Cites] Oncogene. 1999 May 13;18(19):2942-54 [10378691.001]
  • [Cites] Oncogene. 1999 Jul 29;18(30):4348-56 [10439042.001]
  • [Cites] Lancet Oncol. 2005 Feb;6(2):77-84 [15683816.001]
  • [Cites] Clin Cancer Res. 2005 Feb 1;11(3):1190-7 [15709188.001]
  • [Cites] J Cell Biol. 2005 Feb 14;168(4):633-42 [15716380.001]
  • [Cites] Int J Cancer. 2005 May 20;115(1):85-92 [15688409.001]
  • [Cites] Oncologist. 2005 Aug;10(7):518-27 [16079319.001]
  • [Cites] Int J Biochem Cell Biol. 2005 Dec;37(12):2472-7 [16095948.001]
  • [Cites] J Clin Oncol. 2005 Oct 10;23(29):7332-41 [16145063.001]
  • [Cites] Cancer Res. 2005 Oct 15;65(20):9155-8 [16230372.001]
  • [Cites] J Clin Oncol. 2006 Feb 10;24(5):816-22 [16391296.001]
  • [Cites] Cancer Res. 2006 Jul 15;66(14):6936-46 [16849537.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):560-9 [16899776.001]
  • [Cites] J Clin Oncol. 2006 Aug 20;24(24):3844-51 [16921036.001]
  • [Cites] Stat Med. 2006 Sep 30;25(18):3201-16 [16143967.001]
  • [Cites] Nat Rev Genet. 2007 Aug;8(8):601-9 [17607306.001]
  • [Cites] J Clin Oncol. 2008 May 10;26(14):2384-9 [18467730.001]
  • [Cites] J Clin Oncol. 2001 Jun 15;19(12):3091-102 [11408506.001]
  • (PMID = 20124188.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / U01 CA114757; United States / NCI NIH HHS / CA / U10 CA098543; United States / NCI NIH HHS / CA / U01-CA-114757; United States / NCI NIH HHS / CA / U10CA98543
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / PAX3 protein, human; 0 / Paired Box Transcription Factors
  • [Other-IDs] NLM/ PMC3040045
  •  go-up   go-down


95. Hsieh MJ, Yao YL, Lai IL, Yang WM: Transcriptional repression activity of PAX3 is modulated by competition between corepressor KAP1 and heterochromatin protein 1. Biochem Biophys Res Commun; 2006 Oct 20;349(2):573-81
antibodies-online. View related products from antibodies-online.com (subscription/membership/fee required).

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Pax3 has been known to cause Waardenburg syndrome and pediatric alveolar rhabdomyosarcoma, but how Pax3 regulates transcription is not clear.

  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16945326.001).
  • [ISSN] 0006-291X
  • [Journal-full-title] Biochemical and biophysical research communications
  • [ISO-abbreviation] Biochem. Biophys. Res. Commun.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Chromosomal Proteins, Non-Histone; 0 / DNA-Binding Proteins; 0 / Nuclear Proteins; 0 / PAX3 protein, human; 0 / Paired Box Transcription Factors; 0 / Repressor Proteins; 0 / TRIM28 protein, human; 0 / Transcription Factors; 0 / Trim28 protein, mouse; 107283-02-3 / heterochromatin-specific nonhistone chromosomal protein HP-1; 138016-91-8 / Pax3 protein, mouse
  •  go-up   go-down


96. Kurmasheva RT, Peterson CA, Parham DM, Chen B, McDonald RE, Cooney CA: Upstream CpG island methylation of the PAX3 gene in human rhabdomyosarcomas. Pediatr Blood Cancer; 2005 Apr;44(4):328-37
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • In contrast, much less is known about gene hypermethylation in childhood cancers, where methylation changes are not part of the aging process but likely represent developmental dysregulation.
  • PROCEDURES: We examined the methylation status of a PAX3 5'-CpG island in rhabdomyosarcoma subtypes and in normal fetal skeletal muscle.
  • PAX3 methylation was analyzed in 15 embryonal rhabdomyosarcomas, 12 alveolar rhabdomyosarcomas, and in six normal skeletal muscle samples, using semi-quantitative PCR analysis of DNA digested with methyl-sensitive restriction enzymes.
  • CONCLUSIONS: PAX3 CpG island methylation appears to distinguish embryonal subtype of rhabdomyosarcoma from alveolar, and methylation at certain sites within this CpG island is inversely correlated with PAX3 expression.
  • In addition to exemplifying developmental dysregulation, methylation of PAX3 has potential in the development of an epigenetic profile for the diagnosis of rhabdomyosarcoma.
  • [MeSH-major] CpG Islands. DNA Methylation. DNA-Binding Proteins / genetics. Gene Expression Regulation, Neoplastic / genetics. Rhabdomyosarcoma / genetics. Transcription Factors / genetics
  • [MeSH-minor] Child. Humans. Muscle Development / genetics. Muscle, Skeletal / chemistry. Muscle, Skeletal / embryology. Paired Box Transcription Factors. Rhabdomyosarcoma, Alveolar / genetics. Rhabdomyosarcoma, Alveolar / pathology. Rhabdomyosarcoma, Embryonal / genetics. Rhabdomyosarcoma, Embryonal / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15602708.001).
  • [ISSN] 1545-5009
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NIA NIH HHS / AG / AG20941
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / PAX3 protein, human; 0 / Paired Box Transcription Factors; 0 / Transcription Factors
  •  go-up   go-down


97. Mackall CL, Rhee EH, Read EJ, Khuu HM, Leitman SF, Bernstein D, Tesso M, Long LM, Grindler D, Merino M, Kopp W, Tsokos M, Berzofsky JA, Helman LJ: A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas. Clin Cancer Res; 2008 Aug 1;14(15):4850-8
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A pilot study of consolidative immunotherapy in patients with high-risk pediatric sarcomas.
  • PURPOSE: Patients with metastatic or recurrent Ewing's sarcoma family of tumors and alveolar rhabdomyosarcoma have <25% 5-year survival in most studies.
  • EXPERIMENTAL DESIGN: Fifty-two patients with translocation positive, recurrent, or metastatic Ewing's sarcoma family of tumors or alveolar rhabdomyosarcoma underwent prechemotherapy cell harvest via apheresis for potential receipt of immunotherapy.

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Faculty of 1000. commentaries/discussion - See the articles recommended by F1000Prime's Faculty of more than 8,000 leading experts in Biology and Medicine. (subscription/membership/fee required).
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Bone Marrow Transplant. 1997 Feb;19(3):227-31 [9028550.001]
  • [Cites] Semin Hematol. 2006 Jan;43(1):53-61 [16412789.001]
  • [Cites] J Clin Invest. 1998 May 15;101(10):2290-6 [9593785.001]
  • [Cites] J Clin Invest. 1998 Jul 15;102(2):455-62 [9664088.001]
  • [Cites] N Engl J Med. 1999 Jul 29;341(5):342-52 [10423470.001]
  • [Cites] Blood. 1999 Aug 1;94(3):1021-7 [10419894.001]
  • [Cites] Exp Hematol. 1999 Oct;27(10):1477-86 [10517488.001]
  • [Cites] Clin Exp Med. 2004 Oct;4(2):78-85 [15672944.001]
  • [Cites] Cancer Immunol Immunother. 2005 Jun;54(6):526-34 [15838707.001]
  • [Cites] J Clin Oncol. 2005 Apr 20;23(12):2618-28 [15728225.001]
  • [Cites] J Clin Invest. 2005 Apr;115(4):930-9 [15776111.001]
  • [Cites] J Immunother. 2005 Sep-Oct;28(5):505-16 [16113607.001]
  • [Cites] Br J Cancer. 2005 Oct 3;93(7):749-56 [16136047.001]
  • [Cites] Nat Med. 2005 Nov;11(11):1238-43 [16227988.001]
  • [Cites] Oncologist. 1999;4(5):370-8 [10551553.001]
  • [Cites] J Exp Med. 1999 Dec 6;190(11):1669-78 [10587357.001]
  • [Cites] J Clin Oncol. 2000 Sep;18(17):3108-14 [10963639.001]
  • [Cites] J Exp Med. 2001 Jan 15;193(2):233-8 [11208863.001]
  • [Cites] Cancer Res. 2006 Feb 1;66(3):1818-23 [16452243.001]
  • [Cites] J Clin Oncol. 2006 Jul 1;24(19):3089-94 [16809734.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Pediatr Blood Cancer. 2007 Feb;48(2):132-9 [16317751.001]
  • [Cites] J Clin Oncol. 2007 Feb 1;25(4):356-61 [17264330.001]
  • [Cites] Cancer Res. 2007 Feb 15;67(4):1842-52 [17293384.001]
  • [Cites] Cancer Immunol Immunother. 2007 Jul;56(7):1037-46 [17149595.001]
  • [Cites] J Clin Oncol. 2001 Jun 1;19(11):2812-20 [11387352.001]
  • [Cites] J Clin Oncol. 2001 Aug 1;19(15):3463-9 [11481351.001]
  • [Cites] J Clin Oncol. 2001 Aug 15;19(16):3649-59 [11504746.001]
  • [Cites] Cancer Res. 2001 Sep 15;61(18):6868-75 [11559563.001]
  • [Cites] Proc Natl Acad Sci U S A. 2002 Jan 22;99(2):931-6 [11792864.001]
  • [Cites] Med Pediatr Oncol. 2002 Mar;38(3):158-64 [11836714.001]
  • [Cites] J Pediatr Hematol Oncol. 2001 May;23(4):221-4 [11846300.001]
  • [Cites] Crit Rev Oncol Hematol. 2002 Feb;41(2):169-89 [11856593.001]
  • [Cites] Cytotherapy. 2001;3(1):19-29 [12028840.001]
  • [Cites] Science. 2002 Oct 25;298(5594):850-4 [12242449.001]
  • [Cites] J Clin Oncol. 2003 Jan 1;21(1):78-84 [12506174.001]
  • [Cites] N Engl J Med. 2003 Feb 20;348(8):694-701 [12594313.001]
  • [Cites] J Pediatr Surg. 2003 Mar;38(3):347-53 [12632347.001]
  • [Cites] Cancer Biol Ther. 2003 Sep-Oct;2(5):579-86 [14614331.001]
  • [Cites] Curr Opin Oncol. 2004 Mar;16(2):120-5 [15075902.001]
  • [Cites] Nat Med. 2004 Sep;10(9):909-15 [15340416.001]
  • [Cites] Cancer. 1983 Jul 1;52(1):44-50 [6850544.001]
  • [Cites] Immunol Today. 1990 Nov;11(11):406-10 [2078294.001]
  • [Cites] Arch Surg. 1991 Apr;126(4):442-6 [2009059.001]
  • [Cites] Adv Immunol. 1991;49:281-355 [1853786.001]
  • [Cites] N Engl J Med. 1995 Jan 19;332(3):143-9 [7800006.001]
  • [Cites] J Immunol. 1996 Jun 15;156(12):4609-16 [8648103.001]
  • [Cites] J Clin Oncol. 1997 Feb;15(2):433-44 [9053463.001]
  • [Cites] J Immunol. 1997 Oct 15;159(8):3823-37 [9378970.001]
  • (PMID = 18676758.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] ENG
  • [Grant] United States / Intramural NIH HHS / / Z01 SC010289-08; United States / PHS HHS / / N01-C0-12400
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, N.I.H., Intramural
  • [Publication-country] United States
  • [Other-IDs] NLM/ NIHMS42930; NLM/ PMC2497450
  •  go-up   go-down


98. Roeb W, Boyer A, Cavenee WK, Arden KC: Guilt by association: PAX3-FOXO1 regulates gene expression through selective destabilization of the EGR1 transcription factor. Cell Cycle; 2008 Apr 1;7(7):837-41
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The t(2;13) translocation is characteristic of the pediatric muscle tumor, alveolar rhabdomyosarcoma, and produces the chimeric transcription factor, PAX3-FOXO1, that contains the DNA binding elements of PAX3 and the transcriptional activation domain of FOXO1.
  • [MeSH-major] Cell Differentiation / physiology. Early Growth Response Protein 1 / metabolism. Forkhead Transcription Factors / metabolism. Gene Expression Regulation, Neoplastic / physiology. Paired Box Transcription Factors / metabolism. Rhabdomyosarcoma, Alveolar / metabolism

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Cell Cycle. 2008 Oct;7(19):3106
  • (PMID = 18414034.001).
  • [ISSN] 1551-4005
  • [Journal-full-title] Cell cycle (Georgetown, Tex.)
  • [ISO-abbreviation] Cell Cycle
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Early Growth Response Protein 1; 0 / FOXO1 protein, human; 0 / Forkhead Transcription Factors; 0 / PAX3 protein, human; 0 / Paired Box Transcription Factors
  •  go-up   go-down


99. Abhyankar A, Jenney M, Huddart SN, Tilsley DW, Cox R, Saad M: Use of a tissue expander and a polyglactic acid (Vicryl) mesh to reduce radiation enteritis: case report and literature review. Pediatr Surg Int; 2005 Sep;21(9):755-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Management of stage IV rhabdomyosarcoma comprises systemic chemotherapy with local control by conservative surgery and radiotherapy.
  • We report a case of metastatic alveolar rhabdomyosarcoma requiring radiotherapy to the right renal bed.
  • [MeSH-minor] Biopsy. Child. Follow-Up Studies. Humans. Kidney Neoplasms / diagnosis. Kidney Neoplasms / radiotherapy. Kidney Neoplasms / secondary. Male. Mediastinal Neoplasms / diagnostic imaging. Mediastinal Neoplasms / pathology. Mediastinal Neoplasms / radiotherapy. Rhabdomyosarcoma, Alveolar / diagnosis. Rhabdomyosarcoma, Alveolar / radiotherapy. Rhabdomyosarcoma, Alveolar / secondary. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Aust N Z J Surg. 2000 Sep;70(9):690-2 [10976905.001]
  • [Cites] J Am Coll Surg. 1995 May;180(5):568-72 [7749532.001]
  • [Cites] Dis Colon Rectum. 1991 Sep;34(9):833-5 [1914752.001]
  • [Cites] Gynecol Oncol. 2000 Dec;79(3):438-43 [11104616.001]
  • [Cites] Dis Colon Rectum. 1992 Sep;35(9):897-901 [1387358.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1986 Sep;12(9):1565-73 [3759581.001]
  • [Cites] Surg Gynecol Obstet. 1983 Sep;157(3):269-71 [6612575.001]
  • [Cites] Ann Chir. 1996;50(1):58-71 [8734278.001]
  • [Cites] Am Surg. 1994 Jul;60(7):473-82; discussion 482-3 [8010560.001]
  • [Cites] Dig Dis Sci. 1996 Feb;41(2):392-401 [8601388.001]
  • [Cites] Bull Cancer. 1989;76(10):1121-5 [2635639.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1990 Aug;19(2):469-76 [2394624.001]
  • [Cites] Br J Radiol. 1993 Jan;66(781):67-73 [8428254.001]
  • [Cites] Br J Surg. 1987 Aug;74(8):742-7 [3307993.001]
  • [Cites] Radiother Oncol. 1994 Aug;32(2):116-23 [7972904.001]
  • (PMID = 16133520.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 34346-01-5 / Polyglactin 910
  •  go-up   go-down


100. Smith MA, Morton CL, Phelps D, Girtman K, Neale G, Houghton PJ: SK-NEP-1 and Rh1 are Ewing family tumor lines. Pediatr Blood Cancer; 2008 Mar;50(3):703-6
Cellosaurus - a cell line knowledge resource. culture/stock collections - Rh1 (CVCL_1658) .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The utility of preclinical models of childhood cancers is contingent upon reliably classifying them with their corresponding clinical counterparts.
  • Rh1, which was previously categorized as an alveolar rhabdomyosarcoma cell line, also has a gene expression profile suggestive of Ewing sarcoma and expresses EWS-FLI1 fusion transcripts in which exon 7 of EWS is joined with exon 6 of FLI1.
  • These examples illustrate the importance of molecularly characterizing pediatric preclinical models used for testing new agents.
  • [MeSH-major] Cell Line, Tumor. Kidney Neoplasms / pathology. Rhabdomyosarcoma, Alveolar / pathology. Sarcoma, Ewing / pathology. Wilms Tumor / pathology

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • Cellosaurus - a cell line knowledge resource. culture/stock collections - SK-NEP-1 (CVCL_0631) .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] (c) 2007 Wiley-Liss, Inc.
  • (PMID = 17154184.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CM / N01CM42216
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / EWS-FLI fusion protein; 0 / Oncogene Proteins, Fusion; 0 / Proto-Oncogene Protein c-fli-1; 0 / RNA-Binding Protein EWS; 0 / Transcription Factors
  •  go-up   go-down






Advertisement